Created
February 19, 2017 19:05
-
-
Save jackparmer/4e4f4793a5b766aca58b734174caf0bc to your computer and use it in GitHub Desktop.
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| NAME | PAGE | IMG_URL | LOGP | PKA | MW | FORM | SOL | DESC | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | Cyclacillin | https://www.drugbank.ca/drugs/DB01000 | <img src="https://www.drugbank.ca/structures/DB01000/thumb.svg"></img> | 1.31 | 3.3 | 341.426 | C15H23N3O4S | 1.9 mg/ml | A cyclohexylamido analog of penicillanic acid. [PubChem] | |
| 1 | Salbutamol | https://www.drugbank.ca/drugs/DB01001 | <img src="https://www.drugbank.ca/structures/DB01001/thumb.svg"></img> | 1.4 | 10.12 | 239.3107 | C13H21NO3 | 2.15 mg/ml | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma. | |
| 2 | Levobupivacaine | https://www.drugbank.ca/drugs/DB01002 | <img src="https://www.drugbank.ca/structures/DB01002/thumb.svg"></img> | 3.6 | 13.62 | 288.4277 | C18H28N2O | 0.0977 mg/ml | Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur. [Wikipedia] | |
| 3 | Cromoglicic acid | https://www.drugbank.ca/drugs/DB01003 | <img src="https://www.drugbank.ca/structures/DB01003/thumb.svg"></img> | 1.92 | 1.77 | 468.3665 | C23H16O11 | 0.0358 mg/ml | A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. [PubChem] | |
| 4 | Ganciclovir | https://www.drugbank.ca/drugs/DB01004 | <img src="https://www.drugbank.ca/structures/DB01004/thumb.svg"></img> | -1.66 | 10.16 | 255.2306 | C9H13N5O4 | 11.5 mg/ml | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. [PubChem] | |
| 5 | Hydroxyurea | https://www.drugbank.ca/drugs/DB01005 | <img src="https://www.drugbank.ca/structures/DB01005/thumb.svg"></img> | -1.80 | 10.14 | 76.0547 | CH4N2O2 | 269.0 mg/ml | An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. [PubChem] | |
| 6 | Ketoprofen | https://www.drugbank.ca/drugs/DB01009 | <img src="https://www.drugbank.ca/structures/DB01009/thumb.svg"></img> | 3.12 | 3.88 | 254.2806 | C16H14O3 | 0.0213 mg/ml | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | |
| 7 | Edrophonium | https://www.drugbank.ca/drugs/DB01010 | <img src="https://www.drugbank.ca/structures/DB01010/thumb.svg"></img> | -2.95 | 8.59 | 166.2401 | C10H16NO | 0.0486 mg/ml | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. [PubChem] | |
| 8 | Clobetasol propionate | https://www.drugbank.ca/drugs/DB01013 | <img src="https://www.drugbank.ca/structures/DB01013/thumb.svg"></img> | 3.50 | 13.63 | 466.97 | C25H32ClFO5 | 0.00413 mg/ml | A derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than fluocinonide, it is used topically in treatment of psoriasis but may cause marked adrenocortical suppression. [PubChem] | |
| 9 | Balsalazide | https://www.drugbank.ca/drugs/DB01014 | <img src="https://www.drugbank.ca/structures/DB01014/thumb.svg"></img> | 1.3 | 3.06 | 357.3175 | C17H15N3O6 | 0.0621 mg/ml | Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. | |
| 10 | Sulfamethoxazole | https://www.drugbank.ca/drugs/DB01015 | <img src="https://www.drugbank.ca/structures/DB01015/thumb.svg"></img> | 0.89 | 6.16 | 253.278 | C10H11N3O3S | 0.459 mg/ml | A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208) | |
| 11 | Glyburide | https://www.drugbank.ca/drugs/DB01016 | <img src="https://www.drugbank.ca/structures/DB01016/thumb.svg"></img> | 4.7 | 4.32 | 494.004 | C23H28ClN3O5S | 0.00206 mg/ml | Glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide's hypoglycemic effect is thought to be clinically unimportant. Glyburide metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2. | |
| 12 | Minocycline | https://www.drugbank.ca/drugs/DB01017 | <img src="https://www.drugbank.ca/structures/DB01017/thumb.svg"></img> | 0.05 | -2.3 | 457.4764 | C23H27N3O7 | 3.07 mg/ml | A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem] | |
| 13 | Guanfacine | https://www.drugbank.ca/drugs/DB01018 | <img src="https://www.drugbank.ca/structures/DB01018/thumb.svg"></img> | 1.7 | 12.94 | 246.093 | C9H9Cl2N3O | 0.139 mg/ml | A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem] | |
| 14 | Bethanechol | https://www.drugbank.ca/drugs/DB01019 | <img src="https://www.drugbank.ca/structures/DB01019/thumb.svg"></img> | -2.8 | 15.34 | 161.2221 | C7H17N2O2 | 0.311 mg/ml | Bethanechol is a synthetic ester structurally and pharmacologically related to acetylcholine. A slowly hydrolyzed muscarinic agonist with no nicotinic effects, bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, cardiac rate changes, and bronchial spasms. [PubChem] | |
| 15 | Isosorbide Mononitrate | https://www.drugbank.ca/drugs/DB01020 | <img src="https://www.drugbank.ca/structures/DB01020/thumb.svg"></img> | -0.15 | 13.34 | 191.1388 | C6H9NO6 | 57.0 mg/ml | Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur. Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive. Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium. The adverse reactions which follow have been reported in studies with isosorbide mononitrate: Very common. Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues . Common. Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%). Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment. Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment. Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn | |
| 16 | Trichlormethiazide | https://www.drugbank.ca/drugs/DB01021 | <img src="https://www.drugbank.ca/structures/DB01021/thumb.svg"></img> | 0.62 | 8.32 | 380.656 | C8H8Cl3N3O4S2 | 0.415 mg/ml | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | |
| 17 | Mycophenolic acid | https://www.drugbank.ca/drugs/DB01024 | <img src="https://www.drugbank.ca/structures/DB01024/thumb.svg"></img> | 2.8 | 3.57 | 320.3371 | C17H20O6 | 0.0355 mg/ml | Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase). | |
| 18 | Amlexanox | https://www.drugbank.ca/drugs/DB01025 | <img src="https://www.drugbank.ca/structures/DB01025/thumb.svg"></img> | 4.1 | 4.3 | 298.2934 | C16H14N2O4 | 0.146 mg/ml | Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. | |
| 19 | Irbesartan | https://www.drugbank.ca/drugs/DB01029 | <img src="https://www.drugbank.ca/structures/DB01029/thumb.svg"></img> | 6 | 7.4 | 428.5294 | C25H28N6O | 0.00884 mg/ml | Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer. | |
| 20 | Topotecan | https://www.drugbank.ca/drugs/DB01030 | <img src="https://www.drugbank.ca/structures/DB01030/thumb.svg"></img> | 0.8 | 8 | 421.4458 | C23H23N3O5 | 0.861 mg/ml | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem] | |
| 21 | Ethinamate | https://www.drugbank.ca/drugs/DB01031 | <img src="https://www.drugbank.ca/structures/DB01031/thumb.svg"></img> | 1.2 | 15.37 | 167.205 | C9H13NO2 | 0.106 mg/ml | Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia. Regular use leads to tolerance, and it is usually not effective for more than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates. | |
| 22 | Probenecid | https://www.drugbank.ca/drugs/DB01032 | <img src="https://www.drugbank.ca/structures/DB01032/thumb.svg"></img> | 3.21 | 3.53 | 285.359 | C13H19NO4S | 0.425 mg/ml | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. [PubChem] | |
| 23 | Mercaptopurine | https://www.drugbank.ca/drugs/DB01033 | <img src="https://www.drugbank.ca/structures/DB01033/thumb.svg"></img> | 0.01 | 9.5 | 152.177 | C5H4N4S | 0.735 mg/ml | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [PubChem] | |
| 24 | Cerulenin | https://www.drugbank.ca/drugs/DB01034 | <img src="https://www.drugbank.ca/structures/DB01034/thumb.svg"></img> | 1.2 | 14.16 | 223.2683 | C12H17NO3 | 1.6 mg/ml | Cerulenin is an antifungal antibiotic that inhibits sterol and fatty acid biosynthesis. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. [Wikipedia] | |
| 25 | Procainamide | https://www.drugbank.ca/drugs/DB01035 | <img src="https://www.drugbank.ca/structures/DB01035/thumb.svg"></img> | 0.88 | 15.75 | 235.3253 | C13H21N3O | 3.02 mg/ml | A derivative of procaine with less CNS action. [PubChem] | |
| 26 | Tolterodine | https://www.drugbank.ca/drugs/DB01036 | <img src="https://www.drugbank.ca/structures/DB01036/thumb.svg"></img> | 5.6 | 10.28 | 325.4876 | C22H31NO | 0.00534 mg/ml | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | |
| 27 | Carphenazine | https://www.drugbank.ca/drugs/DB01038 | <img src="https://www.drugbank.ca/structures/DB01038/thumb.svg"></img> | 3.3 | 15.56 | 411.56 | C23H29N3O2S | 0.0905 mg/ml | Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses. | |
| 28 | Hydroxystilbamidine Isethionate | https://www.drugbank.ca/drugs/DB01040 | <img src="https://www.drugbank.ca/structures/DB01040/thumb.svg"></img> | 1.679 | 8.22 | 532.58 | C20H28N4O9S2 | 0.0644 mg/ml | Hydroxystilbamidine Isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine Isethionate is also used in pathology for diagnostic purposes. | |
| 29 | Thalidomide | https://www.drugbank.ca/drugs/DB01041 | <img src="https://www.drugbank.ca/structures/DB01041/thumb.svg"></img> | 0.33 | 11.59 | 258.2295 | C13H10N2O4 | 2.55 mg/ml | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] | |
| 30 | Melphalan | https://www.drugbank.ca/drugs/DB01042 | <img src="https://www.drugbank.ca/structures/DB01042/thumb.svg"></img> | -0.52 | 1.29 | 305.2 | C13H18Cl2N2O2 | 0.358 mg/ml | An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen. [PubChem] | |
| 31 | Gatifloxacin | https://www.drugbank.ca/drugs/DB01044 | <img src="https://www.drugbank.ca/structures/DB01044/thumb.svg"></img> | 2.6 | 5.69 | 375.3941 | C19H22FN3O4 | 0.631 mg/ml | Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin® for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar®. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. [Wikipedia] | |
| 32 | Lubiprostone | https://www.drugbank.ca/drugs/DB01046 | <img src="https://www.drugbank.ca/structures/DB01046/thumb.svg"></img> | 4.3 | 4.3 | 390.468 | C20H32F2O5 | 0.0256 mg/ml | Lubiprostone is a medication used in the management of idiopathic chronic constipation. It is a bicyclic fatty acid (prostaglandin E1 derivative) which acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM). | |
| 33 | Fluocinonide | https://www.drugbank.ca/drugs/DB01047 | <img src="https://www.drugbank.ca/structures/DB01047/thumb.svg"></img> | 3.19 | 13.55 | 494.5249 | C26H32F2O7 | 0.0168 mg/ml | A topical glucocorticoid used in the treatment of eczema. [PubChem] | |
| 34 | Abacavir | https://www.drugbank.ca/drugs/DB01048 | <img src="https://www.drugbank.ca/structures/DB01048/thumb.svg"></img> | 1.20 | 15.41 | 286.3323 | C14H18N6O | 1.21 mg/ml | Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir. | |
| 35 | Ibuprofen | https://www.drugbank.ca/drugs/DB01050 | <img src="https://www.drugbank.ca/structures/DB01050/thumb.svg"></img> | 3.97 | 4.85 | 206.2808 | C13H18O2 | 0.0684 mg/ml | Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | |
| 36 | Novobiocin | https://www.drugbank.ca/drugs/DB01051 | <img src="https://www.drugbank.ca/structures/DB01051/thumb.svg"></img> | 4.1 | 6.96 | 612.6243 | C31H36N2O11 | 0.00966 mg/ml | An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) [PubChem] | |
| 37 | Benzylpenicillin | https://www.drugbank.ca/drugs/DB01053 | <img src="https://www.drugbank.ca/structures/DB01053/thumb.svg"></img> | 1.83 | 3.53 | 334.39 | C16H18N2O4S | 0.285 mg/ml | Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms. Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such asStreptococcus pneumoniae, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (S. agalactiae),S. viridans, andEnterococcus faecalis. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such asBacillus anthracis,Corynebacterium diphtheriae, andErysipelothrix rhusiopathiae. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused byNeisseria meningitidisandPasteurella. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions. | |
| 38 | Mimosine | https://www.drugbank.ca/drugs/DB01055 | <img src="https://www.drugbank.ca/structures/DB01055/thumb.svg"></img> | -2.5 | 1.94 | 198.176 | C8H10N2O4 | 13.1 mg/ml | 3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca. [PubChem] | |
| 39 | Tocainide | https://www.drugbank.ca/drugs/DB01056 | <img src="https://www.drugbank.ca/structures/DB01056/thumb.svg"></img> | 0.76 | 13.65 | 192.2575 | C11H16N2O | 1.6 mg/ml | An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. [PubChem] | |
| 40 | Praziquantel | https://www.drugbank.ca/drugs/DB01058 | <img src="https://www.drugbank.ca/structures/DB01058/thumb.svg"></img> | 2.5 | 19.38 | 312.4061 | C19H24N2O2 | 0.381 mg/ml | An anthelmintic used in most schistosome and many cestode infestations. [PubChem] | |
| 41 | Norfloxacin | https://www.drugbank.ca/drugs/DB01059 | <img src="https://www.drugbank.ca/structures/DB01059/thumb.svg"></img> | -1.03 | 5.77 | 319.3308 | C16H18FN3O3 | 1.01 mg/ml | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem] | |
| 42 | Amoxicillin | https://www.drugbank.ca/drugs/DB01060 | <img src="https://www.drugbank.ca/structures/DB01060/thumb.svg"></img> | 0.87 | 3.23 | 365.404 | C16H19N3O5S | 0.958 mg/ml | A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation. [PubChem] | |
| 43 | Azlocillin | https://www.drugbank.ca/drugs/DB01061 | <img src="https://www.drugbank.ca/structures/DB01061/thumb.svg"></img> | 0.2 | 3.49 | 461.492 | C20H23N5O6S | 0.233 mg/ml | A semisynthetic ampicillin-derived acylureido penicillin. [PubChem] | |
| 44 | Oxybutynin | https://www.drugbank.ca/drugs/DB01062 | <img src="https://www.drugbank.ca/structures/DB01062/thumb.svg"></img> | 4.3 | 11.53 | 357.4864 | C22H31NO3 | 0.01 mg/ml | Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. | |
| 45 | Acetophenazine | https://www.drugbank.ca/drugs/DB01063 | <img src="https://www.drugbank.ca/structures/DB01063/thumb.svg"></img> | 2.62 | 15.46 | 411.56 | C23H29N3O2S | 0.0601 mg/ml | Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking. It is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor. | |
| 46 | Isoprenaline | https://www.drugbank.ca/drugs/DB01064 | <img src="https://www.drugbank.ca/structures/DB01064/thumb.svg"></img> | 1.4 | 9.81 | 211.2576 | C11H17NO3 | 5.86 mg/ml | Isopropyl analog of epinephrine; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. [PubChem] | |
| 47 | Melatonin | https://www.drugbank.ca/drugs/DB01065 | <img src="https://www.drugbank.ca/structures/DB01065/thumb.svg"></img> | 1.6 | 15.8 | 232.2783 | C13H16N2O2 | 0.143 mg/ml | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| 48 | Cefditoren | https://www.drugbank.ca/drugs/DB01066 | <img src="https://www.drugbank.ca/structures/DB01066/thumb.svg"></img> | 1.7 | 3.4 | 506.578 | C19H18N6O5S3 | 0.0441 mg/ml | Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | |
| 49 | Glipizide | https://www.drugbank.ca/drugs/DB01067 | <img src="https://www.drugbank.ca/structures/DB01067/thumb.svg"></img> | 1.91 | 4.32 | 445.535 | C21H27N5O4S | 0.0164 mg/ml | An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem] | |
| 50 | Clonazepam | https://www.drugbank.ca/drugs/DB01068 | <img src="https://www.drugbank.ca/structures/DB01068/thumb.svg"></img> | 2.41 | 11.89 | 315.711 | C15H10ClN3O3 | 0.0106 mg/ml | An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. [PubChem] | |
| 51 | Dihydrotachysterol | https://www.drugbank.ca/drugs/DB01070 | <img src="https://www.drugbank.ca/structures/DB01070/thumb.svg"></img> | 7.5 | 18.3 | 398.6642 | C28H46O | 0.000125 mg/ml | A vitamin D that can be regarded as a reduction product of vitamin D2. [PubChem] | |
| 52 | Atazanavir | https://www.drugbank.ca/drugs/DB01072 | <img src="https://www.drugbank.ca/structures/DB01072/thumb.svg"></img> | 4.5 | 11.92 | 704.8555 | C38H52N6O7 | 0.00327 mg/ml | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia] | |
| 53 | Fludarabine | https://www.drugbank.ca/drugs/DB01073 | <img src="https://www.drugbank.ca/structures/DB01073/thumb.svg"></img> | -2.8 | 12.45 | 285.235 | C10H12FN5O4 | 12.1 mg/ml | Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia] | |
| 54 | Atorvastatin | https://www.drugbank.ca/drugs/DB01076 | <img src="https://www.drugbank.ca/structures/DB01076/thumb.svg"></img> | 5.7 | 4.33 | 557.6319 | C33H34FN2O5 | 0.000495 mg/ml | Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels. | |
| 55 | Etidronic acid | https://www.drugbank.ca/drugs/DB01077 | <img src="https://www.drugbank.ca/structures/DB01077/thumb.svg"></img> | -3.8 | 0.7 | 206.0282 | C2H8O7P2 | 11.5 mg/ml | A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. | |
| 56 | Deslanoside | https://www.drugbank.ca/drugs/DB01078 | <img src="https://www.drugbank.ca/structures/DB01078/thumb.svg"></img> | 0.2 | 7.15 | 943.0791 | C47H74O19 | 0.468 mg/ml | Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem] | |
| 57 | Tegaserod | https://www.drugbank.ca/drugs/DB01079 | <img src="https://www.drugbank.ca/structures/DB01079/thumb.svg"></img> | 2.6 | 15.24 | 301.394 | C16H23N5O | 0.0288 mg/ml | Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia] | |
| 58 | Vigabatrin | https://www.drugbank.ca/drugs/DB01080 | <img src="https://www.drugbank.ca/structures/DB01080/thumb.svg"></img> | -2.16 | 4.61 | 129.157 | C6H11NO2 | 96.6 mg/ml | An analogue of gamma-aminobutyric acid, vigabatrin is an irreversible inhibitor of 4-aminobutyrate transaminase, the enzyme responsible for the catabolism of gamma-aminobutyric acid. (From Martindale The Extra Pharmacopoeia, 31st ed). Off-label uses include treatment of cocaine dependence. | |
| 59 | Streptomycin | https://www.drugbank.ca/drugs/DB01082 | <img src="https://www.drugbank.ca/structures/DB01082/thumb.svg"></img> | -6.4 | 10.88 | 581.5741 | C21H39N7O12 | 12.8 mg/ml | Streptomycin is an aminoglycoside antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by binding to the 30S ribosomal subunit of susceptible organisms and disrupting the initiation and elongation steps in protein synthesis. It is bactericidal due to effects that are not fully understood. | |
| 60 | Orlistat | https://www.drugbank.ca/drugs/DB01083 | <img src="https://www.drugbank.ca/structures/DB01083/thumb.svg"></img> | 8.6 | 12.74 | 495.7348 | C29H53NO5 | 9.19e-05 mg/ml | Orlistat is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. | |
| 61 | Primaquine | https://www.drugbank.ca/drugs/DB01087 | <img src="https://www.drugbank.ca/structures/DB01087/thumb.svg"></img> | 2.1 | 17.11 | 259.3467 | C15H21N3O | 0.0564 mg/ml | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | |
| 62 | Iloprost | https://www.drugbank.ca/drugs/DB01088 | <img src="https://www.drugbank.ca/structures/DB01088/thumb.svg"></img> | 4.8 | 4.66 | 360.494 | C22H32O4 | 0.00874 mg/ml | Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH). | |
| 63 | Deserpidine | https://www.drugbank.ca/drugs/DB01089 | <img src="https://www.drugbank.ca/structures/DB01089/thumb.svg"></img> | 3.3 | 16.37 | 578.6527 | C32H38N2O8 | 0.0111 mg/ml | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | |
| 64 | Ouabain | https://www.drugbank.ca/drugs/DB01092 | <img src="https://www.drugbank.ca/structures/DB01092/thumb.svg"></img> | -2.00 | 7.18 | 584.6525 | C29H44O12 | 4.61 mg/ml | A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. [PubChem] | |
| 65 | Hesperetin | https://www.drugbank.ca/drugs/DB01094 | <img src="https://www.drugbank.ca/structures/DB01094/thumb.svg"></img> | 2.60 | 7.92 | 302.2788 | C16H14O6 | 0.138 mg/ml | Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside hesperidin, is the predominant flavonoid in lemons and oranges. | |
| 66 | Fluvastatin | https://www.drugbank.ca/drugs/DB01095 | <img src="https://www.drugbank.ca/structures/DB01095/thumb.svg"></img> | 4.5 | 4.56 | 411.4659 | C24H26FNO4 | 0.00441 mg/ml | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. | |
| 67 | Oxamniquine | https://www.drugbank.ca/drugs/DB01096 | <img src="https://www.drugbank.ca/structures/DB01096/thumb.svg"></img> | 2.24 | 14.55 | 279.3348 | C14H21N3O3 | 0.124 mg/ml | An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121) | |
| 68 | Leflunomide | https://www.drugbank.ca/drugs/DB01097 | <img src="https://www.drugbank.ca/structures/DB01097/thumb.svg"></img> | 2.8 | 10.41 | 270.2073 | C12H9F3N2O2 | 0.0844 mg/ml | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | |
| 69 | Rosuvastatin | https://www.drugbank.ca/drugs/DB01098 | <img src="https://www.drugbank.ca/structures/DB01098/thumb.svg"></img> | 0.13 | 4 | 481.538 | C22H28FN3O6S | 0.0886 mg/ml | Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. | |
| 70 | Flucytosine | https://www.drugbank.ca/drugs/DB01099 | <img src="https://www.drugbank.ca/structures/DB01099/thumb.svg"></img> | -1.1 | 8.16 | 129.0925 | C4H4FN3O | 1.92 mg/ml | A fluorinated cytosine analog that is used as an antifungal agent. [PubChem] | |
| 71 | Pimozide | https://www.drugbank.ca/drugs/DB01100 | <img src="https://www.drugbank.ca/structures/DB01100/thumb.svg"></img> | 6.30 | 12.9 | 461.5462 | C28H29F2N3O | 0.00173 mg/ml | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | |
| 72 | Capecitabine | https://www.drugbank.ca/drugs/DB01101 | <img src="https://www.drugbank.ca/structures/DB01101/thumb.svg"></img> | 0.4 | 8.23 | 359.3501 | C15H22FN3O6 | 0.248 mg/ml | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | |
| 73 | Arbutamine | https://www.drugbank.ca/drugs/DB01102 | <img src="https://www.drugbank.ca/structures/DB01102/thumb.svg"></img> | 2.9 | 8.97 | 317.3795 | C18H23NO4 | 0.0842 mg/ml | Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately . | |
| 74 | Levocabastine | https://www.drugbank.ca/drugs/DB01106 | <img src="https://www.drugbank.ca/structures/DB01106/thumb.svg"></img> | 5 | 3.71 | 420.528 | C26H29FN2O2 | 0.00347 mg/ml | Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979. | |
| 75 | Methyprylon | https://www.drugbank.ca/drugs/DB01107 | <img src="https://www.drugbank.ca/structures/DB01107/thumb.svg"></img> | 0.78 | 14.53 | 183.2475 | C10H17NO2 | 11.3 mg/ml | Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990. [Wikipedia] | |
| 76 | Trilostane | https://www.drugbank.ca/drugs/DB01108 | <img src="https://www.drugbank.ca/structures/DB01108/thumb.svg"></img> | 3 | 5.23 | 329.4333 | C20H27NO3 | 0.0593 mg/ml | Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994. [Wikipedia] | |
| 77 | Colistimethate | https://www.drugbank.ca/drugs/DB01111 | <img src="https://www.drugbank.ca/structures/DB01111/thumb.svg"></img> | -1.2 | -4.3 | 1634.87 | C58H105N16O28S5 | 4.17 mg/ml | Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. | |
| 78 | Cefuroxime | https://www.drugbank.ca/drugs/DB01112 | <img src="https://www.drugbank.ca/structures/DB01112/thumb.svg"></img> | -0.16 | 3.15 | 424.385 | C16H16N4O8S | 0.284 mg/ml | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. [PubChem] | |
| 79 | Atovaquone | https://www.drugbank.ca/drugs/DB01117 | <img src="https://www.drugbank.ca/structures/DB01117/thumb.svg"></img> | 5.8 | 8.23 | 366.837 | C22H19ClO3 | 0.000796 mg/ml | A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. [PubChem] | |
| 80 | Diazoxide | https://www.drugbank.ca/drugs/DB01119 | <img src="https://www.drugbank.ca/structures/DB01119/thumb.svg"></img> | 1.20 | 10.48 | 230.671 | C8H7ClN2O2S | 0.552 mg/ml | A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. [PubChem] | |
| 81 | Gliclazide | https://www.drugbank.ca/drugs/DB01120 | <img src="https://www.drugbank.ca/structures/DB01120/thumb.svg"></img> | 2.6 | 4.07 | 323.411 | C15H21N3O3S | 0.19 mg/ml | Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%). | |
| 82 | Phenacemide | https://www.drugbank.ca/drugs/DB01121 | <img src="https://www.drugbank.ca/structures/DB01121/thumb.svg"></img> | 0.87 | 11.75 | 178.1879 | C9H10N2O2 | 1.06 mg/ml | Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures. | |
| 83 | Ambenonium | https://www.drugbank.ca/drugs/DB01122 | <img src="https://www.drugbank.ca/structures/DB01122/thumb.svg"></img> | 2.27 | 10.78 | 537.565 | C28H42Cl2N4O2 | 9.42e-07 mg/ml | Ambenonium is a cholinesterase inhibitor used in the management of myasthenia gravis. [Wikipedia] | |
| 84 | Tolbutamide | https://www.drugbank.ca/drugs/DB01124 | <img src="https://www.drugbank.ca/structures/DB01124/thumb.svg"></img> | 2.34 | 4.33 | 270.348 | C12H18N2O3S | 0.202 mg/ml | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | |
| 85 | Anisindione | https://www.drugbank.ca/drugs/DB01125 | <img src="https://www.drugbank.ca/structures/DB01125/thumb.svg"></img> | 2.88 | 4.5 | 252.2647 | C16H12O3 | 0.0128 mg/ml | Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins. | |
| 86 | Dutasteride | https://www.drugbank.ca/drugs/DB01126 | <img src="https://www.drugbank.ca/structures/DB01126/thumb.svg"></img> | 6.8 | 12.56 | 528.5297 | C27H30F6N2O2 | 0.000908 mg/ml | Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia] | |
| 87 | Bicalutamide | https://www.drugbank.ca/drugs/DB01128 | <img src="https://www.drugbank.ca/structures/DB01128/thumb.svg"></img> | 2.5 | 11.95 | 430.373 | C18H14F4N2O4S | 0.00928 mg/ml | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor. | |
| 88 | Rabeprazole | https://www.drugbank.ca/drugs/DB01129 | <img src="https://www.drugbank.ca/structures/DB01129/thumb.svg"></img> | 0.6 | 9.35 | 359.443 | C18H21N3O3S | 0.336 mg/ml | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | |
| 89 | Prednicarbate | https://www.drugbank.ca/drugs/DB01130 | <img src="https://www.drugbank.ca/structures/DB01130/thumb.svg"></img> | 2.9 | 14.83 | 488.577 | C27H36O8 | 0.00562 mg/ml | Prednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. It is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. The anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness. | |
| 90 | Proguanil | https://www.drugbank.ca/drugs/DB01131 | <img src="https://www.drugbank.ca/structures/DB01131/thumb.svg"></img> | 2.53 | 19.77 | 253.731 | C11H16ClN5 | 0.286 mg/ml | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | |
| 91 | Pioglitazone | https://www.drugbank.ca/drugs/DB01132 | <img src="https://www.drugbank.ca/structures/DB01132/thumb.svg"></img> | 2.3 | 6.66 | 356.439 | C19H20N2O3S | 0.00442 mg/ml | Pioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver. | |
| 92 | Tiludronic acid | https://www.drugbank.ca/drugs/DB01133 | <img src="https://www.drugbank.ca/structures/DB01133/thumb.svg"></img> | -0.6 | 1.03 | 318.608 | C7H9ClO6P2S | 6.97 mg/ml | Tiludronic acid is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates. | |
| 93 | Desoxycorticosterone Pivalate | https://www.drugbank.ca/drugs/DB01134 | <img src="https://www.drugbank.ca/structures/DB01134/thumb.svg"></img> | 4 | 17.19 | 414.586 | C26H38O4 | 0.00141 mg/ml | Desoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. | |
| 94 | Doxacurium chloride | https://www.drugbank.ca/drugs/DB01135 | <img src="https://www.drugbank.ca/structures/DB01135/thumb.svg"></img> | 3.82 | 18.41 | 1106.14 | C56H78Cl2N2O16 | 8.54e-05 mg/ml | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | |
| 95 | Carvedilol | https://www.drugbank.ca/drugs/DB01136 | <img src="https://www.drugbank.ca/structures/DB01136/thumb.svg"></img> | 4.19 | 14.03 | 406.4742 | C24H26N2O4 | 0.00444 mg/ml | Carvedilol is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). It blocks beta-1 and beta-2 adrenergic receptors as well as the alpha-1 adrenergic receptors. | |
| 96 | Levofloxacin | https://www.drugbank.ca/drugs/DB01137 | <img src="https://www.drugbank.ca/structures/DB01137/thumb.svg"></img> | 2.1 | 5.45 | 361.3675 | C18H20FN3O4 | 1.44 mg/ml | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem] | |
| 97 | Sulfinpyrazone | https://www.drugbank.ca/drugs/DB01138 | <img src="https://www.drugbank.ca/structures/DB01138/thumb.svg"></img> | 2.30 | 3.41 | 404.482 | C23H20N2O3S | 0.323 mg/ml | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. [PubChem] | |
| 98 | Cefapirin | https://www.drugbank.ca/drugs/DB01139 | <img src="https://www.drugbank.ca/structures/DB01139/thumb.svg"></img> | -1.15 | 3.54 | 423.463 | C17H17N3O6S2 | 0.151 mg/ml | Cefapirin (INN, also spelled cephapirin) is an injectable, first-generation cephalosporin antibiotic. It is marketed under the trade name Cefadyl. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms. | |
| 99 | Cefadroxil | https://www.drugbank.ca/drugs/DB01140 | <img src="https://www.drugbank.ca/structures/DB01140/thumb.svg"></img> | -0.4 | 3.45 | 363.388 | C16H17N3O5S | 0.399 mg/ml | Long-acting, broad-spectrum, water-soluble, cephalexin derivative. [PubChem] | |
| 100 | Micafungin | https://www.drugbank.ca/drugs/DB01141 | <img src="https://www.drugbank.ca/structures/DB01141/thumb.svg"></img> | -1.5 | -2.2 | 1270.274 | C56H71N9O23S | 0.218 mg/ml | Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. | |
| 101 | Amifostine | https://www.drugbank.ca/drugs/DB01143 | <img src="https://www.drugbank.ca/structures/DB01143/thumb.svg"></img> | -1.9 | 2.06 | 214.223 | C5H15N2O3PS | 18.7 mg/ml | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. [PubChem] | |
| 102 | Diclofenamide | https://www.drugbank.ca/drugs/DB01144 | <img src="https://www.drugbank.ca/structures/DB01144/thumb.svg"></img> | 0.2 | 7.94 | 305.159 | C6H6Cl2N2O4S2 | 0.398 mg/ml | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. [PubChem] | |
| 103 | Sulfoxone | https://www.drugbank.ca/drugs/DB01145 | <img src="https://www.drugbank.ca/structures/DB01145/thumb.svg"></img> | -2.8 | -1.5 | 404.482 | C14H16N2O6S3 | 2.63 mg/ml | Sulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis. | |
| 104 | Cloxacillin | https://www.drugbank.ca/drugs/DB01147 | <img src="https://www.drugbank.ca/structures/DB01147/thumb.svg"></img> | 2.48 | 3.75 | 435.881 | C19H18ClN3O5S | 0.0532 mg/ml | A semi-synthetic antibiotic that is a chlorinated derivative of oxacillin. [PubChem] | |
| 105 | Cefprozil | https://www.drugbank.ca/drugs/DB01150 | <img src="https://www.drugbank.ca/structures/DB01150/thumb.svg"></img> | 0.6 | 3.53 | 389.426 | C18H19N3O5S | 0.149 mg/ml | Cefprozil is a cephalosporin antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. | |
| 106 | Candicidin | https://www.drugbank.ca/drugs/DB01152 | <img src="https://www.drugbank.ca/structures/DB01152/thumb.svg"></img> | 1.7 | 3.68 | 1109.3009 | C59H84N2O18 | 0.00934 mg/ml | Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans). Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis. | |
| 107 | Thiamylal | https://www.drugbank.ca/drugs/DB01154 | <img src="https://www.drugbank.ca/structures/DB01154/thumb.svg"></img> | 3.23 | 7.2 | 254.349 | C12H18N2O2S | 0.0506 mg/ml | A barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919) | |
| 108 | Gemifloxacin | https://www.drugbank.ca/drugs/DB01155 | <img src="https://www.drugbank.ca/structures/DB01155/thumb.svg"></img> | 2.3 | 5.53 | 389.3809 | C18H20FN5O4 | 0.21 mg/ml | Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | |
| 109 | Bupropion | https://www.drugbank.ca/drugs/DB01156 | <img src="https://www.drugbank.ca/structures/DB01156/thumb.svg"></img> | 3.6 | 18.29 | 239.741 | C13H18ClNO | 0.0693 mg/ml | A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment. [PubChem] | |
| 110 | Trimetrexate | https://www.drugbank.ca/drugs/DB01157 | <img src="https://www.drugbank.ca/structures/DB01157/thumb.svg"></img> | 2.55 | 17.04 | 369.4176 | C19H23N5O3 | 0.0309 mg/ml | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [PubChem] | |
| 111 | Bretylium | https://www.drugbank.ca/drugs/DB01158 | <img src="https://www.drugbank.ca/structures/DB01158/thumb.svg"></img> | -1.4 | 17.58 | 243.163 | C11H17BrN | 0.000154 mg/ml | Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. | |
| 112 | Terazosin | https://www.drugbank.ca/drugs/DB01162 | <img src="https://www.drugbank.ca/structures/DB01162/thumb.svg"></img> | 1 | 19.93 | 387.4329 | C19H25N5O4 | 1.5 mg/ml | Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls. | |
| 113 | Amdinocillin | https://www.drugbank.ca/drugs/DB01163 | <img src="https://www.drugbank.ca/structures/DB01163/thumb.svg"></img> | 1.3 | 3.3 | 325.426 | C15H23N3O3S | 0.979 mg/ml | Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States. | |
| 114 | Ofloxacin | https://www.drugbank.ca/drugs/DB01165 | <img src="https://www.drugbank.ca/structures/DB01165/thumb.svg"></img> | -0.39 | 5.45 | 361.3675 | C18H20FN3O4 | 1.44 mg/ml | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem] | |
| 115 | Cilostazol | https://www.drugbank.ca/drugs/DB01166 | <img src="https://www.drugbank.ca/structures/DB01166/thumb.svg"></img> | 2.3 | 14.42 | 369.4607 | C20H27N5O2 | 0.0324 mg/ml | Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. [Wikipedia] | |
| 116 | Procarbazine | https://www.drugbank.ca/drugs/DB01168 | <img src="https://www.drugbank.ca/structures/DB01168/thumb.svg"></img> | 0.06 | 15.03 | 221.2988 | C12H19N3O | 0.228 mg/ml | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | |
| 117 | Moclobemide | https://www.drugbank.ca/drugs/DB01171 | <img src="https://www.drugbank.ca/structures/DB01171/thumb.svg"></img> | 1.5 | 14.73 | 268.739 | C13H17ClN2O2 | 1.12 mg/ml | A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. | |
| 118 | Kanamycin | https://www.drugbank.ca/drugs/DB01172 | <img src="https://www.drugbank.ca/structures/DB01172/thumb.svg"></img> | -6.3 | 12.11 | 484.4986 | C18H36N4O11 | 92.3 mg/ml | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | |
| 119 | Phenobarbital | https://www.drugbank.ca/drugs/DB01174 | <img src="https://www.drugbank.ca/structures/DB01174/thumb.svg"></img> | 1.47 | 8.14 | 232.2353 | C12H12N2O3 | 0.276 mg/ml | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem] | |
| 120 | Idarubicin | https://www.drugbank.ca/drugs/DB01177 | <img src="https://www.drugbank.ca/structures/DB01177/thumb.svg"></img> | 0.2 | 9.55 | 497.4939 | C26H27NO9 | 0.772 mg/ml | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem] | |
| 121 | Chlormezanone | https://www.drugbank.ca/drugs/DB01178 | <img src="https://www.drugbank.ca/structures/DB01178/thumb.svg"></img> | 1.3 | 19.07 | 273.736 | C11H12ClNO3S | 1.61 mg/ml | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. [PubChem] | |
| 122 | Podofilox | https://www.drugbank.ca/drugs/DB01179 | <img src="https://www.drugbank.ca/structures/DB01179/thumb.svg"></img> | 1.5 | 14.02 | 414.4053 | C22H22O8 | 0.114 mg/ml | A lignan (lignans) found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. [PubChem] | |
| 123 | Rescinnamine | https://www.drugbank.ca/drugs/DB01180 | <img src="https://www.drugbank.ca/structures/DB01180/thumb.svg"></img> | 3.5 | 16.29 | 634.716 | C35H42N2O9 | 0.00349 mg/ml | Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained fromRauwolfia serpentinaand other species ofRauwolfia. [Wikipedia] | |
| 124 | Ifosfamide | https://www.drugbank.ca/drugs/DB01181 | <img src="https://www.drugbank.ca/structures/DB01181/thumb.svg"></img> | 0.86 | 13.24 | 261.086 | C7H15Cl2N2O2P | 15.0 mg/ml | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppresive agent. | |
| 125 | Propafenone | https://www.drugbank.ca/drugs/DB01182 | <img src="https://www.drugbank.ca/structures/DB01182/thumb.svg"></img> | 3.2 | 14.09 | 341.444 | C21H27NO3 | 0.00758 mg/ml | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem] | |
| 126 | Naloxone | https://www.drugbank.ca/drugs/DB01183 | <img src="https://www.drugbank.ca/structures/DB01183/thumb.svg"></img> | 2.09 | 7.27 | 327.3743 | C19H21NO4 | 5.64 mg/ml | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. | |
| 127 | Domperidone | https://www.drugbank.ca/drugs/DB01184 | <img src="https://www.drugbank.ca/structures/DB01184/thumb.svg"></img> | 3.90 | 12.52 | 425.911 | C22H24ClN5O2 | 0.0925 mg/ml | A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem] | |
| 128 | Fluoxymesterone | https://www.drugbank.ca/drugs/DB01185 | <img src="https://www.drugbank.ca/structures/DB01185/thumb.svg"></img> | 2.38 | 13.6 | 336.4409 | C20H29FO3 | 0.0452 mg/ml | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem] | |
| 129 | Pergolide | https://www.drugbank.ca/drugs/DB01186 | <img src="https://www.drugbank.ca/structures/DB01186/thumb.svg"></img> | 4 | 17.35 | 314.488 | C19H26N2S | 0.000584 mg/ml | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. | |
| 130 | Ciclopirox | https://www.drugbank.ca/drugs/DB01188 | <img src="https://www.drugbank.ca/structures/DB01188/thumb.svg"></img> | 2.3 | 6.84 | 207.2689 | C12H17NO2 | 1.41 mg/ml | Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. It is most useful against Tinea versicolor. [Wikipedia] | |
| 131 | Desflurane | https://www.drugbank.ca/drugs/DB01189 | <img src="https://www.drugbank.ca/structures/DB01189/thumb.svg"></img> | 1.9 | 18.87 | 168.0378 | C3H2F6O | 3.54 mg/ml | Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors. | |
| 132 | Clindamycin | https://www.drugbank.ca/drugs/DB01190 | <img src="https://www.drugbank.ca/structures/DB01190/thumb.svg"></img> | 2.16 | 12.16 | 424.983 | C18H33ClN2O5S | 3.1 mg/ml | Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration. | |
| 133 | Oxymorphone | https://www.drugbank.ca/drugs/DB01192 | <img src="https://www.drugbank.ca/structures/DB01192/thumb.svg"></img> | 0.83 | 7.34 | 301.3371 | C17H19NO4 | 25.6 mg/ml | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) | |
| 134 | Acebutolol | https://www.drugbank.ca/drugs/DB01193 | <img src="https://www.drugbank.ca/structures/DB01193/thumb.svg"></img> | 1.71 | 13.91 | 336.4259 | C18H28N2O4 | 0.172 mg/ml | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. [PubChem] | |
| 135 | Brinzolamide | https://www.drugbank.ca/drugs/DB01194 | <img src="https://www.drugbank.ca/structures/DB01194/thumb.svg"></img> | -1.8 | 8.19 | 383.507 | C12H21N3O5S3 | 0.713 mg/ml | Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. | |
| 136 | Flecainide | https://www.drugbank.ca/drugs/DB01195 | <img src="https://www.drugbank.ca/structures/DB01195/thumb.svg"></img> | 3.78 | 13.68 | 414.3427 | C17H20F6N2O3 | 0.0324 mg/ml | A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Paradoxically, however, in myocardial infarct patients with either symptomatic or asymptomatic arrhythmia, flecainide exacerbates the arrhythmia and is not recommended for use in these patients. [PubChem] | |
| 137 | Estramustine | https://www.drugbank.ca/drugs/DB01196 | <img src="https://www.drugbank.ca/structures/DB01196/thumb.svg"></img> | 5.7 | 19.38 | 440.403 | C23H31Cl2NO3 | 0.000385 mg/ml | A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. [PubChem] | |
| 138 | Captopril | https://www.drugbank.ca/drugs/DB01197 | <img src="https://www.drugbank.ca/structures/DB01197/thumb.svg"></img> | 0.34 | 4.02 | 217.285 | C9H15NO3S | 4.52 mg/ml | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. | |
| 139 | Zopiclone | https://www.drugbank.ca/drugs/DB01198 | <img src="https://www.drugbank.ca/structures/DB01198/thumb.svg"></img> | 0.8 | 13.04 | 388.808 | C17H17ClN6O3 | 0.885 mg/ml | Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate like properties. | |
| 140 | Tubocurarine | https://www.drugbank.ca/drugs/DB01199 | <img src="https://www.drugbank.ca/structures/DB01199/thumb.svg"></img> | 3.12 | 6.45 | 609.7312 | C37H41N2O6 | 0.000323 mg/ml | A neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae. [PubChem] | |
| 141 | Bromocriptine | https://www.drugbank.ca/drugs/DB01200 | <img src="https://www.drugbank.ca/structures/DB01200/thumb.svg"></img> | 3.5 | 9.68 | 654.595 | C32H40BrN5O5 | 0.0858 mg/ml | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis. | |
| 142 | Rifapentine | https://www.drugbank.ca/drugs/DB01201 | <img src="https://www.drugbank.ca/structures/DB01201/thumb.svg"></img> | 4 | 7.01 | 877.0307 | C47H64N4O12 | 0.0213 mg/ml | Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. | |
| 143 | Levetiracetam | https://www.drugbank.ca/drugs/DB01202 | <img src="https://www.drugbank.ca/structures/DB01202/thumb.svg"></img> | -0.6 | 16.09 | 170.212 | C8H14N2O2 | 298.0 mg/ml | Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. | |
| 144 | Nadolol | https://www.drugbank.ca/drugs/DB01203 | <img src="https://www.drugbank.ca/structures/DB01203/thumb.svg"></img> | 0.81 | 13.59 | 309.4006 | C17H27NO4 | 2.25 mg/ml | A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem] | |
| 145 | Mitoxantrone | https://www.drugbank.ca/drugs/DB01204 | <img src="https://www.drugbank.ca/structures/DB01204/thumb.svg"></img> | -3.1 | 9.78 | 444.4809 | C22H28N4O6 | 0.734 mg/ml | An anthracenedione-derived antineoplastic agent. [PubChem] | |
| 146 | Lomustine | https://www.drugbank.ca/drugs/DB01206 | <img src="https://www.drugbank.ca/structures/DB01206/thumb.svg"></img> | 2.83 | 13.3 | 233.695 | C9H16ClN3O2 | 0.755 mg/ml | An alkylating agent of value against both hematologic malignancies and solid tumors. [PubChem] | |
| 147 | Ridogrel | https://www.drugbank.ca/drugs/DB01207 | <img src="https://www.drugbank.ca/structures/DB01207/thumb.svg"></img> | 4.3 | 3.5 | 366.3344 | C18H17F3N2O3 | 0.00839 mg/ml | Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin. | |
| 148 | Sparfloxacin | https://www.drugbank.ca/drugs/DB01208 | <img src="https://www.drugbank.ca/structures/DB01208/thumb.svg"></img> | 2.5 | 5.75 | 392.3998 | C19H22F2N4O3 | 0.113 mg/ml | Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | |
| 149 | Dezocine | https://www.drugbank.ca/drugs/DB01209 | <img src="https://www.drugbank.ca/structures/DB01209/thumb.svg"></img> | 3.3 | 10.43 | 245.3599 | C16H23NO | 0.014 mg/ml | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | |
| 150 | Levobunolol | https://www.drugbank.ca/drugs/DB01210 | <img src="https://www.drugbank.ca/structures/DB01210/thumb.svg"></img> | 2.40 | 14.09 | 291.3853 | C17H25NO3 | 0.251 mg/ml | A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma. [PubChem] | |
| 151 | Clarithromycin | https://www.drugbank.ca/drugs/DB01211 | <img src="https://www.drugbank.ca/structures/DB01211/thumb.svg"></img> | 3.16 | 12.46 | 747.9534 | C38H69NO13 | 0.217 mg/ml | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | |
| 152 | Ceftriaxone | https://www.drugbank.ca/drugs/DB01212 | <img src="https://www.drugbank.ca/structures/DB01212/thumb.svg"></img> | -1.7 | 3.19 | 554.58 | C18H18N8O7S3 | 0.105 mg/ml | A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem] | |
| 153 | Fomepizole | https://www.drugbank.ca/drugs/DB01213 | <img src="https://www.drugbank.ca/structures/DB01213/thumb.svg"></img> | 0.9 | 15.82 | 82.1038 | C4H6N2 | 559.0 mg/ml | Fomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites. | |
| 154 | Metipranolol | https://www.drugbank.ca/drugs/DB01214 | <img src="https://www.drugbank.ca/structures/DB01214/thumb.svg"></img> | 2.66 | 14.09 | 309.4006 | C17H27NO4 | 0.173 mg/ml | A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem] | |
| 155 | Estazolam | https://www.drugbank.ca/drugs/DB01215 | <img src="https://www.drugbank.ca/structures/DB01215/thumb.svg"></img> | 4.7 | 18.4 | 294.738 | C16H11ClN4 | 0.0423 mg/ml | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. [PubChem] | |
| 156 | Finasteride | https://www.drugbank.ca/drugs/DB01216 | <img src="https://www.drugbank.ca/structures/DB01216/thumb.svg"></img> | 3.03 | 14.53 | 372.5441 | C23H36N2O2 | 0.00198 mg/ml | An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem] | |
| 157 | Halofantrine | https://www.drugbank.ca/drugs/DB01218 | <img src="https://www.drugbank.ca/structures/DB01218/thumb.svg"></img> | 8.9 | 14.47 | 500.424 | C26H30Cl2F3NO | 0.000111 mg/ml | Halofantrine is a drug used to treat malaria. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity. | |
| 158 | Dantrolene | https://www.drugbank.ca/drugs/DB01219 | <img src="https://www.drugbank.ca/structures/DB01219/thumb.svg"></img> | 1.70 | 9.23 | 314.253 | C14H10N4O5 | 0.0805 mg/ml | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | |
| 159 | Rifaximin | https://www.drugbank.ca/drugs/DB01220 | <img src="https://www.drugbank.ca/structures/DB01220/thumb.svg"></img> | 2.6 | 3.66 | 785.8785 | C43H51N3O11 | 0.00738 mg/ml | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals. | |
| 160 | Ketamine | https://www.drugbank.ca/drugs/DB01221 | <img src="https://www.drugbank.ca/structures/DB01221/thumb.svg"></img> | 2.9 | 18.78 | 237.725 | C13H16ClNO | 0.0464 mg/ml | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. | |
| 161 | Budesonide | https://www.drugbank.ca/drugs/DB01222 | <img src="https://www.drugbank.ca/structures/DB01222/thumb.svg"></img> | 1.9 | 13.74 | 430.5339 | C25H34O6 | 0.0457 mg/ml | Budesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was FDA approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert. | |
| 162 | Quetiapine | https://www.drugbank.ca/drugs/DB01224 | <img src="https://www.drugbank.ca/structures/DB01224/thumb.svg"></img> | 2.8 | 15.12 | 383.507 | C21H25N3O2S | 0.0403 mg/ml | Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor. | |
| 163 | Mivacurium | https://www.drugbank.ca/drugs/DB01226 | <img src="https://www.drugbank.ca/structures/DB01226/thumb.svg"></img> | 3.8 | 18.59 | 1029.2608 | C58H80N2O14 | 3.26e-05 mg/ml | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | |
| 164 | Encainide | https://www.drugbank.ca/drugs/DB01228 | <img src="https://www.drugbank.ca/structures/DB01228/thumb.svg"></img> | 4 | 12.37 | 352.4699 | C22H28N2O2 | 0.00401 mg/ml | All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. | |
| 165 | Paclitaxel | https://www.drugbank.ca/drugs/DB01229 | <img src="https://www.drugbank.ca/structures/DB01229/thumb.svg"></img> | 3 | 10.36 | 853.9061 | C47H51NO14 | 0.00556 mg/ml | Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia] | |
| 166 | Pemoline | https://www.drugbank.ca/drugs/DB01230 | <img src="https://www.drugbank.ca/structures/DB01230/thumb.svg"></img> | 0.7 | 14.95 | 176.172 | C9H8N2O2 | 0.979 mg/ml | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | |
| 167 | Diphenidol | https://www.drugbank.ca/drugs/DB01231 | <img src="https://www.drugbank.ca/structures/DB01231/thumb.svg"></img> | 4.3 | 13.4 | 309.4452 | C21H27NO | 0.00587 mg/ml | Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children. | |
| 168 | Saquinavir | https://www.drugbank.ca/drugs/DB01232 | <img src="https://www.drugbank.ca/structures/DB01232/thumb.svg"></img> | 3.8 | 5.11 | 670.8408 | C38H50N6O5 | 0.00765 mg/ml | An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem] | |
| 169 | Metoclopramide | https://www.drugbank.ca/drugs/DB01233 | <img src="https://www.drugbank.ca/structures/DB01233/thumb.svg"></img> | 2.62 | 14.49 | 299.796 | C14H22ClN3O2 | 0.31 mg/ml | A dopamine D2 antagonist that is used as an antiemetic. [PubChem] | |
| 170 | Dexamethasone | https://www.drugbank.ca/drugs/DB01234 | <img src="https://www.drugbank.ca/structures/DB01234/thumb.svg"></img> | 1.83 | 12.42 | 392.4611 | C22H29FO5 | 0.0505 mg/ml | An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem] | |
| 171 | Levodopa | https://www.drugbank.ca/drugs/DB01235 | <img src="https://www.drugbank.ca/structures/DB01235/thumb.svg"></img> | -2.39 | 1.65 | 197.1879 | C9H11NO4 | 3.3 mg/ml | The naturally occurring form of dihydroxyphenylalanine and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. [PubChem] | |
| 172 | Sevoflurane | https://www.drugbank.ca/drugs/DB01236 | <img src="https://www.drugbank.ca/structures/DB01236/thumb.svg"></img> | 2.4 | 15.07 | 200.0548 | C4H3F7O | 1.48 mg/ml | Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia] | |
| 173 | Aripiprazole | https://www.drugbank.ca/drugs/DB01238 | <img src="https://www.drugbank.ca/structures/DB01238/thumb.svg"></img> | 4.5 | 13.51 | 448.385 | C23H27Cl2N3O2 | 0.00777 mg/ml | Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors. | |
| 174 | Epoprostenol | https://www.drugbank.ca/drugs/DB01240 | <img src="https://www.drugbank.ca/structures/DB01240/thumb.svg"></img> | 3 | 4.43 | 352.4651 | C20H32O5 | 0.136 mg/ml | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | |
| 175 | Gemfibrozil | https://www.drugbank.ca/drugs/DB01241 | <img src="https://www.drugbank.ca/structures/DB01241/thumb.svg"></img> | 3.4 | 4.42 | 250.3334 | C15H22O3 | 0.0278 mg/ml | A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established. [PubChem] | |
| 176 | Chloroxine | https://www.drugbank.ca/drugs/DB01243 | <img src="https://www.drugbank.ca/structures/DB01243/thumb.svg"></img> | 3 | 6.95 | 214.048 | C9H5Cl2NO | 0.138 mg/ml | Chloroxine is a synthetic antibacterial compound. Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp. | |
| 177 | Isocarboxazid | https://www.drugbank.ca/drugs/DB01247 | <img src="https://www.drugbank.ca/structures/DB01247/thumb.svg"></img> | 1.49 | 12.02 | 231.2505 | C12H13N3O2 | 0.224 mg/ml | An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311) | |
| 178 | Docetaxel | https://www.drugbank.ca/drugs/DB01248 | <img src="https://www.drugbank.ca/structures/DB01248/thumb.svg"></img> | 2.4 | 10.96 | 807.8792 | C43H53NO14 | 0.0127 mg/ml | Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules. | |
| 179 | Iodixanol | https://www.drugbank.ca/drugs/DB01249 | <img src="https://www.drugbank.ca/structures/DB01249/thumb.svg"></img> | 0.5 | 11.43 | 1550.1819 | C35H44I6N6O15 | 0.185 mg/ml | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | |
| 180 | Olsalazine | https://www.drugbank.ca/drugs/DB01250 | <img src="https://www.drugbank.ca/structures/DB01250/thumb.svg"></img> | 2.3 | 2.93 | 302.239 | C14H10N2O6 | 0.0781 mg/ml | Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines. | |
| 181 | Gliquidone | https://www.drugbank.ca/drugs/DB01251 | <img src="https://www.drugbank.ca/structures/DB01251/thumb.svg"></img> | 4.5 | 4.32 | 527.632 | C27H33N3O6S | 0.0022 mg/ml | Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release. | |
| 182 | Mitiglinide | https://www.drugbank.ca/drugs/DB01252 | <img src="https://www.drugbank.ca/structures/DB01252/thumb.svg"></img> | 2.9 | 4.62 | 315.413 | C19H25NO3 | 0.0708 mg/ml | Mitiglinide is a drug for the treatment of type 2 diabetes. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells. | |
| 183 | Ergonovine | https://www.drugbank.ca/drugs/DB01253 | <img src="https://www.drugbank.ca/structures/DB01253/thumb.svg"></img> | 0.9 | 15 | 325.4048 | C19H23N3O2 | 0.321 mg/ml | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. [PubChem] | |
| 184 | Dasatinib | https://www.drugbank.ca/drugs/DB01254 | <img src="https://www.drugbank.ca/structures/DB01254/thumb.svg"></img> | 1.8 | 8.49 | 488.006 | C22H26ClN7O2S | 0.0128 mg/ml | Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR. | |
| 185 | Lisdexamfetamine | https://www.drugbank.ca/drugs/DB01255 | <img src="https://www.drugbank.ca/structures/DB01255/thumb.svg"></img> | 1.06 | 15.89 | 263.3785 | C15H25N3O | 0.0877 mg/ml | Lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin. | |
| 186 | Retapamulin | https://www.drugbank.ca/drugs/DB01256 | <img src="https://www.drugbank.ca/structures/DB01256/thumb.svg"></img> | 5 | 14.43 | 517.763 | C30H47NO4S | 0.000394 mg/ml | Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. It is marketed as an ointment under the name brand Altabax. | |
| 187 | Lapatinib | https://www.drugbank.ca/drugs/DB01259 | <img src="https://www.drugbank.ca/structures/DB01259/thumb.svg"></img> | 5.4 | 15.99 | 581.058 | C29H26ClFN4O4S | 0.0223 mg/ml | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | |
| 188 | Desonide | https://www.drugbank.ca/drugs/DB01260 | <img src="https://www.drugbank.ca/structures/DB01260/thumb.svg"></img> | 1.4 | 13.74 | 416.5073 | C24H32O6 | 0.0594 mg/ml | A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem] | |
| 189 | Decitabine | https://www.drugbank.ca/drugs/DB01262 | <img src="https://www.drugbank.ca/structures/DB01262/thumb.svg"></img> | -2 | 13.89 | 228.2053 | C8H12N4O4 | 5.5 mg/ml | Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate. | |
| 190 | Posaconazole | https://www.drugbank.ca/drugs/DB01263 | <img src="https://www.drugbank.ca/structures/DB01263/thumb.svg"></img> | 5.5 | 14.83 | 700.7774 | C37H42F2N8O4 | 0.012 mg/ml | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | |
| 191 | Darunavir | https://www.drugbank.ca/drugs/DB01264 | <img src="https://www.drugbank.ca/structures/DB01264/thumb.svg"></img> | 1.8 | 13.59 | 547.664 | C27H37N3O7S | 0.0668 mg/ml | Darunavir is a protease inhibitor used to treat HIV. It acts on the HIV aspartyl protease which the virus needs to cleave the HIV polyprotein into its functional fragments. | |
| 192 | Telbivudine | https://www.drugbank.ca/drugs/DB01265 | <img src="https://www.drugbank.ca/structures/DB01265/thumb.svg"></img> | -1.4 | 9.96 | 242.2286 | C10H14N2O5 | 66.8 mg/ml | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | |
| 193 | Paliperidone | https://www.drugbank.ca/drugs/DB01267 | <img src="https://www.drugbank.ca/structures/DB01267/thumb.svg"></img> | 1.8 | 13.74 | 426.4839 | C23H27FN4O3 | 0.297 mg/ml | Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. | |
| 194 | Sunitinib | https://www.drugbank.ca/drugs/DB01268 | <img src="https://www.drugbank.ca/structures/DB01268/thumb.svg"></img> | 5.2 | 11.46 | 398.4738 | C22H27FN4O2 | 0.0308 mg/ml | Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | |
| 195 | Arformoterol | https://www.drugbank.ca/drugs/DB01274 | <img src="https://www.drugbank.ca/structures/DB01274/thumb.svg"></img> | 2.2 | 8.61 | 344.4049 | C19H24N2O4 | 0.0416 mg/ml | Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma. | |
| 196 | Hydralazine | https://www.drugbank.ca/drugs/DB01275 | <img src="https://www.drugbank.ca/structures/DB01275/thumb.svg"></img> | 1.00 | 17.69 | 160.1759 | C8H8N4 | 2.61 mg/ml | A direct-acting vasodilator that is used as an antihypertensive agent. [PubChem] | |
| 197 | Nelarabine | https://www.drugbank.ca/drugs/DB01280 | <img src="https://www.drugbank.ca/structures/DB01280/thumb.svg"></img> | -1 | 12.45 | 297.2673 | C11H15N5O5 | 13.9 mg/ml | Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. | |
| 198 | Carbetocin | https://www.drugbank.ca/drugs/DB01282 | <img src="https://www.drugbank.ca/structures/DB01282/thumb.svg"></img> | -2 | 11.42 | 988.161 | C45H69N11O12S | 0.0265 mg/ml | Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus. | |
| 199 | Lumiracoxib | https://www.drugbank.ca/drugs/DB01283 | <img src="https://www.drugbank.ca/structures/DB01283/thumb.svg"></img> | 3.9 | 4.11 | 293.721 | C15H13ClFNO2 | 0.00549 mg/ml | Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug. | |
| 200 | Tetracosactide | https://www.drugbank.ca/drugs/DB01284 | <img src="https://www.drugbank.ca/structures/DB01284/thumb.svg"></img> | -0.95 | 3.03 | 2933.49 | C136H210N40O31S | 0.0481 mg/ml | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | |
| 201 | Fenoterol | https://www.drugbank.ca/drugs/DB01288 | <img src="https://www.drugbank.ca/structures/DB01288/thumb.svg"></img> | 1.36 | 8.85 | 303.3529 | C17H21NO4 | 0.162 mg/ml | An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem] | |
| 202 | Glisoxepide | https://www.drugbank.ca/drugs/DB01289 | <img src="https://www.drugbank.ca/structures/DB01289/thumb.svg"></img> | 1.57 | 4.07 | 449.524 | C20H27N5O5S | 0.103 mg/ml | Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and by sulphate. These results are consistent with the transport of glisoxepide via the transport system for the unconjugated bile acid cholate. (PMID:1618280, 9017793) | |
| 203 | Pirbuterol | https://www.drugbank.ca/drugs/DB01291 | <img src="https://www.drugbank.ca/structures/DB01291/thumb.svg"></img> | 0.38 | 8.79 | 240.2988 | C12H20N2O3 | 6.22 mg/ml | Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. | |
| 204 | Bismuth Subsalicylate | https://www.drugbank.ca/drugs/DB01294 | <img src="https://www.drugbank.ca/structures/DB01294/thumb.svg"></img> | 0.37 | 14.3 | 362.0926 | C7H5BiO4 | 59.7 mg/ml | Bismuth subsalicylate is the active ingredient in the popular medication Pepto-Bismol that is used to treat nausea, heartburn, indigestion, upset stomach, diarrhea, and other temporary discomforts of the stomach and gastrointestinal tract. It is also the main ingredient of Kaopectate. It displays anti-inflammatory action (due to salicylic acid) and also acts as an antacid and mild antibiotic. | |
| 205 | Bevantolol | https://www.drugbank.ca/drugs/DB01295 | <img src="https://www.drugbank.ca/structures/DB01295/thumb.svg"></img> | 3.00 | 14.09 | 345.4327 | C20H27NO4 | 0.0137 mg/ml | Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. | |
| 206 | Glucosamine | https://www.drugbank.ca/drugs/DB01296 | <img src="https://www.drugbank.ca/structures/DB01296/thumb.svg"></img> | -2.7 | 11.73 | 179.1711 | C6H13NO5 | 551.0 mg/ml | Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies. It is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. | |
| 207 | Practolol | https://www.drugbank.ca/drugs/DB01297 | <img src="https://www.drugbank.ca/structures/DB01297/thumb.svg"></img> | 0.79 | 14.03 | 266.3361 | C14H22N2O3 | 0.49 mg/ml | A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. [PubChem] | |
| 208 | Sulfacytine | https://www.drugbank.ca/drugs/DB01298 | <img src="https://www.drugbank.ca/structures/DB01298/thumb.svg"></img> | 0.51 | 10.55 | 294.33 | C12H14N4O3S | 0.468 mg/ml | Sulfacytine is a short-acting sulfonamide. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. | |
| 209 | Sulfadoxine | https://www.drugbank.ca/drugs/DB01299 | <img src="https://www.drugbank.ca/structures/DB01299/thumb.svg"></img> | 0.70 | 6.12 | 310.329 | C12H14N4O4S | 0.296 mg/ml | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. [PubChem] | |
| 210 | Rolitetracycline | https://www.drugbank.ca/drugs/DB01301 | <img src="https://www.drugbank.ca/structures/DB01301/thumb.svg"></img> | -0.08 | 0.31 | 527.5662 | C27H33N3O8 | 1.81 mg/ml | A pyrrolidinylmethyl tetracycline. [PubChem] | |
| 211 | Oxtriphylline | https://www.drugbank.ca/drugs/DB01303 | <img src="https://www.drugbank.ca/structures/DB01303/thumb.svg"></img> | -0.99 | 7.82 | 283.3268 | C12H21N5O3 | 3.84 mg/ml | Oxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). It is marketed under the name Choledyl SA, and several forms of oxytriphylline have been discontinued. In the US, oxtriphylline is no longer available. | |
| 212 | Fosamprenavir | https://www.drugbank.ca/drugs/DB01319 | <img src="https://www.drugbank.ca/structures/DB01319/thumb.svg"></img> | 0.84 | 1.22 | 585.607 | C25H36N3O9PS | 0.685 mg/ml | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | |
| 213 | Fosphenytoin | https://www.drugbank.ca/drugs/DB01320 | <img src="https://www.drugbank.ca/structures/DB01320/thumb.svg"></img> | 1.08 | 1.46 | 362.2739 | C16H15N2O6P | 0.145 mg/ml | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | |
| 214 | Josamycin | https://www.drugbank.ca/drugs/DB01321 | <img src="https://www.drugbank.ca/structures/DB01321/thumb.svg"></img> | 3.47 | 12.67 | 827.995 | C42H69NO15 | 0.0535 mg/ml | A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens. [PubChem] | |
| 215 | Kava | https://www.drugbank.ca/drugs/DB01322 | <img src="https://www.drugbank.ca/structures/DB01322/thumb.svg"></img> | 2.74 | 16.55 | 232.275 | C14H16O3 | 0.0632 mg/ml | Not Available | |
| 216 | Polythiazide | https://www.drugbank.ca/drugs/DB01324 | <img src="https://www.drugbank.ca/structures/DB01324/thumb.svg"></img> | 1.90 | 9.31 | 439.882 | C11H13ClF3N3O4S3 | 0.264 mg/ml | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | |
| 217 | Quinethazone | https://www.drugbank.ca/drugs/DB01325 | <img src="https://www.drugbank.ca/structures/DB01325/thumb.svg"></img> | 1.6 | 9.56 | 289.739 | C10H12ClN3O3S | 2.51 mg/ml | Quinethazone (INN, brand name Hydromox) is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels. | |
| 218 | Cefamandole | https://www.drugbank.ca/drugs/DB01326 | <img src="https://www.drugbank.ca/structures/DB01326/thumb.svg"></img> | 0.50 | 3.32 | 462.503 | C18H18N6O5S2 | 0.581 mg/ml | Cefamandole (INN, also known as cephamandole) is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally. Cefamandole is no longer available in the United States. | |
| 219 | Cefazolin | https://www.drugbank.ca/drugs/DB01327 | <img src="https://www.drugbank.ca/structures/DB01327/thumb.svg"></img> | -0.58 | 3.03 | 454.507 | C14H14N8O4S3 | 0.487 mg/ml | A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. [PubChem] | |
| 220 | Cefonicid | https://www.drugbank.ca/drugs/DB01328 | <img src="https://www.drugbank.ca/structures/DB01328/thumb.svg"></img> | -0.71 | -1.4 | 542.566 | C18H18N6O8S3 | 0.895 mg/ml | A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. [PubChem] | |
| 221 | Cefoperazone | https://www.drugbank.ca/drugs/DB01329 | <img src="https://www.drugbank.ca/structures/DB01329/thumb.svg"></img> | -0.74 | 3.38 | 645.667 | C25H27N9O8S2 | 0.286 mg/ml | Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially againstPseudomonasinfections. | |
| 222 | Cefotetan | https://www.drugbank.ca/drugs/DB01330 | <img src="https://www.drugbank.ca/structures/DB01330/thumb.svg"></img> | -0.65 | 3.23 | 575.619 | C17H17N7O8S4 | 0.521 mg/ml | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem] | |
| 223 | Cefoxitin | https://www.drugbank.ca/drugs/DB01331 | <img src="https://www.drugbank.ca/structures/DB01331/thumb.svg"></img> | -0.02 | 3.59 | 427.452 | C16H17N3O7S2 | 0.195 mg/ml | Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced byStreptomyces lactamdurans. | |
| 224 | Ceftizoxime | https://www.drugbank.ca/drugs/DB01332 | <img src="https://www.drugbank.ca/structures/DB01332/thumb.svg"></img> | 0.4 | 3.13 | 383.403 | C13H13N5O5S2 | 0.229 mg/ml | A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. [PubChem] | |
| 225 | Cefradine | https://www.drugbank.ca/drugs/DB01333 | <img src="https://www.drugbank.ca/structures/DB01333/thumb.svg"></img> | 0.7 | 3.46 | 349.405 | C16H19N3O4S | 0.778 mg/ml | A semi-synthetic cephalosporin antibiotic. [PubChem] | |
| 226 | Doxacurium chloride | https://www.drugbank.ca/drugs/DB01334 | <img src="https://www.drugbank.ca/structures/DB01135/thumb.svg"></img> | 3.82 | 18.41 | 1106.14 | C56H78Cl2N2O16 | 8.54e-05 mg/ml | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | |
| 227 | Metocurine | https://www.drugbank.ca/drugs/DB01336 | <img src="https://www.drugbank.ca/structures/DB01336/thumb.svg"></img> | 2.36 | 12.99 | 652.8189 | C40H48N2O6 | 6.42e-06 mg/ml | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.(PMID: 9915319) | |
| 228 | Cilazapril | https://www.drugbank.ca/drugs/DB01340 | <img src="https://www.drugbank.ca/structures/DB01340/thumb.svg"></img> | 0.8 | 3.41 | 417.4986 | C22H31N3O5 | 1.06 mg/ml | Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. | |
| 229 | Forasartan | https://www.drugbank.ca/drugs/DB01342 | <img src="https://www.drugbank.ca/structures/DB01342/thumb.svg"></img> | 4.51 | 7.35 | 416.522 | C23H28N8 | 0.00667 mg/ml | Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. | |
| 230 | Saprisartan | https://www.drugbank.ca/drugs/DB01347 | <img src="https://www.drugbank.ca/structures/DB01347/thumb.svg"></img> | 5.89 | 2.27 | 611.431 | C25H22BrF3N4O4S | 0.0151 mg/ml | Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism[1]. | |
| 231 | Spirapril | https://www.drugbank.ca/drugs/DB01348 | <img src="https://www.drugbank.ca/structures/DB01348/thumb.svg"></img> | 1.79 | 3.62 | 466.614 | C22H30N2O5S2 | 0.0293 mg/ml | Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure. | |
| 232 | Tasosartan | https://www.drugbank.ca/drugs/DB01349 | <img src="https://www.drugbank.ca/structures/DB01349/thumb.svg"></img> | 3.07 | 7.4 | 411.4591 | C23H21N7O | 0.0325 mg/ml | Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension | |
| 233 | Amobarbital | https://www.drugbank.ca/drugs/DB01351 | <img src="https://www.drugbank.ca/structures/DB01351/thumb.svg"></img> | 2.07 | 8.48 | 226.2722 | C11H18N2O3 | 0.897 mg/ml | A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) | |
| 234 | Aprobarbital | https://www.drugbank.ca/drugs/DB01352 | <img src="https://www.drugbank.ca/structures/DB01352/thumb.svg"></img> | 1.15 | 8.48 | 210.2298 | C10H14N2O3 | 5.17 mg/ml | Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed. | |
| 235 | Butethal | https://www.drugbank.ca/drugs/DB01353 | <img src="https://www.drugbank.ca/structures/DB01353/thumb.svg"></img> | 1.73 | 8.48 | 212.2456 | C10H16N2O3 | 1.27 mg/ml | Butethal is a sedative and a hypnotic drug. | |
| 236 | Heptabarbital | https://www.drugbank.ca/drugs/DB01354 | <img src="https://www.drugbank.ca/structures/DB01354/thumb.svg"></img> | 2.03 | 8.14 | 250.2936 | C13H18N2O3 | 0.324 mg/ml | Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis. | |
| 237 | Hexobarbital | https://www.drugbank.ca/drugs/DB01355 | <img src="https://www.drugbank.ca/structures/DB01355/thumb.svg"></img> | 1.98 | 8.41 | 236.267 | C12H16N2O3 | 1.51 mg/ml | A barbiturate that is effective as a hypnotic and sedative. | |
| 238 | Mestranol | https://www.drugbank.ca/drugs/DB01357 | <img src="https://www.drugbank.ca/structures/DB01357/thumb.svg"></img> | 3.89 | 17.59 | 310.4299 | C21H26O2 | 0.00377 mg/ml | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. [PubChem] | |
| 239 | Penbutolol | https://www.drugbank.ca/drugs/DB01359 | <img src="https://www.drugbank.ca/structures/DB01359/thumb.svg"></img> | 4.15 | 14.09 | 291.4284 | C18H29NO2 | 0.0212 mg/ml | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. | |
| 240 | Troleandomycin | https://www.drugbank.ca/drugs/DB01361 | <img src="https://www.drugbank.ca/structures/DB01361/thumb.svg"></img> | 3.76 | 16.75 | 813.9684 | C41H67NO15 | 0.0192 mg/ml | A macrolide antibiotic that is similar to erythromycin. | |
| 241 | Iohexol | https://www.drugbank.ca/drugs/DB01362 | <img src="https://www.drugbank.ca/structures/DB01362/thumb.svg"></img> | -3.05 | 11.73 | 821.1379 | C19H26I3N3O9 | 0.796 mg/ml | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. [PubChem] | |
| 242 | Ephedrine | https://www.drugbank.ca/drugs/DB01364 | <img src="https://www.drugbank.ca/structures/DB01364/thumb.svg"></img> | 1.13 | 13.89 | 165.2322 | C10H15NO | 8.26 mg/ml | An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. [PubChem] | |
| 243 | Procaterol | https://www.drugbank.ca/drugs/DB01366 | <img src="https://www.drugbank.ca/structures/DB01366/thumb.svg"></img> | 1.28 | 8.52 | 290.3575 | C16H22N2O3 | 0.329 mg/ml | A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation. [PubChem] | |
| 244 | Quinupristin | https://www.drugbank.ca/drugs/DB01369 | <img src="https://www.drugbank.ca/structures/DB01369/thumb.svg"></img> | 2.99 | 7.45 | 1022.23 | C53H67N9O10S | 0.0445 mg/ml | Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone. | |
| 245 | Aluminium monostearate | https://www.drugbank.ca/drugs/DB01375 | <img src="https://www.drugbank.ca/structures/DB01375/thumb.svg"></img> | -1.85 | 14.62 | 344.472 | C18H37AlO4 | 0.000685 mg/ml | Aluminium monostearate is an organic compound which is a salt of stearic acid and aluminium. It has the molecular formula Al(OH)2C18H35O2. It is also referred to as dihydroxyaluminium or dihydroxy(stearato)aluminium. It is used to form gels in the packaging of pharmaceuticals, and in the preparation of colors for cosmetics. It is usually safe in commercial products, but aluminium may accumulate in the body. | |
| 246 | Cortisone acetate | https://www.drugbank.ca/drugs/DB01380 | <img src="https://www.drugbank.ca/structures/DB01380/thumb.svg"></img> | 2.10 | 12.6 | 402.4807 | C23H30O6 | 0.0278 mg/ml | Cortisone acetate is a steroid hormone that has both glucocoriticoid and mineral corticoid activities. Corticosteroids are used to provide relief for inflamed areas of the body. They lessen swelling, redness, itching, and allergic reactions. They are often used as part of the treatment for a number of different diseases, such as severe allergies or skin problems, asthma, or arthritis. Endogenous glucocorticoids and some synthetic corticoids have high affinity to the protein transcortin (also called CBG, corticosteroid-binding protein), whereas all of them bind albumin. Glucocorticoids also bind to the cytosolic glucocorticoid receptor. | |
| 247 | Glycodiazine | https://www.drugbank.ca/drugs/DB01382 | <img src="https://www.drugbank.ca/structures/DB01382/thumb.svg"></img> | 1.27 | 6.92 | 309.341 | C13H15N3O4S | 0.124 mg/ml | Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. | |
| 248 | Paramethasone | https://www.drugbank.ca/drugs/DB01384 | <img src="https://www.drugbank.ca/structures/DB01384/thumb.svg"></img> | 1.51 | 12.45 | 392.4611 | C22H29FO5 | 0.145 mg/ml | A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737) | |
| 249 | Mibefradil | https://www.drugbank.ca/drugs/DB01388 | <img src="https://www.drugbank.ca/structures/DB01388/thumb.svg"></img> | 5.34 | 12.54 | 495.6287 | C29H38FN3O3 | 0.00104 mg/ml | Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs. | |
| 250 | Sodium bicarbonate | https://www.drugbank.ca/drugs/DB01390 | <img src="https://www.drugbank.ca/structures/DB01390/thumb.svg"></img> | -0.06 | 6.05 | 84.0066 | CHNaO3 | 764.0 mg/ml | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | |
| 251 | Yohimbine | https://www.drugbank.ca/drugs/DB01392 | <img src="https://www.drugbank.ca/structures/DB01392/thumb.svg"></img> | 2.73 | 14.68 | 354.4427 | C21H26N2O3 | 0.348 mg/ml | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] | |
| 252 | Bezafibrate | https://www.drugbank.ca/drugs/DB01393 | <img src="https://www.drugbank.ca/structures/DB01393/thumb.svg"></img> | 3.97 | 3.83 | 361.819 | C19H20ClNO4 | 0.00155 mg/ml | Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. [PubChem] | |
| 253 | Colchicine | https://www.drugbank.ca/drugs/DB01394 | <img src="https://www.drugbank.ca/structures/DB01394/thumb.svg"></img> | 1.30 | 15.06 | 399.437 | C22H25NO6 | 0.0276 mg/ml | A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (periodic disease). [PubChem] | |
| 254 | Digitoxin | https://www.drugbank.ca/drugs/DB01396 | <img src="https://www.drugbank.ca/structures/DB01396/thumb.svg"></img> | 1.85 | 7.18 | 764.9391 | C41H64O13 | 0.0289 mg/ml | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | |
| 255 | Magnesium salicylate | https://www.drugbank.ca/drugs/DB01397 | <img src="https://www.drugbank.ca/structures/DB01397/thumb.svg"></img> | 2.86 | 2.79 | 298.531 | C14H10MgO6 | 0.0686 mg/ml | Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis. It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results. | |
| 256 | Salicylic acid | https://www.drugbank.ca/drugs/DB01398 | <img src="https://www.drugbank.ca/structures/DB00936/thumb.svg"></img> | 2.26 | 2.79 | 138.1207 | C7H6O3 | 11.3 mg/ml | A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics. | |
| 257 | Salsalate | https://www.drugbank.ca/drugs/DB01399 | <img src="https://www.drugbank.ca/structures/DB01399/thumb.svg"></img> | 3.44 | 3.4 | 258.2262 | C14H10O5 | 0.246 mg/ml | Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. | |
| 258 | Bismuth Subsalicylate | https://www.drugbank.ca/drugs/DB01402 | <img src="https://www.drugbank.ca/structures/DB01294/thumb.svg"></img> | 0.37 | 14.3 | 362.0926 | C7H5BiO4 | 59.7 mg/ml | Bismuth subsalicylate is the active ingredient in the popular medication Pepto-Bismol that is used to treat nausea, heartburn, indigestion, upset stomach, diarrhea, and other temporary discomforts of the stomach and gastrointestinal tract. It is also the main ingredient of Kaopectate. It displays anti-inflammatory action (due to salicylic acid) and also acts as an antacid and mild antibiotic. | |
| 259 | Temafloxacin | https://www.drugbank.ca/drugs/DB01405 | <img src="https://www.drugbank.ca/structures/DB01405/thumb.svg"></img> | -0.20 | 5.6 | 417.3811 | C21H18F3N3O3 | 0.0144 mg/ml | Temafloxacin is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths. [Wikipedia] | |
| 260 | Danazol | https://www.drugbank.ca/drugs/DB01406 | <img src="https://www.drugbank.ca/structures/DB01406/thumb.svg"></img> | 0.51 | 17.59 | 337.4553 | C22H27NO2 | 0.0176 mg/ml | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [PubChem] | |
| 261 | Clenbuterol | https://www.drugbank.ca/drugs/DB01407 | <img src="https://www.drugbank.ca/structures/DB01407/thumb.svg"></img> | 2.94 | 14.06 | 277.19 | C12H18Cl2N2O | 0.112 mg/ml | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] | |
| 262 | Bambuterol | https://www.drugbank.ca/drugs/DB01408 | <img src="https://www.drugbank.ca/structures/DB01408/thumb.svg"></img> | 1.69 | 13.91 | 367.44 | C18H29N3O5 | 0.469 mg/ml | Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline. | |
| 263 | Tiotropium | https://www.drugbank.ca/drugs/DB01409 | <img src="https://www.drugbank.ca/structures/DB01409/thumb.svg"></img> | -0.55 | 10.35 | 392.512 | C19H22NO4S2 | 0.0156 mg/ml | Tiotropium is a long-acting, 24 hour, anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD). Tiotropium is a muscarinic receptor antagonist, on topical application it acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation, thus producing a bronchodilatory effect. | |
| 264 | Ciclesonide | https://www.drugbank.ca/drugs/DB01410 | <img src="https://www.drugbank.ca/structures/DB01410/thumb.svg"></img> | 4.08 | 14.78 | 540.697 | C32H44O7 | 0.00157 mg/ml | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | |
| 265 | Pranlukast | https://www.drugbank.ca/drugs/DB01411 | <img src="https://www.drugbank.ca/structures/DB01411/thumb.svg"></img> | 4.82 | 6.86 | 481.512 | C27H23N5O4 | 0.0032 mg/ml | Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. | |
| 266 | Theobromine | https://www.drugbank.ca/drugs/DB01412 | <img src="https://www.drugbank.ca/structures/DB01412/thumb.svg"></img> | -0.78 | 9.28 | 180.164 | C7H8N4O2 | 9.74 mg/ml | 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than theophylline and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9) | |
| 267 | Cefepime | https://www.drugbank.ca/drugs/DB01413 | <img src="https://www.drugbank.ca/structures/DB01413/thumb.svg"></img> | -0.37 | 3.25 | 480.561 | C19H24N6O5S2 | 0.0173 mg/ml | Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia. | |
| 268 | Cefacetrile | https://www.drugbank.ca/drugs/DB01414 | <img src="https://www.drugbank.ca/structures/DB01414/thumb.svg"></img> | -0.45 | 3.31 | 339.324 | C13H13N3O6S | 2.43 mg/ml | A derivative of 7-aminocephalosporanic acid. | |
| 269 | Ceftibuten | https://www.drugbank.ca/drugs/DB01415 | <img src="https://www.drugbank.ca/structures/DB01415/thumb.svg"></img> | 0.31 | 2.99 | 410.425 | C15H14N4O6S2 | 0.0705 mg/ml | Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent. Cefalexin is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. | |
| 270 | Cefpodoxime | https://www.drugbank.ca/drugs/DB01416 | <img src="https://www.drugbank.ca/structures/DB01416/thumb.svg"></img> | 0.05 | 3.22 | 427.455 | C15H17N5O6S2 | 0.185 mg/ml | Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | |
| 271 | Acenocoumarol | https://www.drugbank.ca/drugs/DB01418 | <img src="https://www.drugbank.ca/structures/DB01418/thumb.svg"></img> | 1.98 | 5.79 | 353.3255 | C19H15NO6 | 0.0106 mg/ml | Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, XI and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood. | |
| 272 | Antrafenine | https://www.drugbank.ca/drugs/DB01419 | <img src="https://www.drugbank.ca/structures/DB01419/thumb.svg"></img> | 6.3 | 16.69 | 588.5435 | C30H26F6N4O2 | 0.00284 mg/ml | Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs. | |
| 273 | Testosterone Propionate | https://www.drugbank.ca/drugs/DB01420 | <img src="https://www.drugbank.ca/structures/DB01420/thumb.svg"></img> | 3.65 | 19.09 | 344.4877 | C22H32O3 | 0.00502 mg/ml | An ester of testosterone with a propionate substitution at the 17-beta position. [PubChem] | |
| 274 | Paromomycin | https://www.drugbank.ca/drugs/DB01421 | <img src="https://www.drugbank.ca/structures/DB01421/thumb.svg"></img> | -2.9 | 12.23 | 615.6285 | C23H45N5O14 | 79.7 mg/ml | An oligosaccharide antibiotic produced by various streptomyces. [PubChem] | |
| 275 | Nitroxoline | https://www.drugbank.ca/drugs/DB01422 | <img src="https://www.drugbank.ca/structures/DB01422/thumb.svg"></img> | 1.99 | 6.88 | 190.1555 | C9H6N2O3 | 2.73 mg/ml | Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a fluorquinolone that is active against bacterial gyrases. | |
| 276 | Stepronin | https://www.drugbank.ca/drugs/DB01423 | <img src="https://www.drugbank.ca/structures/DB01423/thumb.svg"></img> | 1.29 | 3.56 | 273.329 | C10H11NO4S2 | 0.211 mg/ml | Strepronin is a mucolytic drug. A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties. The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA. | |
| 277 | Alizapride | https://www.drugbank.ca/drugs/DB01425 | <img src="https://www.drugbank.ca/structures/DB01425/thumb.svg"></img> | 1.79 | 8.86 | 315.3702 | C16H21N5O2 | 0.495 mg/ml | Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. | |
| 278 | Ajmaline | https://www.drugbank.ca/drugs/DB01426 | <img src="https://www.drugbank.ca/structures/DB01426/thumb.svg"></img> | 1.81 | 13.28 | 326.4326 | C20H26N2O2 | 4.09 mg/ml | An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. Ajmaline produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation. | |
| 279 | Amrinone | https://www.drugbank.ca/drugs/DB01427 | <img src="https://www.drugbank.ca/structures/DB01427/thumb.svg"></img> | 0.27 | 11.01 | 187.198 | C10H9N3O | 5.6 mg/ml | Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure. | |
| 280 | Oxybenzone | https://www.drugbank.ca/drugs/DB01428 | <img src="https://www.drugbank.ca/structures/DB01428/thumb.svg"></img> | 3.79 | 8.07 | 228.2433 | C14H12O3 | 0.128 mg/ml | Oxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays. | |
| 281 | Almitrine | https://www.drugbank.ca/drugs/DB01430 | <img src="https://www.drugbank.ca/structures/DB01430/thumb.svg"></img> | 4.9 | 14.27 | 477.5522 | C26H29F2N7 | 0.0144 mg/ml | A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. [PubChem] | |
| 282 | 19-norandrostenedione | https://www.drugbank.ca/drugs/DB01434 | <img src="https://www.drugbank.ca/structures/DB01434/thumb.svg"></img> | 2.53 | 19.19 | 272.382 | C18H24O2 | 0.0454 mg/ml | 19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone. | |
| 283 | Alfacalcidol | https://www.drugbank.ca/drugs/DB01436 | <img src="https://www.drugbank.ca/structures/DB01436/thumb.svg"></img> | 6.68 | 14.39 | 400.6371 | C27H44O2 | 0.00163 mg/ml | Alfacalcidol is an active metabolite of Vitamin D, which performs important functions in regulation of the calcium balance and the bone metabolism. Alfacalcidol is Vitamin D-hormone analog which is activated by the enzyme 25-hydroxylase in the liver for systemic and in osteoblasts for local D-hormone actions. It possesses a unique pattern of pleiotropic effects on, e.g. gut, bone, pararthyroids, muscle and brain. Alfacalcidol is superior to plain vitamin D (cholecalciferol) because the final kidney activation of the latter is regulated by a negative feedback mechanism. (PMID:17438884,17668216) | |
| 284 | Glutethimide | https://www.drugbank.ca/drugs/DB01437 | <img src="https://www.drugbank.ca/structures/DB01437/thumb.svg"></img> | 1.90 | 11.69 | 217.2637 | C13H15NO2 | 0.327 mg/ml | A hypnotic and sedative. Its use has been largely superseded by other drugs. [PubChem] | |
| 285 | Phenazopyridine | https://www.drugbank.ca/drugs/DB01438 | <img src="https://www.drugbank.ca/structures/DB01438/thumb.svg"></img> | 2.31 | 18.85 | 213.2385 | C11H11N5 | 0.202 mg/ml | A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. [PubChem] | |
| 286 | Gamma Hydroxybutyric Acid | https://www.drugbank.ca/drugs/DB01440 | <img src="https://www.drugbank.ca/structures/DB01440/thumb.svg"></img> | -0.6 | 4.44 | 103.0966 | C4H7O3 | 711.0 mg/ml | Gamma Hydroxybutyric Acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy. | |
| 287 | 5-Methoxy-N,N-diisopropyltryptamine | https://www.drugbank.ca/drugs/DB01441 | <img src="https://www.drugbank.ca/structures/DB01441/thumb.svg"></img> | 4.35 | 17.44 | 274.4011 | C17H26N2O | 0.0673 mg/ml | 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects. | |
| 288 | Bufotenine | https://www.drugbank.ca/drugs/DB01445 | <img src="https://www.drugbank.ca/structures/DB01445/thumb.svg"></img> | 2.04 | 9.23 | 204.2682 | C12H16N2O | 3.2 mg/ml | A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic. | |
| 289 | Alpha-methyltryptamine | https://www.drugbank.ca/drugs/DB01446 | <img src="https://www.drugbank.ca/structures/DB01446/thumb.svg"></img> | 2 | 17.14 | 174.2423 | C11H14N2 | 1.15 mg/ml | A stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, alpha-methyltryptamine became regulated as a Schedule I controlled substance in the United states. | |
| 290 | Dihydroetorphine | https://www.drugbank.ca/drugs/DB01450 | <img src="https://www.drugbank.ca/structures/DB01450/thumb.svg"></img> | 2.98 | 7.5 | 413.5497 | C25H35NO4 | 0.114 mg/ml | Not Available | |
| 291 | Beta-hydroxyfentanyl | https://www.drugbank.ca/drugs/DB01453 | <img src="https://www.drugbank.ca/structures/DB01453/thumb.svg"></img> | 2.96 | 14.11 | 352.4699 | C22H28N2O2 | 0.114 mg/ml | Not Available | |
| 292 | 5-androstenedione | https://www.drugbank.ca/drugs/DB01456 | <img src="https://www.drugbank.ca/structures/DB01456/thumb.svg"></img> | 3.21 | 16.23 | 286.415 | C19H26O2 | 0.0366 mg/ml | 5-androstenedione is a prohormone of testosterone. In the United States, the Controlled Substance Act is inclusive to anabolic steroids and their precursors. Thus 5-androstenedione is a controlled substance. The World Anti-Doping Agency also prohibits use of 5-androstenedione in athletes. 5-androstenedione is structurally similar to 4-androstenedione, with the exception of the positioning of a carbon-carbon double bond. 4-Androstenedione is a prohormone which is naturally produced in the body by the adrenal glands and gonads, and acts as precursor to testosterone, as well as estrone and estradiol. [Wikipedia] | |
| 293 | Diethyltryptamine | https://www.drugbank.ca/drugs/DB01460 | <img src="https://www.drugbank.ca/structures/DB01460/thumb.svg"></img> | 3.64 | 17.16 | 216.322 | C14H20N2 | 0.353 mg/ml | Diethyltryptamine (DET) is an orally active hallucinogenic drug and psychedelic compound of moderate duration. DET is a substituted tryptamine, structurally similar to DMT and dipropyltryptamine (DPT). [Wikipedia] | |
| 294 | Ethylmorphine | https://www.drugbank.ca/drugs/DB01466 | <img src="https://www.drugbank.ca/structures/DB01466/thumb.svg"></img> | 1.72 | 13.78 | 313.3908 | C19H23NO3 | 0.835 mg/ml | A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). | |
| 295 | Acetorphine | https://www.drugbank.ca/drugs/DB01469 | <img src="https://www.drugbank.ca/structures/DB01469/thumb.svg"></img> | 3.59 | 14.68 | 453.579 | C27H35NO5 | 0.0197 mg/ml | Not Available | |
| 296 | Bolasterone | https://www.drugbank.ca/drugs/DB01471 | <img src="https://www.drugbank.ca/structures/DB01471/thumb.svg"></img> | 3.55 | 19.56 | 316.4776 | C21H32O2 | 0.0112 mg/ml | Not Available | |
| 297 | Haloxazolam | https://www.drugbank.ca/drugs/DB01476 | <img src="https://www.drugbank.ca/structures/DB01476/thumb.svg"></img> | 2.98 | 12.68 | 377.208 | C17H14BrFN2O2 | 0.0308 mg/ml | Not Available | |
| 298 | Codeine methylbromide | https://www.drugbank.ca/drugs/DB01477 | <img src="https://www.drugbank.ca/structures/DB01477/thumb.svg"></img> | -1.9 | 13.78 | 394.303 | C19H24BrNO3 | 0.000959 mg/ml | Not Available | |
| 299 | Cyprenorphine | https://www.drugbank.ca/drugs/DB01480 | <img src="https://www.drugbank.ca/structures/DB01480/thumb.svg"></img> | 3.33 | 10.35 | 423.553 | C26H33NO4 | 0.0582 mg/ml | Not Available | |
| 300 | Delta1-dihydrotestosterone | https://www.drugbank.ca/drugs/DB01481 | <img src="https://www.drugbank.ca/structures/DB01481/thumb.svg"></img> | 3.38 | 19.38 | 288.4244 | C19H28O2 | 0.0128 mg/ml | Delta1-dihydrotestosterone is an anabolic steroid that differs from testosterone by having a 1,2-double bond instead of 4,5-double bond in its A ring. [Wikipedia] | |
| 301 | Barbital | https://www.drugbank.ca/drugs/DB01483 | <img src="https://www.drugbank.ca/structures/DB01483/thumb.svg"></img> | 0.65 | 8.48 | 184.1925 | C8H12N2O3 | 3.23 mg/ml | A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug. | |
| 302 | Cathine | https://www.drugbank.ca/drugs/DB01486 | <img src="https://www.drugbank.ca/structures/DB01486/thumb.svg"></img> | 0.83 | 13.9 | 151.2056 | C9H13NO | 20.6 mg/ml | Cathine (β-hydroxyamphetamine) is a monoamine alkaloid found in the shrub Catha edulis (khat). Cathine is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, it is classified as a Schedule IV controlled substance. [Wikipedia] | |
| 303 | Embutramide | https://www.drugbank.ca/drugs/DB01487 | <img src="https://www.drugbank.ca/structures/DB01487/thumb.svg"></img> | 2.98 | 15.63 | 293.4012 | C17H27NO3 | 0.0417 mg/ml | Not Available | |
| 304 | Dimethyltryptamine | https://www.drugbank.ca/drugs/DB01488 | <img src="https://www.drugbank.ca/structures/DB01488/thumb.svg"></img> | 2.41 | 17.16 | 188.2688 | C12H16N2 | 1.69 mg/ml | An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others. [PubChem] | |
| 305 | Aminorex | https://www.drugbank.ca/drugs/DB01490 | <img src="https://www.drugbank.ca/structures/DB01490/thumb.svg"></img> | 1.16 | 19.48 | 162.1885 | C9H10N2O | 0.792 mg/ml | An amphetamine-like anorectic agent. It may cause pulmonary hypertension. [PubChem] | |
| 306 | Dipipanone | https://www.drugbank.ca/drugs/DB01491 | <img src="https://www.drugbank.ca/structures/DB01491/thumb.svg"></img> | 5.28 | 18.77 | 349.509 | C24H31NO | 0.000757 mg/ml | Not Available | |
| 307 | Barbituric acid derivative | https://www.drugbank.ca/drugs/DB01496 | <img src="https://www.drugbank.ca/structures/DB01496/thumb.svg"></img> | 3.19 | 3.41 | 368.33 | C16H11F3N2O3S | 0.0206 mg/ml | Not Available | |
| 308 | Etorphine | https://www.drugbank.ca/drugs/DB01497 | <img src="https://www.drugbank.ca/structures/DB01497/thumb.svg"></img> | 2.79 | 7.48 | 411.5338 | C25H33NO4 | 0.112 mg/ml | A narcotic analgesic morphinan used as a sedative in veterinary practice. In Hong Kong, Etorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II. | |
| 309 | Alphamethadol | https://www.drugbank.ca/drugs/DB01498 | <img src="https://www.drugbank.ca/structures/DB01498/thumb.svg"></img> | 4.21 | 14.52 | 311.4611 | C21H29NO | 0.0128 mg/ml | Not Available | |
| 310 | Oxabolone | https://www.drugbank.ca/drugs/DB01500 | <img src="https://www.drugbank.ca/structures/DB01500/thumb.svg"></img> | 1.95 | 9.3 | 290.403 | C18H26O3 | 0.0883 mg/ml | Not Available | |
| 311 | Difenoxin | https://www.drugbank.ca/drugs/DB01501 | <img src="https://www.drugbank.ca/structures/DB01501/thumb.svg"></img> | 4.39 | 3.38 | 424.5341 | C28H28N2O2 | 0.00208 mg/ml | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. | |
| 312 | Etoxeridine | https://www.drugbank.ca/drugs/DB01505 | <img src="https://www.drugbank.ca/structures/DB01505/thumb.svg"></img> | 2 | 15.12 | 321.4113 | C18H27NO4 | 1.37 mg/ml | Not Available | |
| 313 | 5-Alpha-Androstane-3-Beta,17beta-Diol | https://www.drugbank.ca/drugs/DB01507 | <img src="https://www.drugbank.ca/structures/DB03882/thumb.svg"></img> | 3.56 | 18.3 | 292.4562 | C19H32O2 | 0.0193 mg/ml | Not Available | |
| 314 | Delorazepam | https://www.drugbank.ca/drugs/DB01511 | <img src="https://www.drugbank.ca/structures/DB01511/thumb.svg"></img> | 3.15 | 12.29 | 305.159 | C15H10Cl2N2O | 0.00642 mg/ml | Delorazepam is a benzodiazepine which, like other drugs in its class, possesses anxiolytic, skeletal muscle relaxant, hypnotic and anticonvulsant properties. It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. [4] Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam. In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. [Wikipedia] It has been approved for marketing in Italy. | |
| 315 | Hydromorphinol | https://www.drugbank.ca/drugs/DB01512 | <img src="https://www.drugbank.ca/structures/DB01512/thumb.svg"></img> | 0.53 | 7.44 | 303.3529 | C17H21NO4 | 20.6 mg/ml | Not Available | |
| 316 | Benzoylecgonine | https://www.drugbank.ca/drugs/DB01515 | <img src="https://www.drugbank.ca/structures/DB01515/thumb.svg"></img> | 1.71 | 3.15 | 289.3264 | C16H19NO4 | 3.82 mg/ml | Benzoylecgonine is the major metabolite of cocaine. It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. It is excreted in the urine of cocaine users after processing in the liver. [Wikipedia] | |
| 317 | Clostebol | https://www.drugbank.ca/drugs/DB01521 | <img src="https://www.drugbank.ca/structures/DB01521/thumb.svg"></img> | 3.57 | 19.31 | 322.869 | C19H27ClO2 | 0.0153 mg/ml | Not Available | |
| 318 | Androstenediol | https://www.drugbank.ca/drugs/DB01524 | <img src="https://www.drugbank.ca/structures/DB01524/thumb.svg"></img> | 3.42 | 18.2 | 290.4403 | C19H30O2 | 0.055 mg/ml | An intermediate in testosterone biosynthesis, found in the testis or the adrenal glands. Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-hydroxysteroid dehydrogenases). [PubChem] | |
| 319 | Ecgonine | https://www.drugbank.ca/drugs/DB01525 | <img src="https://www.drugbank.ca/structures/DB01525/thumb.svg"></img> | -0.69 | 3.48 | 185.2203 | C9H15NO3 | 1050.0 mg/ml | Not Available | |
| 320 | 4-Androstenediol | https://www.drugbank.ca/drugs/DB01526 | <img src="https://www.drugbank.ca/structures/DB01526/thumb.svg"></img> | 3.1 | 17.5 | 290.4403 | C19H30O2 | 0.0481 mg/ml | Not Available | |
| 321 | 5alpha-androstane-3alpha,17beta-diol | https://www.drugbank.ca/drugs/DB01530 | <img src="https://www.drugbank.ca/structures/DB01530/thumb.svg"></img> | 3.56 | 18.3 | 292.4562 | C19H32O2 | 0.0193 mg/ml | Not Available | |
| 322 | Desomorphine | https://www.drugbank.ca/drugs/DB01531 | <img src="https://www.drugbank.ca/structures/DB01531/thumb.svg"></img> | 2.5 | 10.35 | 271.36 | C17H21NO2 | 0.86 mg/ml | Not Available | |
| 323 | Chlorhexadol | https://www.drugbank.ca/drugs/DB01534 | <img src="https://www.drugbank.ca/structures/DB01534/thumb.svg"></img> | 2.34 | 9.67 | 265.562 | C8H15Cl3O3 | 1.24 mg/ml | Chlorhexadol is a sedative and hypnotic which is regulated in the United States as a Schedule III controlled substance. It is a derivative of chloral hydrate. | |
| 324 | 4-Androstenedione | https://www.drugbank.ca/drugs/DB01536 | <img src="https://www.drugbank.ca/structures/DB01536/thumb.svg"></img> | 2.75 | 19.03 | 286.4085 | C19H26O2 | 0.027 mg/ml | A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol. [PubChem] | |
| 325 | 17alpha-methyl-4-hydroxynandrolone | https://www.drugbank.ca/drugs/DB01540 | <img src="https://www.drugbank.ca/structures/DB01540/thumb.svg"></img> | 2.46 | 9.33 | 304.43 | C19H28O3 | 0.0575 mg/ml | 17Alpha-methyl-4-hydroxynandrolone is a schedule 3 anabolic steroid. | |
| 326 | Boldenone | https://www.drugbank.ca/drugs/DB01541 | <img src="https://www.drugbank.ca/structures/DB01541/thumb.svg"></img> | 3.08 | 18.86 | 286.4085 | C19H26O2 | 0.0259 mg/ml | Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics. | |
| 327 | Ethyl loflazepate | https://www.drugbank.ca/drugs/DB01545 | <img src="https://www.drugbank.ca/structures/DB01545/thumb.svg"></img> | 3.36 | 9.51 | 360.767 | C18H14ClFN2O3 | 0.00525 mg/ml | Not Available | |
| 328 | Alpha-ethyltryptamine | https://www.drugbank.ca/drugs/DB01546 | <img src="https://www.drugbank.ca/structures/DB01546/thumb.svg"></img> | 2.55 | 17.13 | 188.2688 | C12H16N2 | 0.481 mg/ml | In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development of Monase was halted and the drug was withdrawn from potential market use. In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. Currently, αET is an illegal substance; however, it's activity is still under scientific investigation. αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. Instead, the effects of αET, a tryptamine derivative, more closely resemble the amphetamine derived drug 3,4-methylenedioxy-N-methylamphetamine (MDMA). Similarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration. | |
| 329 | Drotebanol | https://www.drugbank.ca/drugs/DB01547 | <img src="https://www.drugbank.ca/structures/DB01547/thumb.svg"></img> | 1.61 | 13.64 | 333.422 | C19H27NO4 | 2.15 mg/ml | Not Available | |
| 330 | Diprenorphine | https://www.drugbank.ca/drugs/DB01548 | <img src="https://www.drugbank.ca/structures/DB01548/thumb.svg"></img> | 3.52 | 10.42 | 425.569 | C26H35NO4 | 0.104 mg/ml | A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem] | |
| 331 | Dihydrocodeine | https://www.drugbank.ca/drugs/DB01551 | <img src="https://www.drugbank.ca/structures/DB01551/thumb.svg"></img> | 1.58 | 14.15 | 301.3801 | C18H23NO3 | 2.38 mg/ml | Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia] | |
| 332 | Cloxazolam | https://www.drugbank.ca/drugs/DB01553 | <img src="https://www.drugbank.ca/structures/DB01553/thumb.svg"></img> | 3.56 | 12.69 | 349.211 | C17H14Cl2N2O2 | 0.0266 mg/ml | Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. | |
| 333 | Bromazepam | https://www.drugbank.ca/drugs/DB01558 | <img src="https://www.drugbank.ca/structures/DB01558/thumb.svg"></img> | 2.05 | 12.24 | 316.153 | C14H10BrN3O | 0.0399 mg/ml | One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepines. | |
| 334 | Cathinone | https://www.drugbank.ca/drugs/DB01560 | <img src="https://www.drugbank.ca/structures/DB01560/thumb.svg"></img> | 0.51 | 18.65 | 149.1897 | C9H11NO | 2.46 mg/ml | Cathinone (β-ketoamphetamine) is a monoamine alkaloid found in the shrub Catha edulis (Khat). Closely related to ephedrine, cathine and other amphetamines, it is probably the main contributor to the stimulant effect of Catha edulis. Cathinone differs from many other amphetamines in that its structure is a ketone. Other amphetamines to share this structure include the antidepressant bupropion and the stimulant methcathinone, among others. Internationally, cathinone is a Schedule I drug under the Convention on Psychotropic Substances. Circa 1993, the DEA added cathinone to the Controlled Substances Act's Schedule I in order to fulfill the requirements of international law. [Wikipedia] | |
| 335 | Androstanedione | https://www.drugbank.ca/drugs/DB01561 | <img src="https://www.drugbank.ca/structures/DB01561/thumb.svg"></img> | 3.4 | 19.78 | 288.4244 | C19H28O2 | 0.00739 mg/ml | Not Available | |
| 336 | Chloral hydrate | https://www.drugbank.ca/drugs/DB01563 | <img src="https://www.drugbank.ca/structures/DB01563/thumb.svg"></img> | 0.99 | 9.51 | 165.403 | C2H3Cl3O2 | 43.4 mg/ml | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. [PubChem] | |
| 337 | Calusterone | https://www.drugbank.ca/drugs/DB01564 | <img src="https://www.drugbank.ca/structures/DB01564/thumb.svg"></img> | 3.55 | 19.56 | 316.4776 | C21H32O2 | 0.0112 mg/ml | A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada. | |
| 338 | Dihydromorphine | https://www.drugbank.ca/drugs/DB01565 | <img src="https://www.drugbank.ca/structures/DB01565/thumb.svg"></img> | 1.26 | 10.29 | 287.3535 | C17H21NO3 | 1.82 mg/ml | A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem] | |
| 339 | Codeine-N-oxide | https://www.drugbank.ca/drugs/DB01568 | <img src="https://www.drugbank.ca/structures/DB01568/thumb.svg"></img> | -0.48 | 13.78 | 315.3636 | C18H21NO4 | 0.138 mg/ml | Not Available | |
| 340 | Formebolone | https://www.drugbank.ca/drugs/DB01569 | <img src="https://www.drugbank.ca/structures/DB01569/thumb.svg"></img> | 2.59 | 14.39 | 344.4446 | C21H28O4 | 0.0605 mg/ml | Formebolone, a derivative of androstane [1], is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass. [1] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery. | |
| 341 | Ohmefentanyl | https://www.drugbank.ca/drugs/DB01570 | <img src="https://www.drugbank.ca/structures/DB01570/thumb.svg"></img> | 3.12 | 14.11 | 366.4965 | C23H30N2O2 | 0.0865 mg/ml | Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are used for tranquilizing large animals such as elephants in veterinary medicine. In mouse studies, the most active isomer 3R,4S,βS-ohmefentanyl was 28 times more powerful as a painkiller than fentanyl, the chemical from which it is derived, and 6300 times more effective than morphine. Ohmefentanyl has three stereogenic centers and so has eight stereoisomers, which are named F9201–F9208. Researchers are studying the different pharmaceutical properties of these isomers. | |
| 342 | Benzylmorphine | https://www.drugbank.ca/drugs/DB01573 | <img src="https://www.drugbank.ca/structures/DB01573/thumb.svg"></img> | 2.71 | 13.78 | 375.4602 | C24H25NO3 | 0.0456 mg/ml | Not Available | |
| 343 | Metrizamide | https://www.drugbank.ca/drugs/DB01578 | <img src="https://www.drugbank.ca/structures/DB01578/thumb.svg"></img> | -1.89 | 4.5 | 789.1 | C18H22I3N3O8 | 0.0911 mg/ml | Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium. | |
| 344 | Oxprenolol | https://www.drugbank.ca/drugs/DB01580 | <img src="https://www.drugbank.ca/structures/DB01580/thumb.svg"></img> | 2.10 | 14.09 | 265.348 | C15H23NO3 | 0.68 mg/ml | A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. [PubChem] | |
| 345 | Sulfamerazine | https://www.drugbank.ca/drugs/DB01581 | <img src="https://www.drugbank.ca/structures/DB01581/thumb.svg"></img> | 0.14 | 6.99 | 264.304 | C11H12N4O2S | 0.304 mg/ml | A sulfanilamide that is used as an antibacterial agent. [PubChem] | |
| 346 | Sulfamethazine | https://www.drugbank.ca/drugs/DB01582 | <img src="https://www.drugbank.ca/structures/DB01582/thumb.svg"></img> | 0.89 | 6.99 | 278.33 | C12H14N4O2S | 0.23 mg/ml | A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. [PubChem] | |
| 347 | Ursodeoxycholic acid | https://www.drugbank.ca/drugs/DB01586 | <img src="https://www.drugbank.ca/structures/DB01586/thumb.svg"></img> | 3.00 | 4.6 | 392.572 | C24H40O4 | 0.0197 mg/ml | Ursodeoxycholic acid is an epimer of chenodeoxycholic acid (DB06777). It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic. [PubChem] | |
| 348 | Ketazolam | https://www.drugbank.ca/drugs/DB01587 | <img src="https://www.drugbank.ca/structures/DB01587/thumb.svg"></img> | 2.6 | 14.2 | 368.814 | C20H17ClN2O3 | 0.0839 mg/ml | Ketazolam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Ketazolam is not approved for sale in the United States or Canada. | |
| 349 | Quazepam | https://www.drugbank.ca/drugs/DB01589 | <img src="https://www.drugbank.ca/structures/DB01589/thumb.svg"></img> | 4.03 | 18.93 | 386.794 | C17H11ClF4N2S | 0.00231 mg/ml | Quazepam is a drug which is a benzodiazepine derivative. It induces impairment of motor function and has hypnotic properties. Quazepam is used to treat insomnia. | |
| 350 | Everolimus | https://www.drugbank.ca/drugs/DB01590 | <img src="https://www.drugbank.ca/structures/DB01590/thumb.svg"></img> | 5.01 | 9.96 | 958.24 | C53H83NO14 | 0.00163 mg/ml | Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. | |
| 351 | Cinolazepam | https://www.drugbank.ca/drugs/DB01594 | <img src="https://www.drugbank.ca/structures/DB01594/thumb.svg"></img> | 2.42 | 10.68 | 357.766 | C18H13ClFN3O2 | 0.012 mg/ml | Cinolazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Cinolazepam is not approved for sale in the United States or Canada. | |
| 352 | Nitrazepam | https://www.drugbank.ca/drugs/DB01595 | <img src="https://www.drugbank.ca/structures/DB01595/thumb.svg"></img> | 2.25 | 11.9 | 281.2661 | C15H11N3O3 | 0.0299 mg/ml | A benzodiazepine derivative used as an anticonvulsant and hypnotic. | |
| 353 | Cilastatin | https://www.drugbank.ca/drugs/DB01597 | <img src="https://www.drugbank.ca/structures/DB01597/thumb.svg"></img> | -0.29 | 2.53 | 358.453 | C16H26N2O5S | 0.1 mg/ml | A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. [PubChem] | |
| 354 | Imipenem | https://www.drugbank.ca/drugs/DB01598 | <img src="https://www.drugbank.ca/structures/DB01598/thumb.svg"></img> | -0.19 | 3.63 | 299.346 | C12H17N3O4S | 0.776 mg/ml | Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with cilastatin, a renal dipeptidase inhibitor. [PubChem] | |
| 355 | Probucol | https://www.drugbank.ca/drugs/DB01599 | <img src="https://www.drugbank.ca/structures/DB01599/thumb.svg"></img> | 8.92 | 10.29 | 516.842 | C31H48O2S2 | 4.18e-05 mg/ml | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | |
| 356 | Tiaprofenic acid | https://www.drugbank.ca/drugs/DB01600 | <img src="https://www.drugbank.ca/structures/DB01600/thumb.svg"></img> | 3.22 | 4.03 | 260.308 | C14H12O3S | 0.0324 mg/ml | Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. | |
| 357 | Lopinavir | https://www.drugbank.ca/drugs/DB01601 | <img src="https://www.drugbank.ca/structures/DB01601/thumb.svg"></img> | 3.91 | 13.39 | 628.8008 | C37H48N4O5 | 0.00192 mg/ml | Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS. | |
| 358 | Bacampicillin | https://www.drugbank.ca/drugs/DB01602 | <img src="https://www.drugbank.ca/structures/DB01602/thumb.svg"></img> | 1.17 | 11.72 | 465.52 | C21H27N3O7S | 0.123 mg/ml | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides. It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc. | |
| 359 | Meticillin | https://www.drugbank.ca/drugs/DB01603 | <img src="https://www.drugbank.ca/structures/DB01603/thumb.svg"></img> | 1.22 | 2.96 | 380.415 | C17H20N2O6S | 0.31 mg/ml | One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. [PubChem] | |
| 360 | Pivampicillin | https://www.drugbank.ca/drugs/DB01604 | <img src="https://www.drugbank.ca/structures/DB01604/thumb.svg"></img> | 1.43 | 11.71 | 463.547 | C22H29N3O6S | 0.0354 mg/ml | Pivalate ester analog of ampicillin. | |
| 361 | Pivmecillinam | https://www.drugbank.ca/drugs/DB01605 | <img src="https://www.drugbank.ca/structures/DB01605/thumb.svg"></img> | 3.23 | 13.66 | 439.569 | C21H33N3O5S | 0.0526 mg/ml | Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem] | |
| 362 | Tazobactam | https://www.drugbank.ca/drugs/DB01606 | <img src="https://www.drugbank.ca/structures/DB01606/thumb.svg"></img> | -1.8 | 2.86 | 300.291 | C10H12N4O5S | 9.59 mg/ml | Tazobactam is a antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases. | |
| 363 | Ticarcillin | https://www.drugbank.ca/drugs/DB01607 | <img src="https://www.drugbank.ca/structures/DB01607/thumb.svg"></img> | 0.99 | 3.09 | 384.427 | C15H16N2O6S2 | 0.0716 mg/ml | An antibiotic derived from penicillin similar to carbenicillin in action. | |
| 364 | Propericiazine | https://www.drugbank.ca/drugs/DB01608 | <img src="https://www.drugbank.ca/structures/DB01608/thumb.svg"></img> | 3.52 | 15.18 | 365.492 | C21H23N3OS | 0.059 mg/ml | Propericiazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade. | |
| 365 | Deferasirox | https://www.drugbank.ca/drugs/DB01609 | <img src="https://www.drugbank.ca/structures/DB01609/thumb.svg"></img> | 3.52 | 4.55 | 373.3615 | C21H15N3O4 | 0.0343 mg/ml | Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. | |
| 366 | Valganciclovir | https://www.drugbank.ca/drugs/DB01610 | <img src="https://www.drugbank.ca/structures/DB01610/thumb.svg"></img> | -0.81 | 8.1 | 354.3617 | C14H22N6O5 | 4.79 mg/ml | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | |
| 367 | Hydroxychloroquine | https://www.drugbank.ca/drugs/DB01611 | <img src="https://www.drugbank.ca/structures/DB01611/thumb.svg"></img> | 3.87 | 15.59 | 335.872 | C18H26ClN3O | 0.0261 mg/ml | A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. | |
| 368 | Acepromazine | https://www.drugbank.ca/drugs/DB01614 | <img src="https://www.drugbank.ca/structures/DB01614/thumb.svg"></img> | 4.32 | 16.06 | 326.456 | C19H22N2OS | 0.0098 mg/ml | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. | |
| 369 | Aceprometazine | https://www.drugbank.ca/drugs/DB01615 | <img src="https://www.drugbank.ca/structures/DB01615/thumb.svg"></img> | 4.35 | 16.06 | 326.456 | C19H22N2OS | 0.0122 mg/ml | Aceprometazine (INN) is a prescription drug with neuroleptic and anti-histamine properties. It is not widely prescribed. It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine. [Wikipedia] | |
| 370 | Molindone | https://www.drugbank.ca/drugs/DB01618 | <img src="https://www.drugbank.ca/structures/DB01618/thumb.svg"></img> | 2.09 | 15.34 | 276.374 | C16H24N2O2 | 0.474 mg/ml | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) | |
| 371 | Phenindamine | https://www.drugbank.ca/drugs/DB01619 | <img src="https://www.drugbank.ca/structures/DB01619/thumb.svg"></img> | 4.04 | 18.01 | 261.3609 | C19H19N | 0.0277 mg/ml | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. | |
| 372 | Pipotiazine | https://www.drugbank.ca/drugs/DB01621 | <img src="https://www.drugbank.ca/structures/DB01621/thumb.svg"></img> | 3.94 | 17.09 | 475.667 | C24H33N3O3S2 | 0.0127 mg/ml | Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation. | |
| 373 | Zuclopenthixol | https://www.drugbank.ca/drugs/DB01624 | <img src="https://www.drugbank.ca/structures/DB01624/thumb.svg"></img> | 4.46 | 15.59 | 400.965 | C22H25ClN2OS | 0.0026 mg/ml | Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. | |
| 374 | Isopropamide | https://www.drugbank.ca/drugs/DB01625 | <img src="https://www.drugbank.ca/structures/DB01625/thumb.svg"></img> | 2.27 | 16.31 | 353.5209 | C23H33N2O | 4.24e-05 mg/ml | Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. | |
| 375 | Lincomycin | https://www.drugbank.ca/drugs/DB01627 | <img src="https://www.drugbank.ca/structures/DB01627/thumb.svg"></img> | 0.56 | 3.24 | 406.54 | C18H34N2O6S | 3.02 mg/ml | An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. | |
| 376 | Etoricoxib | https://www.drugbank.ca/drugs/DB01628 | <img src="https://www.drugbank.ca/structures/DB01628/thumb.svg"></img> | 3.7 | 19.69 | 358.842 | C18H15ClN2O2S | 0.00328 mg/ml | Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid. | |
| 377 | 5-Fluorouridine | https://www.drugbank.ca/drugs/DB01629 | <img src="https://www.drugbank.ca/structures/DB01629/thumb.svg"></img> | -1.4 | 7.67 | 262.1918 | C9H11FN2O6 | 60.7 mg/ml | 5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid. This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. FUrd is often used in chemical and biochemical comparison studies with fluorouracil and thymine analogs. | |
| 378 | SC-74020 | https://www.drugbank.ca/drugs/DB01630 | <img src="https://www.drugbank.ca/structures/DB01630/thumb.svg"></img> | 3.78 | 8.71 | 574.732 | C29H42N4O6S | 0.0101 mg/ml | Not Available | |
| 379 | Alpha-Phosphoribosylpyrophosphoric Acid | https://www.drugbank.ca/drugs/DB01632 | <img src="https://www.drugbank.ca/structures/DB01632/thumb.svg"></img> | -0.74 | 1.09 | 390.0696 | C5H13O14P3 | 11.6 mg/ml | The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides. | |
| 380 | Deoxy-2-Fluoro-B-D-Cellotrioside | https://www.drugbank.ca/drugs/DB01633 | <img src="https://www.drugbank.ca/structures/DB01633/thumb.svg"></img> | -2.2 | 10.98 | 505.4202 | C18H30FO15 | 360.0 mg/ml | Not Available | |
| 381 | 2-Oxy-4-Hydroxy-5-(2-Hydrazinopyridine)Phenylalanine | https://www.drugbank.ca/drugs/DB01634 | <img src="https://www.drugbank.ca/structures/DB01634/thumb.svg"></img> | -1.3 | 1.63 | 304.3012 | C14H16N4O4 | 1.12 mg/ml | Not Available | |
| 382 | 2,2-Dimethylthiazolidine-4-Carboxylic Acid;(Dmt)Thiazolidine | https://www.drugbank.ca/drugs/DB01635 | <img src="https://www.drugbank.ca/structures/DB01635/thumb.svg"></img> | -1.3 | 2.97 | 161.222 | C6H11NO2S | 31.9 mg/ml | Not Available | |
| 383 | Clorocruoro Hem | https://www.drugbank.ca/drugs/DB01636 | <img src="https://www.drugbank.ca/structures/DB01636/thumb.svg"></img> | 4.28 | 4.02 | 618.46 | C33H30FeN4O5 | 0.0266 mg/ml | Not Available | |
| 384 | 3,7,11,15-Tetramethyl-Hexadecan-1-Ol | https://www.drugbank.ca/drugs/DB01637 | <img src="https://www.drugbank.ca/structures/DB01637/thumb.svg"></img> | 8.18 | 17.11 | 298.5469 | C20H42O | 2.31e-05 mg/ml | Not Available | |
| 385 | Sorbitol | https://www.drugbank.ca/drugs/DB01638 | <img src="https://www.drugbank.ca/structures/DB01638/thumb.svg"></img> | -2.20 | 12.59 | 182.1718 | C6H14O6 | 229.0 mg/ml | A polyhydric alcohol with about half the sweetness of sucrose. Sorbitol occurs naturally and is also produced synthetically from glucose. It was formerly used as a diuretic and may still be used as a laxative and in irrigating solutions for some surgical procedures. | |
| 386 | N-Methyl-Pyridoxal-5'-Phosphate | https://www.drugbank.ca/drugs/DB01639 | <img src="https://www.drugbank.ca/structures/DB01639/thumb.svg"></img> | -2.1 | 1.59 | 262.1764 | C9H13NO6P | 0.499 mg/ml | Not Available | |
| 387 | (5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One | https://www.drugbank.ca/drugs/DB01640 | <img src="https://www.drugbank.ca/structures/DB01640/thumb.svg"></img> | 4.78 | 11.79 | 513.3707 | C24H24IN3O2 | 0.00239 mg/ml | Not Available | |
| 388 | (5z)-2-[(1s,2r)-1-Amino-2-Hydroxypropyl]-5-[(4-Amino-1h-Indol-3-Yl)Methylene]-3-(2-Hydroxyethyl)-3,5-Dihydro-4h-Imidazol-4-One | https://www.drugbank.ca/drugs/DB01641 | <img src="https://www.drugbank.ca/structures/DB01641/thumb.svg"></img> | -0.62 | 3.76 | 357.3639 | C17H19N5O4 | 0.211 mg/ml | Not Available | |
| 389 | O1-Methyl-Glucose | https://www.drugbank.ca/drugs/DB01642 | <img src="https://www.drugbank.ca/structures/DB01642/thumb.svg"></img> | -2.5 | 12.21 | 194.1825 | C7H14O6 | 862.0 mg/ml | Not Available | |
| 390 | Thymidine-5'-Phosphate | https://www.drugbank.ca/drugs/DB01643 | <img src="https://www.drugbank.ca/structures/DB01643/thumb.svg"></img> | -1.4 | 1.23 | 322.2085 | C10H15N2O8P | 6.78 mg/ml | 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety. | |
| 391 | 3,6-Dihydroxy-Xanthene-9-Propionic Acid | https://www.drugbank.ca/drugs/DB01644 | <img src="https://www.drugbank.ca/structures/DB01644/thumb.svg"></img> | 2.58 | 3.6 | 286.2794 | C16H14O5 | 0.0589 mg/ml | Not Available | |
| 392 | Genistein | https://www.drugbank.ca/drugs/DB01645 | <img src="https://www.drugbank.ca/structures/DB01645/thumb.svg"></img> | 3.04 | 6.55 | 270.2369 | C15H10O5 | 0.123 mg/ml | An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient inFelmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. [Wikipedia] Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. [1] Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. [Wikipedia] | |
| 393 | N-Acetylmethionine | https://www.drugbank.ca/drugs/DB01646 | <img src="https://www.drugbank.ca/structures/DB01646/thumb.svg"></img> | -0.15 | 4.02 | 191.248 | C7H13NO3S | 6.84 mg/ml | Not Available | |
| 394 | (R)-Mesopram | https://www.drugbank.ca/drugs/DB01647 | <img src="https://www.drugbank.ca/structures/DB01647/thumb.svg"></img> | 2.28 | 12.73 | 265.305 | C14H19NO4 | 0.313 mg/ml | Not Available | |
| 395 | O1-Methyl-4-Deoxy-4-Thio-Beta-D-Glucose | https://www.drugbank.ca/drugs/DB01648 | <img src="https://www.drugbank.ca/structures/DB01648/thumb.svg"></img> | -0.79 | 9.5 | 210.248 | C7H14O5S | 40.6 mg/ml | Not Available | |
| 396 | 7-Methyl-Gpppa | https://www.drugbank.ca/drugs/DB01649 | <img src="https://www.drugbank.ca/structures/DB01649/thumb.svg"></img> | -0.18 | 0.9 | 787.441 | C21H30N10O17P3 | 2.89 mg/ml | Not Available | |
| 397 | trans-2-hydroxycinnamic acid | https://www.drugbank.ca/drugs/DB01650 | <img src="https://www.drugbank.ca/structures/DB01650/thumb.svg"></img> | 1.9 | 4.04 | 164.158 | C9H8O3 | 1.15 mg/ml | Not Available | |
| 398 | Methyl 4,6-O-[(1r)-1-Carboxyethylidene]-Beta-D-Galactopyranoside | https://www.drugbank.ca/drugs/DB01651 | <img src="https://www.drugbank.ca/structures/DB01651/thumb.svg"></img> | -1.1 | 2.96 | 264.2292 | C10H16O8 | 264.0 mg/ml | Not Available | |
| 399 | 4-Hydroxybenzoyl Coenzyme A | https://www.drugbank.ca/drugs/DB01652 | <img src="https://www.drugbank.ca/structures/DB01652/thumb.svg"></img> | 0.01 | 0.83 | 887.64 | C28H40N7O18P3S | 3.28 mg/ml | Not Available | |
| 400 | (5z)-5-(1h-Indol-3-Ylmethylene)-4h-Imidazol-4-One | https://www.drugbank.ca/drugs/DB01653 | <img src="https://www.drugbank.ca/structures/DB01653/thumb.svg"></img> | 0.21 | 14.65 | 328.3657 | C17H20N4O3 | 0.191 mg/ml | Not Available | |
| 401 | Thiorphan | https://www.drugbank.ca/drugs/DB01654 | <img src="https://www.drugbank.ca/structures/DB08626/thumb.svg"></img> | 1.78 | 4.02 | 253.317 | C12H15NO3S | 0.445 mg/ml | A potent inhibitor of membrane metalloendopeptidase (enkephalinase). Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms. | |
| 402 | L-Guluronic Acid 6-Phosphate | https://www.drugbank.ca/drugs/DB01655 | <img src="https://www.drugbank.ca/structures/DB01655/thumb.svg"></img> | -2.3 | 1.49 | 276.1352 | C6H13O10P | 20.7 mg/ml | Not Available | |
| 403 | Roflumilast | https://www.drugbank.ca/drugs/DB01656 | <img src="https://www.drugbank.ca/structures/DB01656/thumb.svg"></img> | 4.47 | 8.18 | 403.207 | C17H14Cl2F2N2O3 | 0.0062 mg/ml | Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor. Due to its selective inhibition of the PDE4 isoenzyme in lung cells, roflumilast is indicated for the management of chronic obstrtuctive pulmonary disease (COPD) exacerbations. Treatment with Roflumilast is associated with an increase in psychiatric adverse reactions, including suicide and suicidal attempts. | |
| 404 | 2-Amino-3-[4-Hydroxy-6-Oxo-3-(2-Phenyl-Cyclopropylimino)-Cyclohexa-1,4-Dienyl]-Propionic Acid | https://www.drugbank.ca/drugs/DB01657 | <img src="https://www.drugbank.ca/structures/DB01657/thumb.svg"></img> | -1 | 1.88 | 328.3624 | C18H20N2O4 | 0.166 mg/ml | Not Available | |
| 405 | 1'-Deazo-Thiamin Diphosphate | https://www.drugbank.ca/drugs/DB01658 | <img src="https://www.drugbank.ca/structures/DB01658/thumb.svg"></img> | -0.88 | 1.78 | 423.318 | C13H19N3O7P2S | 0.157 mg/ml | Not Available | |
| 406 | 3-(1,10-Phenanthrol-2-Yl)-L-Alanine | https://www.drugbank.ca/drugs/DB01659 | <img src="https://www.drugbank.ca/structures/DB01659/thumb.svg"></img> | -0.73 | 2.14 | 267.2826 | C15H13N3O2 | 0.121 mg/ml | Not Available | |
| 407 | Adenosine-5'-Diphosphate Monothiophosphate | https://www.drugbank.ca/drugs/DB01660 | <img src="https://www.drugbank.ca/structures/DB01660/thumb.svg"></img> | -0.5 | 1.03 | 523.247 | C10H16N5O12P3S | 2.26 mg/ml | Not Available | |
| 408 | Phosphoribosyl Atp | https://www.drugbank.ca/drugs/DB01661 | <img src="https://www.drugbank.ca/structures/DB01661/thumb.svg"></img> | -0.59 | 0.66 | 713.2279 | C15H19N5O20P4 | 17.9 mg/ml | Not Available | |
| 409 | Trans-O-Hydroxy-Alpha-Methyl Cinnamate | https://www.drugbank.ca/drugs/DB01662 | <img src="https://www.drugbank.ca/structures/DB01662/thumb.svg"></img> | 1.65 | 4.28 | 180.2005 | C10H12O3 | 1.97 mg/ml | Not Available | |
| 410 | (S)-Des-Me-Ampa | https://www.drugbank.ca/drugs/DB01664 | <img src="https://www.drugbank.ca/structures/DB01664/thumb.svg"></img> | -2.8 | 1.77 | 172.1387 | C6H8N2O4 | 48.9 mg/ml | Not Available | |
| 411 | ZK-800270 | https://www.drugbank.ca/drugs/DB01665 | <img src="https://www.drugbank.ca/structures/DB01665/thumb.svg"></img> | -0.19 | 14.86 | 133.1506 | C7H7N3 | 1.95 mg/ml | Not Available | |
| 412 | D-Myo-Inositol-Hexasulphate | https://www.drugbank.ca/drugs/DB01666 | <img src="https://www.drugbank.ca/structures/DB01666/thumb.svg"></img> | -1.3 | -3.5 | 660.535 | C6H12O24S6 | 0.394 mg/ml | Not Available | |
| 413 | 8-azaguanine | https://www.drugbank.ca/drugs/DB01667 | <img src="https://www.drugbank.ca/structures/DB01667/thumb.svg"></img> | -0.71 | 7.89 | 152.1142 | C4H4N6O | 5.66 mg/ml | One of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids. [PubChem] | |
| 414 | Nanaomycin D | https://www.drugbank.ca/drugs/DB01668 | <img src="https://www.drugbank.ca/structures/DB01668/thumb.svg"></img> | 1.98 | 9.41 | 300.2629 | C16H12O6 | 1.95 mg/ml | Not Available | |
| 415 | Virginiamycin M1 | https://www.drugbank.ca/drugs/DB01669 | <img src="https://www.drugbank.ca/structures/DB01669/thumb.svg"></img> | 2.6 | 11.38 | 525.5934 | C28H35N3O7 | 0.0601 mg/ml | Pristinamycin IIA is a macrolide antibiotic. It is a member of the streptogramin A group of antibiotics and one component of pristinamycin (the other being pristinamycin IA). It is produced by Streptomyces graminofaciens and other bacteria. | |
| 416 | 4-(Hydroxymercury)Benzoic Acid | https://www.drugbank.ca/drugs/DB01671 | <img src="https://www.drugbank.ca/structures/DB01671/thumb.svg"></img> | 0.43 | 3.86 | 338.71 | C7H6HgO3 | 52.2 mg/ml | Not Available | |
| 417 | 2,3-Dihydroxy-Benzoic Acid | https://www.drugbank.ca/drugs/DB01672 | <img src="https://www.drugbank.ca/structures/DB01672/thumb.svg"></img> | 1.20 | 2.56 | 154.1201 | C7H6O4 | 6.88 mg/ml | Not Available | |
| 418 | Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine | https://www.drugbank.ca/drugs/DB01673 | <img src="https://www.drugbank.ca/structures/DB01673/thumb.svg"></img> | -1.4 | 1.73 | 750.4943 | C23H36N4O20P2 | 9.58 mg/ml | Not Available | |
| 419 | Methacrylyl-Coenzyme A | https://www.drugbank.ca/drugs/DB01675 | <img src="https://www.drugbank.ca/structures/DB01675/thumb.svg"></img> | -0.38 | 0.83 | 835.608 | C25H40N7O17P3S | 4.11 mg/ml | Not Available | |
| 420 | Trinitrotoluene | https://www.drugbank.ca/drugs/DB01676 | <img src="https://www.drugbank.ca/structures/DB01676/thumb.svg"></img> | 1.60 | 16.99 | 227.1311 | C7H5N3O6 | 0.0778 mg/ml | A 2,4,6-trinitrotoluene is an explosive chemical that can cause skin irritation and other toxic consequences. [PubChem] | |
| 421 | Fumarate | https://www.drugbank.ca/drugs/DB01677 | <img src="https://www.drugbank.ca/structures/DB01677/thumb.svg"></img> | 0.46 | 3.55 | 114.0563 | C4H2O4 | 206.0 mg/ml | Not Available | |
| 422 | RU84687 | https://www.drugbank.ca/drugs/DB01678 | <img src="https://www.drugbank.ca/structures/DB01678/thumb.svg"></img> | 2.34 | 1.75 | 607.5907 | C31H34N3O8P | 0.000744 mg/ml | RU84687 is a subnanomolar and Src SH2 selective binder. | |
| 423 | Propyl Trihydrogen Diphosphate | https://www.drugbank.ca/drugs/DB01679 | <img src="https://www.drugbank.ca/structures/DB01679/thumb.svg"></img> | -0.07 | 1.78 | 220.0548 | C3H10O7P2 | 11.9 mg/ml | Not Available | |
| 424 | Benzene Hexacarboxylic Acid | https://www.drugbank.ca/drugs/DB01681 | <img src="https://www.drugbank.ca/structures/DB01681/thumb.svg"></img> | 1.50 | 0.77 | 342.1688 | C12H6O12 | 0.204 mg/ml | Not Available | |
| 425 | 6'-Methyl-Thiamin Diphosphate | https://www.drugbank.ca/drugs/DB01682 | <img src="https://www.drugbank.ca/structures/DB01682/thumb.svg"></img> | -1 | 1.78 | 438.333 | C13H20N4O7P2S | 0.259 mg/ml | Not Available | |
| 426 | Chymostatin | https://www.drugbank.ca/drugs/DB01683 | <img src="https://www.drugbank.ca/structures/DB01683/thumb.svg"></img> | 1.03 | 3.71 | 607.7005 | C31H41N7O6 | 0.0182 mg/ml | Not Available | |
| 427 | 1-Hydroxy-1-Thio-Glycerol | https://www.drugbank.ca/drugs/DB01684 | <img src="https://www.drugbank.ca/structures/DB01684/thumb.svg"></img> | -1.8 | 13.63 | 124.159 | C3H8O3S | 607.0 mg/ml | Not Available | |
| 428 | 4-[5-Pyridin-4-Yl-1h-[1,2,4]Triazol-3-Yl]-Pyridine-2-Carbonitrile | https://www.drugbank.ca/drugs/DB01685 | <img src="https://www.drugbank.ca/structures/DB01685/thumb.svg"></img> | 1.47 | 11.06 | 248.2428 | C13H8N6 | 0.0779 mg/ml | Not Available | |
| 429 | N,N-dimethylarginine | https://www.drugbank.ca/drugs/DB01686 | <img src="https://www.drugbank.ca/structures/DB01686/thumb.svg"></img> | -3.1 | 2.54 | 202.2541 | C8H18N4O2 | 6.77 mg/ml | Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. [Wikipedia] | |
| 430 | beta-Mannobiose | https://www.drugbank.ca/drugs/DB01687 | <img src="https://www.drugbank.ca/structures/DB01687/thumb.svg"></img> | -3 | 11.25 | 342.2965 | C12H22O11 | 586.0 mg/ml | Not Available | |
| 431 | P-Cresol | https://www.drugbank.ca/drugs/DB01688 | <img src="https://www.drugbank.ca/structures/DB01688/thumb.svg"></img> | 1.94 | 10.36 | 108.1378 | C7H8O | 23.1 mg/ml | Not Available | |
| 432 | Inhibitor Idd 384 | https://www.drugbank.ca/drugs/DB01689 | <img src="https://www.drugbank.ca/structures/DB01689/thumb.svg"></img> | 1.04 | 3.12 | 390.453 | C19H22N2O5S | 0.0134 mg/ml | Not Available | |
| 433 | Bis(Adenosine)-5'-Triphosphate | https://www.drugbank.ca/drugs/DB01690 | <img src="https://www.drugbank.ca/structures/DB01690/thumb.svg"></img> | -1.3 | 0.91 | 756.4071 | C20H27N10O16P3 | 4.39 mg/ml | Not Available | |
| 434 | Indole Naphthyridinone | https://www.drugbank.ca/drugs/DB01691 | <img src="https://www.drugbank.ca/structures/DB01691/thumb.svg"></img> | 2.57 | 12.03 | 374.4357 | C22H22N4O2 | 0.0196 mg/ml | Not Available | |
| 435 | Dithioerythritol | https://www.drugbank.ca/drugs/DB01692 | <img src="https://www.drugbank.ca/structures/DB01692/thumb.svg"></img> | 0.18 | 9.62 | 154.251 | C4H10O2S2 | 5.14 mg/ml | A compound that, along with its isomer, Cleland's reagent (dithiothreitol), is used for the protection of sulfhydryl groups against oxidation to disulfides and for the reduction of disulfides to sulfhydryl groups. [PubChem] | |
| 436 | Ribavirin | https://www.drugbank.ca/drugs/DB01693 | <img src="https://www.drugbank.ca/structures/DB00811/thumb.svg"></img> | -1.85 | 11.88 | 244.2047 | C8H12N4O5 | 33.2 mg/ml | A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem] | |
| 437 | D-tartaric acid | https://www.drugbank.ca/drugs/DB01694 | <img src="https://www.drugbank.ca/structures/DB01694/thumb.svg"></img> | -1.3 | 2.72 | 150.0868 | C4H6O6 | 161.0 mg/ml | Not Available | |
| 438 | N-Hydroxy-4-Phosphono-Butanamide | https://www.drugbank.ca/drugs/DB01695 | <img src="https://www.drugbank.ca/structures/DB01695/thumb.svg"></img> | -1.1 | 1.81 | 181.0838 | C4H8NO5P | 46.4 mg/ml | Not Available | |
| 439 | Uric Acid | https://www.drugbank.ca/drugs/DB01696 | <img src="https://www.drugbank.ca/structures/DB08844/thumb.svg"></img> | -2.17 | 7.61 | 168.1103 | C5H4N4O3 | 1.76 mg/ml | Uric acid is the last product of purine metabolism in humans. The formation of uric acid is through the enzyme xanthine oxidase, which oxidizes oxypurines. Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. At present (August 2013), there is no approved formulation or indication for uric acid. In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke. | |
| 440 | beta-cellotriose | https://www.drugbank.ca/drugs/DB01697 | <img src="https://www.drugbank.ca/structures/DB01697/thumb.svg"></img> | -2.7 | 11.22 | 504.4371 | C18H32O16 | 554.0 mg/ml | Not Available | |
| 441 | Rutin | https://www.drugbank.ca/drugs/DB01698 | <img src="https://www.drugbank.ca/structures/DB01698/thumb.svg"></img> | 0.15 | 6.43 | 610.5175 | C27H30O16 | 3.54 mg/ml | A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility. [PubChem] | |
| 442 | (4e)-4-Aminohex-4-Enoic Acid | https://www.drugbank.ca/drugs/DB01699 | <img src="https://www.drugbank.ca/structures/DB01699/thumb.svg"></img> | 0.41 | 4.6 | 129.157 | C6H11NO2 | 52.4 mg/ml | Not Available | |
| 443 | Aicar | https://www.drugbank.ca/drugs/DB01700 | <img src="https://www.drugbank.ca/structures/DB01700/thumb.svg"></img> | -2.2 | 1.22 | 338.2112 | C9H15N4O8P | 2.79 mg/ml | Not Available | |
| 444 | 2-(3,4-Dihydroxyphenyl)Acetic Acid | https://www.drugbank.ca/drugs/DB01702 | <img src="https://www.drugbank.ca/structures/DB01702/thumb.svg"></img> | 0.98 | 3.61 | 168.1467 | C8H8O4 | 7.23 mg/ml | A deaminated metabolite of levodopa. [PubChem] | |
| 445 | 2,4-Dihydroxy-Trans Cinnamic Acid | https://www.drugbank.ca/drugs/DB01704 | <img src="https://www.drugbank.ca/structures/DB01704/thumb.svg"></img> | 1.49 | 3.64 | 180.1574 | C9H8O4 | 1.59 mg/ml | Not Available | |
| 446 | L-Alfa-Lysophosphatidylcholine, Lauroyl | https://www.drugbank.ca/drugs/DB01707 | <img src="https://www.drugbank.ca/structures/DB01707/thumb.svg"></img> | 0.1 | 1.86 | 440.5317 | C20H43NO7P | 0.00134 mg/ml | Not Available | |
| 447 | Prasterone | https://www.drugbank.ca/drugs/DB01708 | <img src="https://www.drugbank.ca/structures/DB01708/thumb.svg"></img> | 3.23 | 18.2 | 288.4244 | C19H28O2 | 0.0438 mg/ml | Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion. In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. In Canada, a prescription is required to buy DHEA. | |
| 448 | 2-Phosphoglyceric Acid | https://www.drugbank.ca/drugs/DB01709 | <img src="https://www.drugbank.ca/structures/DB01709/thumb.svg"></img> | -2.2 | 0.81 | 186.0572 | C3H7O7P | 20.3 mg/ml | Not Available | |
| 449 | 2,3,4,5,6-Pentafluorobenzyl Alcohol | https://www.drugbank.ca/drugs/DB01711 | <img src="https://www.drugbank.ca/structures/DB01711/thumb.svg"></img> | 1.52 | 13.68 | 198.0901 | C7H3F5O | 0.481 mg/ml | Not Available | |
| 450 | (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester | https://www.drugbank.ca/drugs/DB01712 | <img src="https://www.drugbank.ca/structures/DB01712/thumb.svg"></img> | 2.59 | 11.85 | 476.609 | C23H28N2O5S2 | 0.00348 mg/ml | Not Available | |
| 451 | Udp-Alpha-D-Xylopyranose | https://www.drugbank.ca/drugs/DB01713 | <img src="https://www.drugbank.ca/structures/DB01713/thumb.svg"></img> | -1.3 | 1.73 | 536.2758 | C14H22N2O16P2 | 13.6 mg/ml | The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans. [PubChem] | |
| 452 | N-Methyl-Lysine | https://www.drugbank.ca/drugs/DB01714 | <img src="https://www.drugbank.ca/structures/DB01714/thumb.svg"></img> | -2.4 | 2.8 | 160.2141 | C7H16N2O2 | 51.5 mg/ml | Not Available | |
| 453 | 7,8-Diamino-Nonanoic Acid | https://www.drugbank.ca/drugs/DB01715 | <img src="https://www.drugbank.ca/structures/DB01715/thumb.svg"></img> | -2.1 | 4.73 | 188.2673 | C9H20N2O2 | 4.94 mg/ml | Not Available | |
| 454 | 2-Propenyl-N-Acetyl-Neuramic Acid | https://www.drugbank.ca/drugs/DB01716 | <img src="https://www.drugbank.ca/structures/DB01716/thumb.svg"></img> | -1.8 | 3.68 | 333.3343 | C14H23NO8 | 76.8 mg/ml | Not Available | |
| 455 | Bis(Adenosine)-5'-Pentaphosphate | https://www.drugbank.ca/drugs/DB01717 | <img src="https://www.drugbank.ca/structures/DB01717/thumb.svg"></img> | -0.2 | 0.42 | 916.3669 | C20H29N10O22P5 | 6.92 mg/ml | Not Available | |
| 456 | Thio-Maltopentaose | https://www.drugbank.ca/drugs/DB01719 | <img src="https://www.drugbank.ca/structures/DB01719/thumb.svg"></img> | -2.5 | 8.64 | 876.915 | C30H52O23S3 | 95.9 mg/ml | Not Available | |
| 457 | (2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid | https://www.drugbank.ca/drugs/DB01720 | <img src="https://www.drugbank.ca/structures/DB01720/thumb.svg"></img> | 4.72 | 3.24 | 438.271 | C22H16BrNO4 | 0.000356 mg/ml | Not Available | |
| 458 | Analogue of Indinavir Drug | https://www.drugbank.ca/drugs/DB01721 | <img src="https://www.drugbank.ca/structures/DB01721/thumb.svg"></img> | 4.37 | 13.21 | 670.8375 | C39H50N4O6 | 0.0233 mg/ml | Not Available | |
| 459 | {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid | https://www.drugbank.ca/drugs/DB01723 | <img src="https://www.drugbank.ca/structures/DB01723/thumb.svg"></img> | 5.32 | 3.44 | 693.7799 | C38H47NO11 | 0.00094 mg/ml | Not Available | |
| 460 | Reduced Threonine | https://www.drugbank.ca/drugs/DB01724 | <img src="https://www.drugbank.ca/structures/DB01724/thumb.svg"></img> | -1.4 | 14.64 | 105.1356 | C4H11NO2 | 805.0 mg/ml | Not Available | |
| 461 | 2-Aminophenol | https://www.drugbank.ca/drugs/DB01726 | <img src="https://www.drugbank.ca/structures/DB01726/thumb.svg"></img> | 0.62 | 10.35 | 109.1259 | C6H7NO | 116.0 mg/ml | Not Available | |
| 462 | Isocitric Acid | https://www.drugbank.ca/drugs/DB01727 | <img src="https://www.drugbank.ca/structures/DB01727/thumb.svg"></img> | -0.35 | 3.07 | 192.1235 | C6H8O7 | 52.5 mg/ml | Not Available | |
| 463 | 3-[Aminoethylphosphoryl]-[1,2-Di-Palmitoyl]-Sn-Glycerol | https://www.drugbank.ca/drugs/DB01728 | <img src="https://www.drugbank.ca/structures/DB01728/thumb.svg"></img> | 8.08 | 1.87 | 691.9591 | C37H74NO8P | 9.45e-05 mg/ml | Not Available | |
| 464 | (1s,3s,4s)-1,3,4-Triphospho-Myo-Inositol | https://www.drugbank.ca/drugs/DB01729 | <img src="https://www.drugbank.ca/structures/DB01729/thumb.svg"></img> | -0.86 | 0.54 | 420.0956 | C6H15O15P3 | 14.8 mg/ml | Not Available | |
| 465 | Penciclovir | https://www.drugbank.ca/drugs/DB01730 | <img src="https://www.drugbank.ca/structures/DB00299/thumb.svg"></img> | -1.1 | 8.01 | 253.2578 | C10H15N5O3 | 7.45 mg/ml | Penciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. [Wikipedia] | |
| 466 | (S)-Wiskostatin | https://www.drugbank.ca/drugs/DB01731 | <img src="https://www.drugbank.ca/structures/DB01731/thumb.svg"></img> | 4.17 | 14.43 | 426.146 | C17H18Br2N2O | 0.0162 mg/ml | Not Available | |
| 467 | (4r,5s,6s,7r)-1,3-Dibenzyl-4,7-Bis(Phenoxymethyl)-5,6-Dihydroxy-1,3 Diazepan-2-One | https://www.drugbank.ca/drugs/DB01732 | <img src="https://www.drugbank.ca/structures/DB01732/thumb.svg"></img> | 4.05 | 13.16 | 538.6335 | C33H34N2O5 | 0.0305 mg/ml | Not Available | |
| 468 | L-Phospholactate | https://www.drugbank.ca/drugs/DB01733 | <img src="https://www.drugbank.ca/structures/DB01733/thumb.svg"></img> | -1.6 | 1.13 | 170.0578 | C3H7O6P | 21.0 mg/ml | Not Available | |
| 469 | 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid | https://www.drugbank.ca/drugs/DB01734 | <img src="https://www.drugbank.ca/structures/DB01734/thumb.svg"></img> | 1.21 | 2.48 | 259.2143 | C13H9NO5 | 0.0778 mg/ml | Not Available | |
| 470 | 3-Chloroalaninate | https://www.drugbank.ca/drugs/DB01735 | <img src="https://www.drugbank.ca/structures/DB01735/thumb.svg"></img> | -1.6 | 1.7 | 123.538 | C3H6ClNO2 | 16.6 mg/ml | Not Available | |
| 471 | [3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium | https://www.drugbank.ca/drugs/DB01736 | <img src="https://www.drugbank.ca/structures/DB01736/thumb.svg"></img> | 2.24 | 15.85 | 300.4799 | C17H36N2O2 | 0.0019 mg/ml | Not Available | |
| 472 | Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester | https://www.drugbank.ca/drugs/DB01737 | <img src="https://www.drugbank.ca/structures/DB01737/thumb.svg"></img> | 0.43 | 10.32 | 432.493 | C20H24N4O5S | 0.0392 mg/ml | Not Available | |
| 473 | O-Phosphoethanolamine | https://www.drugbank.ca/drugs/DB01738 | <img src="https://www.drugbank.ca/structures/DB01738/thumb.svg"></img> | -1.3 | 1.77 | 155.0896 | C3H10NO4P | 25.5 mg/ml | Not Available | |
| 474 | Allo-Isoleucine | https://www.drugbank.ca/drugs/DB01739 | <img src="https://www.drugbank.ca/structures/DB01739/thumb.svg"></img> | -1.7 | 2.79 | 131.1729 | C6H13NO2 | 114.0 mg/ml | Not Available | |
| 475 | 2-Amino-4-Butyl-5-Propylselenazole | https://www.drugbank.ca/drugs/DB01740 | <img src="https://www.drugbank.ca/structures/DB01740/thumb.svg"></img> | 2.52 | 17.41 | 245.22 | C10H18N2Se | 1.84 mg/ml | Not Available | |
| 476 | CRA_17693 | https://www.drugbank.ca/drugs/DB01741 | <img src="https://www.drugbank.ca/structures/DB01741/thumb.svg"></img> | 1.43 | 4.39 | 460.414 | C24H17FN4O5 | 0.00623 mg/ml | Not Available | |
| 477 | Pyoverdine-Chromophore | https://www.drugbank.ca/drugs/DB01743 | <img src="https://www.drugbank.ca/structures/DB01743/thumb.svg"></img> | -1.7 | 3.6 | 1336.3641 | C55H85N17O22 | 1.62 mg/ml | Not Available | |
| 478 | N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester | https://www.drugbank.ca/drugs/DB01745 | <img src="https://www.drugbank.ca/structures/DB01745/thumb.svg"></img> | 2.25 | 10.02 | 522.616 | C27H30N4O5S | 0.0097 mg/ml | Not Available | |
| 479 | D-Leucine | https://www.drugbank.ca/drugs/DB01746 | <img src="https://www.drugbank.ca/structures/DB01746/thumb.svg"></img> | -1.8 | 2.79 | 131.1729 | C6H13NO2 | 69.8 mg/ml | An essential branched-chain amino acid important for hemoglobin formation. [PubChem] | |
| 480 | Coprogen | https://www.drugbank.ca/drugs/DB01747 | <img src="https://www.drugbank.ca/structures/DB01747/thumb.svg"></img> | 2.31 | 4.14 | 821.683 | C35H53FeN6O13 | 0.0285 mg/ml | Not Available | |
| 481 | N-Benzyl-4-Sulfamoyl-Benzamide | https://www.drugbank.ca/drugs/DB01748 | <img src="https://www.drugbank.ca/structures/DB01748/thumb.svg"></img> | 1.27 | 9.95 | 290.338 | C14H14N2O3S | 0.0451 mg/ml | Not Available | |
| 482 | Naphthalen-1-Yl-Acetic Acid | https://www.drugbank.ca/drugs/DB01750 | <img src="https://www.drugbank.ca/structures/DB01750/thumb.svg"></img> | 2.24 | 4.75 | 186.2066 | C12H10O2 | 0.11 mg/ml | Not Available | |
| 483 | 3,3',5,5'-Tetraiodothyroacetic Acid | https://www.drugbank.ca/drugs/DB01751 | <img src="https://www.drugbank.ca/structures/DB01751/thumb.svg"></img> | 4.99 | 2.25 | 747.8288 | C14H8I4O4 | 0.00489 mg/ml | Not Available | |
| 484 | S-Adenosyl-L-Homocysteine | https://www.drugbank.ca/drugs/DB01752 | <img src="https://www.drugbank.ca/structures/DB01752/thumb.svg"></img> | -2.4 | 1.81 | 384.411 | C14H20N6O5S | 4.08 mg/ml | 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. [PubChem] | |
| 485 | 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One | https://www.drugbank.ca/drugs/DB01754 | <img src="https://www.drugbank.ca/structures/DB01754/thumb.svg"></img> | 0.03 | 6.09 | 191.1834 | C10H9NO3 | 13.6 mg/ml | Not Available | |
| 486 | N-[Isoleucinyl]-N'-[Adenosyl]-Diaminosufone | https://www.drugbank.ca/drugs/DB01755 | <img src="https://www.drugbank.ca/structures/DB01755/thumb.svg"></img> | -0.81 | 3.78 | 458.493 | C16H26N8O6S | 2.26 mg/ml | Not Available | |
| 487 | D-4-Phosphoerythronic Acid | https://www.drugbank.ca/drugs/DB01756 | <img src="https://www.drugbank.ca/structures/DB01756/thumb.svg"></img> | -2.3 | 1.47 | 216.0832 | C4H9O8P | 19.6 mg/ml | Not Available | |
| 488 | 3-Iodo-Tyrosine | https://www.drugbank.ca/drugs/DB01758 | <img src="https://www.drugbank.ca/structures/DB01758/thumb.svg"></img> | -1.5 | 0.99 | 307.0851 | C9H10INO3 | 0.937 mg/ml | Not Available | |
| 489 | 5-Hydroxy-2-(Hydroxymethyl)-4h-Pyran-4-One | https://www.drugbank.ca/drugs/DB01759 | <img src="https://www.drugbank.ca/structures/DB01759/thumb.svg"></img> | -0.64 | 9.3 | 142.1094 | C6H6O4 | 92.3 mg/ml | Not Available | |
| 490 | 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine | https://www.drugbank.ca/drugs/DB01761 | <img src="https://www.drugbank.ca/structures/DB01761/thumb.svg"></img> | 5.43 | 14.11 | 506.5653 | C28H29F3N6 | 0.00438 mg/ml | Not Available | |
| 491 | Acetoacetic Acid | https://www.drugbank.ca/drugs/DB01762 | <img src="https://www.drugbank.ca/structures/DB01762/thumb.svg"></img> | -0.47 | 4.02 | 102.0886 | C4H6O3 | 240.0 mg/ml | Not Available | |
| 492 | 7-thionicotinamide-adenine-dinucleotide phosphate | https://www.drugbank.ca/drugs/DB01763 | <img src="https://www.drugbank.ca/structures/DB01763/thumb.svg"></img> | -0.95 | 0.66 | 759.471 | C21H28N7O16P3S | 7.49 mg/ml | Not Available | |
| 493 | Dalfopristin | https://www.drugbank.ca/drugs/DB01764 | <img src="https://www.drugbank.ca/structures/DB01764/thumb.svg"></img> | 2.57 | 11.38 | 690.847 | C34H50N4O9S | 0.0716 mg/ml | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. | |
| 494 | (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid | https://www.drugbank.ca/drugs/DB01765 | <img src="https://www.drugbank.ca/structures/DB01765/thumb.svg"></img> | 2.3 | 4.22 | 292.2888 | C17H12N2O3 | 0.13 mg/ml | Not Available | |
| 495 | Beta-(2-Naphthyl)-Alanine | https://www.drugbank.ca/drugs/DB01766 | <img src="https://www.drugbank.ca/structures/DB01766/thumb.svg"></img> | -0.41 | 2.61 | 215.2478 | C13H13NO2 | 0.201 mg/ml | Not Available | |
| 496 | Hemi-Babim | https://www.drugbank.ca/drugs/DB01767 | <img src="https://www.drugbank.ca/structures/DB01767/thumb.svg"></img> | 1.86 | 11.47 | 290.3226 | C16H14N6 | 0.0274 mg/ml | Not Available | |
| 497 | Methylumbelliferyl Sialic Acid | https://www.drugbank.ca/drugs/DB01768 | <img src="https://www.drugbank.ca/structures/DB01768/thumb.svg"></img> | -0.91 | 2.81 | 467.4233 | C21H25NO11 | 3.88 mg/ml | Not Available | |
| 498 | 3-Sulfinoalanine | https://www.drugbank.ca/drugs/DB01769 | <img src="https://www.drugbank.ca/structures/DB02153/thumb.svg"></img> | -2.1 | -0.78 | 153.157 | C3H7NO4S | 30.2 mg/ml | Not Available | |
| 499 | CRA_10991 | https://www.drugbank.ca/drugs/DB01771 | <img src="https://www.drugbank.ca/structures/DB01771/thumb.svg"></img> | 1.81 | 9.49 | 369.845 | C20H20ClN3O2 | 0.000264 mg/ml | Not Available | |
| 500 | 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione | https://www.drugbank.ca/drugs/DB01772 | <img src="https://www.drugbank.ca/structures/DB01772/thumb.svg"></img> | 2.16 | 9.47 | 409.4103 | C22H20FN3O4 | 0.0455 mg/ml | Not Available | |
| 501 | 4-[3-Carboxymethyl-3-(4-Phosphonooxy-Benzyl)-Ureido]-4-[(3-Cyclohexyl-Propyl)-Methyl-Carbamoyl]Butyric Acid | https://www.drugbank.ca/drugs/DB01773 | <img src="https://www.drugbank.ca/structures/DB01773/thumb.svg"></img> | 1.86 | 1.78 | 571.5571 | C25H38N3O10P | 0.00321 mg/ml | Not Available | |
| 502 | Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester | https://www.drugbank.ca/drugs/DB01774 | <img src="https://www.drugbank.ca/structures/DB01774/thumb.svg"></img> | -1.8 | 1.73 | 589.3417 | C16H25N5O15P2 | 4.84 mg/ml | Serves as the glycosyl donor for formation of bacterial glycogen, amylose in green algae, and amylopectin in higher plants. [PubChem] | |
| 503 | Dihydroxyacetone | https://www.drugbank.ca/drugs/DB01775 | <img src="https://www.drugbank.ca/structures/DB01775/thumb.svg"></img> | -1.6 | 13.49 | 90.0779 | C3H6O3 | 838.0 mg/ml | A ketotriose compound. Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem] | |
| 504 | M-Cresol | https://www.drugbank.ca/drugs/DB01776 | <img src="https://www.drugbank.ca/structures/DB01776/thumb.svg"></img> | 1.96 | 10.13 | 108.1378 | C7H8O | 25.1 mg/ml | Not Available | |
| 505 | Coa-S-Trimethylene-Acetyl-Tryptamine | https://www.drugbank.ca/drugs/DB01777 | <img src="https://www.drugbank.ca/structures/DB01777/thumb.svg"></img> | 0.52 | 0.83 | 1008.842 | C36H53N9O17P3S | 2.1 mg/ml | Not Available | |
| 506 | Glycerol-2-Phosphate | https://www.drugbank.ca/drugs/DB01779 | <img src="https://www.drugbank.ca/structures/DB01779/thumb.svg"></img> | -1.8 | 1.13 | 172.0737 | C3H9O6P | 30.7 mg/ml | Not Available | |
| 507 | Fusicoccin | https://www.drugbank.ca/drugs/DB01780 | <img src="https://www.drugbank.ca/structures/DB01780/thumb.svg"></img> | 2.42 | 12.24 | 680.8226 | C36H56O12 | 0.0849 mg/ml | Not Available | |
| 508 | 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One | https://www.drugbank.ca/drugs/DB01782 | <img src="https://www.drugbank.ca/structures/DB01782/thumb.svg"></img> | 2.76 | 12.77 | 220.2261 | C14H8N2O | 0.186 mg/ml | Not Available | |
| 509 | Pantothenic acid | https://www.drugbank.ca/drugs/DB01783 | <img src="https://www.drugbank.ca/structures/DB01783/thumb.svg"></img> | -1.1 | 4.35 | 219.235 | C9H17NO5 | 60.5 mg/ml | Pantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919. For many animals, pantothenic acid is an essential nutrient. Animals require pantothenic acid to synthesize coenzyme-A (CoA), as well as to synthesize and metabolize proteins, carbohydrates, and fats. Pantothenic acid is the amide between pantoic acid and β-alanine. Small quantities of pantothenic acid are found in nearly every food, with high amounts in whole-grain cereals, legumes, eggs, meat, royal jelly, avocado, and yogurt. It is commonly found as its alcohol analog, the provitamin panthenol, and as calcium pantothenate. Pantothenic acid is an ingredient in some hair and skin care products. Only the dextrorotatory (D) isomer of pantothenic acid possesses biologic activity. The levorotatory (L) form may antagonize the effects of the dextrorotatory isomer. [Wikipedia] | |
| 510 | 4-Flourobenzenesulfonamide | https://www.drugbank.ca/drugs/DB01784 | <img src="https://www.drugbank.ca/structures/DB01784/thumb.svg"></img> | 0.62 | 9.81 | 175.181 | C6H6FNO2S | 2.16 mg/ml | Not Available | |
| 511 | Dimethylallyl Diphosphate | https://www.drugbank.ca/drugs/DB01785 | <img src="https://www.drugbank.ca/structures/DB01785/thumb.svg"></img> | 0.3 | 1.77 | 246.0921 | C5H12O7P2 | 6.54 mg/ml | Not Available | |
| 512 | D-Alanine | https://www.drugbank.ca/drugs/DB01786 | <img src="https://www.drugbank.ca/structures/DB01786/thumb.svg"></img> | -3 | 2.47 | 89.0932 | C3H7NO2 | 447.0 mg/ml | Not Available | |
| 513 | 1-Amino-2,3-Dihydroxy-5-Hydroxymethyl Cyclohex-5-Ene | https://www.drugbank.ca/drugs/DB01789 | <img src="https://www.drugbank.ca/structures/DB01789/thumb.svg"></img> | -1.9 | 13.43 | 159.183 | C7H13NO3 | 293.0 mg/ml | Not Available | |
| 514 | Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate | https://www.drugbank.ca/drugs/DB01790 | <img src="https://www.drugbank.ca/structures/DB01790/thumb.svg"></img> | -0.93 | 1.89 | 345.272 | C10H12N5O5PS | 1.84 mg/ml | Not Available | |
| 515 | Piclamilast | https://www.drugbank.ca/drugs/DB01791 | <img src="https://www.drugbank.ca/structures/DB01791/thumb.svg"></img> | 4.65 | 8.25 | 381.253 | C18H18Cl2N2O3 | 0.0061 mg/ml | Piclamilast (RP-73,401), is a selective PDE4 inhibitor. It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. It is a second generation compound that exhibits structural functionalities of the PDE4 inhibitors cilomilast and roflumilast. The structure for piclamilast was first elucidated in a 1995 European patent application. | |
| 516 | Adenylyl-3'-5'-Phospho-Uridine-3'-Monophosphate | https://www.drugbank.ca/drugs/DB01792 | <img src="https://www.drugbank.ca/structures/DB01792/thumb.svg"></img> | -1.8 | 0.83 | 653.3872 | C19H25N7O15P2 | 3.64 mg/ml | Not Available | |
| 517 | I-5 | https://www.drugbank.ca/drugs/DB01793 | <img src="https://www.drugbank.ca/structures/DB01793/thumb.svg"></img> | 3.43 | 3.73 | 377.178 | C17H10Cl2N2O4 | 0.00214 mg/ml | Not Available | |
| 518 | Phenyl Boronic Acid | https://www.drugbank.ca/drugs/DB01795 | <img src="https://www.drugbank.ca/structures/DB01795/thumb.svg"></img> | 0.53 | 8.76 | 121.93 | C6H7BO2 | 10.1 mg/ml | Not Available | |
| 519 | Quinolinic Acid | https://www.drugbank.ca/drugs/DB01796 | <img src="https://www.drugbank.ca/structures/DB01796/thumb.svg"></img> | 0.15 | 0.29 | 167.1189 | C7H5NO4 | 4.07 mg/ml | A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS. [PubChem] | |
| 520 | (2r)-2-(Aminomethyl)-2,4-Dihydroxy-5-Oxo-3-(2-Oxoethyl)-2,5-Dihydro-1h-Imidazol-3-Ium | https://www.drugbank.ca/drugs/DB01797 | <img src="https://www.drugbank.ca/structures/DB01797/thumb.svg"></img> | -0.41 | 1.77 | 204.1607 | C6H10N3O5 | 12.0 mg/ml | Not Available | |
| 521 | Ethyl Dihydrogen Diphosphate | https://www.drugbank.ca/drugs/DB01798 | <img src="https://www.drugbank.ca/structures/DB01798/thumb.svg"></img> | -0.3 | 1.78 | 206.0282 | C2H8O7P2 | 13.0 mg/ml | Not Available | |
| 522 | 4-Hydroxy-3-Methyl Butyl Diphosphate | https://www.drugbank.ca/drugs/DB01799 | <img src="https://www.drugbank.ca/structures/DB01799/thumb.svg"></img> | -0.45 | 1.78 | 264.1074 | C5H14O8P2 | 10.5 mg/ml | Not Available | |
| 523 | N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium | https://www.drugbank.ca/drugs/DB01800 | <img src="https://www.drugbank.ca/structures/DB01800/thumb.svg"></img> | -0.63 | -3 | 235.171 | C6H5NO7S | 1.14 mg/ml | Not Available | |
| 524 | 2-(Trimethylammonium)Ethyl Thiol | https://www.drugbank.ca/drugs/DB01803 | <img src="https://www.drugbank.ca/structures/DB01803/thumb.svg"></img> | -3.1 | 9.7 | 120.236 | C5H14NS | 0.0511 mg/ml | Not Available | |
| 525 | 2-Ammoniobut-3-Enoate, 2-Amino-3-Butenoate | https://www.drugbank.ca/drugs/DB01804 | <img src="https://www.drugbank.ca/structures/DB01804/thumb.svg"></img> | -1.7 | 2.42 | 101.1039 | C4H7NO2 | 7.71 mg/ml | Not Available | |
| 526 | Monoisopropylphosphorylserine | https://www.drugbank.ca/drugs/DB01805 | <img src="https://www.drugbank.ca/structures/DB01805/thumb.svg"></img> | -1.6 | 1.67 | 227.1522 | C6H14NO6P | 26.8 mg/ml | Not Available | |
| 527 | 10-{4-Dimethylamino-5-[4-Hydroxy-6-Methyl-5-(6-Methyl-5-Oxo-Tetrahydro-Pyran-2-Yloxy)-Tetrahydro-Pyrane-2-Yloxy]-6-Methyl-Tetrahydro-Pyran-2-Yloxy}-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione | https://www.drugbank.ca/drugs/DB01806 | <img src="https://www.drugbank.ca/structures/DB01806/thumb.svg"></img> | 2.94 | 8.94 | 753.8318 | C40H51NO13 | 0.134 mg/ml | Not Available | |
| 528 | N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea | https://www.drugbank.ca/drugs/DB01807 | <img src="https://www.drugbank.ca/structures/DB01807/thumb.svg"></img> | 4.34 | 7.15 | 368.86 | C20H21ClN4O | 0.0123 mg/ml | Not Available | |
| 529 | Thiarsahydroxy-Cysteine | https://www.drugbank.ca/drugs/DB01808 | <img src="https://www.drugbank.ca/structures/DB01808/thumb.svg"></img> | -3 | 1.47 | 213.087 | C3H8AsNO3S | 33.7 mg/ml | Not Available | |
| 530 | 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine | https://www.drugbank.ca/drugs/DB01809 | <img src="https://www.drugbank.ca/structures/DB01809/thumb.svg"></img> | 3.06 | 19.69 | 281.3556 | C16H19N5 | 0.0953 mg/ml | Not Available | |
| 531 | [1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester | https://www.drugbank.ca/drugs/DB01810 | <img src="https://www.drugbank.ca/structures/DB01810/thumb.svg"></img> | 2.49 | 13.43 | 408.4471 | C23H24N2O5 | 0.0017 mg/ml | Not Available | |
| 532 | Adenosine-3'-5'-Diphosphate | https://www.drugbank.ca/drugs/DB01812 | <img src="https://www.drugbank.ca/structures/DB01812/thumb.svg"></img> | -1.6 | 0.71 | 427.2011 | C10H15N5O10P2 | 3.33 mg/ml | Not Available | |
| 533 | Pyridoxyl-Glutamic Acid-5'-Monophosphate | https://www.drugbank.ca/drugs/DB01813 | <img src="https://www.drugbank.ca/structures/DB01813/thumb.svg"></img> | -1.1 | 0.98 | 379.2797 | C13H20N2O9P | 0.257 mg/ml | Not Available | |
| 534 | 2-Tridecanoyloxy-Pentadecanoic Acid | https://www.drugbank.ca/drugs/DB01814 | <img src="https://www.drugbank.ca/structures/DB01814/thumb.svg"></img> | 9.13 | 4.52 | 454.726 | C28H54O4 | 2.97e-05 mg/ml | Not Available | |
| 535 | Nz-(Dicarboxymethyl)Lysine | https://www.drugbank.ca/drugs/DB01815 | <img src="https://www.drugbank.ca/structures/DB01815/thumb.svg"></img> | -3.1 | 0.082 | 248.2331 | C9H16N2O6 | 6.37 mg/ml | Not Available | |
| 536 | Castanospermine | https://www.drugbank.ca/drugs/DB01816 | <img src="https://www.drugbank.ca/structures/DB01816/thumb.svg"></img> | -2.1 | 12.89 | 189.209 | C8H15NO4 | 1110.0 mg/ml | Not Available | |
| 537 | Threonine-Aspartic Ester | https://www.drugbank.ca/drugs/DB01817 | <img src="https://www.drugbank.ca/structures/DB01817/thumb.svg"></img> | -4.2 | 1.62 | 236.2224 | C8H16N2O6 | 28.1 mg/ml | Not Available | |
| 538 | O3-Sulfonylgalactose | https://www.drugbank.ca/drugs/DB01818 | <img src="https://www.drugbank.ca/structures/DB01818/thumb.svg"></img> | -2.1 | -2 | 260.219 | C6H12O9S | 104.0 mg/ml | Not Available | |
| 539 | Phosphoenolpyruvate | https://www.drugbank.ca/drugs/DB01819 | <img src="https://www.drugbank.ca/structures/DB01819/thumb.svg"></img> | -1.2 | 0.76 | 168.042 | C3H5O6P | 13.2 mg/ml | Not Available | |
| 540 | Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide | https://www.drugbank.ca/drugs/DB01820 | <img src="https://www.drugbank.ca/structures/DB01820/thumb.svg"></img> | 2.77 | 2.53 | 533.5723 | C29H31N3O7 | 0.000812 mg/ml | Not Available | |
| 541 | L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide | https://www.drugbank.ca/drugs/DB01821 | <img src="https://www.drugbank.ca/structures/DB01821/thumb.svg"></img> | -1.9 | 10.15 | 318.3329 | C10H22N8O4 | 0.256 mg/ml | Not Available | |
| 542 | Dithiane Diol | https://www.drugbank.ca/drugs/DB01822 | <img src="https://www.drugbank.ca/structures/DB01822/thumb.svg"></img> | -0.44 | 13.48 | 152.235 | C4H8O2S2 | 70.5 mg/ml | Not Available | |
| 543 | Beta-D-Glucopyranose Spirohydantoin | https://www.drugbank.ca/drugs/DB01823 | <img src="https://www.drugbank.ca/structures/DB01823/thumb.svg"></img> | -2.3 | 9.09 | 248.1901 | C8H12N2O7 | 230.0 mg/ml | Not Available | |
| 544 | (3s)-Tetrahydrofuran-3-Yl (1r,2s)-3-[4-((1r)-2-{[(S)-Amino(Hydroxy)Methyl]Oxy}-2,3-Dihydro-1h-Inden-1-Yl)-2-Benzyl-3-Oxopyrrolidin-2-Yl]-1-Benzyl-2-Hydroxypropylcarbamate | https://www.drugbank.ca/drugs/DB01824 | <img src="https://www.drugbank.ca/structures/DB01824/thumb.svg"></img> | 1.63 | 11.4 | 629.7425 | C36H43N3O7 | 0.00753 mg/ml | Not Available | |
| 545 | 2-Amino-8-Methylquinazolin-4(3h)-One | https://www.drugbank.ca/drugs/DB01825 | <img src="https://www.drugbank.ca/structures/DB01825/thumb.svg"></img> | 0.73 | 10 | 175.1873 | C9H9N3O | 1.12 mg/ml | Not Available | |
| 546 | N-Butyl Isocyanide | https://www.drugbank.ca/drugs/DB01826 | <img src="https://www.drugbank.ca/structures/DB01826/thumb.svg"></img> | 2.16 | 16.22 | 83.1317 | C5H9N | 0.5 mg/ml | Not Available | |
| 547 | 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide | https://www.drugbank.ca/drugs/DB01827 | <img src="https://www.drugbank.ca/structures/DB01827/thumb.svg"></img> | 1.31 | 10.49 | 223.1244 | C8H5F4NO2 | 0.309 mg/ml | Not Available | |
| 548 | Desulfo-Coenzyme A | https://www.drugbank.ca/drugs/DB01829 | <img src="https://www.drugbank.ca/structures/DB01829/thumb.svg"></img> | -0.63 | 0.83 | 735.4691 | C21H36N7O16P3 | 4.61 mg/ml | Not Available | |
| 549 | {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid | https://www.drugbank.ca/drugs/DB01830 | <img src="https://www.drugbank.ca/structures/DB01830/thumb.svg"></img> | 1.25 | 1.27 | 665.6082 | C30H41N3O10P2 | 0.0101 mg/ml | Not Available | |
| 550 | Tryptophanyl-5'amp | https://www.drugbank.ca/drugs/DB01831 | <img src="https://www.drugbank.ca/structures/DB01831/thumb.svg"></img> | -0.62 | 0.77 | 533.4311 | C21H24N7O8P | 1.11 mg/ml | Not Available | |
| 551 | 4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid | https://www.drugbank.ca/drugs/DB01832 | <img src="https://www.drugbank.ca/structures/DB01832/thumb.svg"></img> | -1.9 | 1.85 | 180.0957 | C5H9O5P | 29.9 mg/ml | Not Available | |
| 552 | L-2-Amino-4-(Guanidinooxy)Butyric Acid | https://www.drugbank.ca/drugs/DB01833 | <img src="https://www.drugbank.ca/structures/DB01833/thumb.svg"></img> | -3.9 | 2.1 | 176.1738 | C5H12N4O3 | 2.77 mg/ml | Not Available | |
| 553 | (9r,10r)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene | https://www.drugbank.ca/drugs/DB01834 | <img src="https://www.drugbank.ca/structures/DB01834/thumb.svg"></img> | -1.3 | 1.8 | 501.552 | C24H27N3O7S | 0.031 mg/ml | Not Available | |
| 554 | 4r-Fluoro-N6-Ethanimidoyl-L-Lysine | https://www.drugbank.ca/drugs/DB01835 | <img src="https://www.drugbank.ca/structures/DB01835/thumb.svg"></img> | -3.2 | 2.54 | 205.2299 | C8H16FN3O2 | 0.442 mg/ml | Not Available | |
| 555 | O-acetyl-L-serine | https://www.drugbank.ca/drugs/DB01837 | <img src="https://www.drugbank.ca/structures/DB01837/thumb.svg"></img> | -2.9 | 1.86 | 147.1293 | C5H9NO4 | 174.0 mg/ml | Not Available | |
| 556 | 6,4'-Dihydroxy-3-Methyl-3',5'-Dibromoflavone | https://www.drugbank.ca/drugs/DB01838 | <img src="https://www.drugbank.ca/structures/DB01838/thumb.svg"></img> | 4.9 | 6.01 | 426.056 | C16H10Br2O4 | 0.0196 mg/ml | Not Available | |
| 557 | 1,2-Propanediol | https://www.drugbank.ca/drugs/DB01839 | <img src="https://www.drugbank.ca/structures/DB01839/thumb.svg"></img> | -0.92 | 14.47 | 76.0944 | C3H8O2 | 952.0 mg/ml | A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations. [PubChem] | |
| 558 | 2-Deoxy-D-Glucitol 6-(E)-Vinylhomophosphonate | https://www.drugbank.ca/drugs/DB01840 | <img src="https://www.drugbank.ca/structures/DB01840/thumb.svg"></img> | -1.9 | 3.54 | 242.1636 | C7H15O7P | 21.0 mg/ml | Not Available | |
| 559 | 4,6-Dideoxyglucose | https://www.drugbank.ca/drugs/DB01841 | <img src="https://www.drugbank.ca/structures/DB01841/thumb.svg"></img> | -1.8 | 11.33 | 148.1571 | C6H12O4 | 904.0 mg/ml | Not Available | |
| 560 | 3'-Phosphate-Adenosine-5'-Diphosphate | https://www.drugbank.ca/drugs/DB01842 | <img src="https://www.drugbank.ca/structures/DB01842/thumb.svg"></img> | -1.1 | 0.82 | 507.181 | C10H16N5O13P3 | 4.61 mg/ml | Not Available | |
| 561 | 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione | https://www.drugbank.ca/drugs/DB01843 | <img src="https://www.drugbank.ca/structures/DB01843/thumb.svg"></img> | -2.2 | 9.63 | 263.2047 | C8H13N3O7 | 212.0 mg/ml | Not Available | |
| 562 | Oxidized Coenzyme A | https://www.drugbank.ca/drugs/DB01846 | <img src="https://www.drugbank.ca/structures/DB01846/thumb.svg"></img> | -0.87 | 0.83 | 783.534 | C21H36N7O17P3S | 4.91 mg/ml | Not Available | |
| 563 | N-Carbamyl-D-Valine | https://www.drugbank.ca/drugs/DB01847 | <img src="https://www.drugbank.ca/structures/DB01847/thumb.svg"></img> | -0.63 | 4.02 | 160.1711 | C6H12N2O3 | 21.4 mg/ml | Not Available | |
| 564 | Isocitrate Calcium Complex | https://www.drugbank.ca/drugs/DB01848 | <img src="https://www.drugbank.ca/structures/DB01848/thumb.svg"></img> | 0.21 | 2.72 | 231.194 | C6H7CaO7 | 99.3 mg/ml | Not Available | |
| 565 | 3,4-Dihydrouracil | https://www.drugbank.ca/drugs/DB01849 | <img src="https://www.drugbank.ca/structures/DB01849/thumb.svg"></img> | -1.3 | 11.73 | 114.1026 | C4H6N2O2 | 25.9 mg/ml | Not Available | |
| 566 | (2s,3s,8s,9s)-3-Amino-9-Methoxy-2,6,8-Trimethyl-10-Phenyldeca-4,6-Dienoic Acid | https://www.drugbank.ca/drugs/DB01850 | <img src="https://www.drugbank.ca/structures/DB01850/thumb.svg"></img> | 0.71 | 4.01 | 331.4492 | C20H29NO3 | 0.00813 mg/ml | Not Available | |
| 567 | Kaempherol | https://www.drugbank.ca/drugs/DB01852 | <img src="https://www.drugbank.ca/structures/DB01852/thumb.svg"></img> | 1.99 | 6.44 | 286.2363 | C15H10O6 | 0.178 mg/ml | Not Available | |
| 568 | Bacteriochlorophyll A | https://www.drugbank.ca/drugs/DB01853 | <img src="https://www.drugbank.ca/structures/DB01853/thumb.svg"></img> | 3.45 | 4.19 | 911.504 | C55H74MgN4O6 | 2.84e-05 mg/ml | A specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A. [PubChem] | |
| 569 | 5-Bromonicotinamide | https://www.drugbank.ca/drugs/DB01854 | <img src="https://www.drugbank.ca/structures/DB01854/thumb.svg"></img> | 0.08 | 13.07 | 201.021 | C6H5BrN2O | 16.7 mg/ml | Not Available | |
| 570 | 5-(Hydroxy-Methyl-Amino)-3-Methyl-Pyrrolidine-2-Carboxylic Acid | https://www.drugbank.ca/drugs/DB01855 | <img src="https://www.drugbank.ca/structures/DB01855/thumb.svg"></img> | -2.5 | 3.11 | 174.1977 | C7H14N2O3 | 170.0 mg/ml | Not Available | |
| 571 | Pimelic Acid | https://www.drugbank.ca/drugs/DB01856 | <img src="https://www.drugbank.ca/structures/DB01856/thumb.svg"></img> | 0.61 | 4.05 | 160.1678 | C7H12O4 | 13.3 mg/ml | A group of compounds that are derivatives of heptanedioic acid with the general formula R-C7H11O4. [PubChem] | |
| 572 | Phosphoaspartate | https://www.drugbank.ca/drugs/DB01857 | <img src="https://www.drugbank.ca/structures/DB01857/thumb.svg"></img> | -1.9 | 1.08 | 213.0826 | C4H8NO7P | 13.2 mg/ml | Not Available | |
| 573 | [1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate | https://www.drugbank.ca/drugs/DB01858 | <img src="https://www.drugbank.ca/structures/DB01858/thumb.svg"></img> | 2.92 | 11.9 | 444.4992 | C23H29FN4O4 | 0.00446 mg/ml | Not Available | |
| 574 | 4-Diphosphocytidyl-2-C-Methyl-D-Erythritol 2-Phosphate | https://www.drugbank.ca/drugs/DB01859 | <img src="https://www.drugbank.ca/structures/DB01859/thumb.svg"></img> | -0.88 | 1.07 | 601.2874 | C14H26N3O17P3 | 15.1 mg/ml | Not Available | |
| 575 | Cordycepin Triphosphate | https://www.drugbank.ca/drugs/DB01860 | <img src="https://www.drugbank.ca/structures/DB01860/thumb.svg"></img> | -0.68 | 0.9 | 491.1816 | C10H16N5O12P3 | 3.83 mg/ml | Not Available | |
| 576 | Uridine diphosphate glucose | https://www.drugbank.ca/drugs/DB01861 | <img src="https://www.drugbank.ca/structures/DB01861/thumb.svg"></img> | -1.4 | 1.73 | 566.3018 | C15H24N2O17P2 | 15.0 mg/ml | A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids. | |
| 577 | Isopropyl beta-D-thiogalactopyranoside | https://www.drugbank.ca/drugs/DB01862 | <img src="https://www.drugbank.ca/structures/DB01862/thumb.svg"></img> | -1.26 | 12.48 | 238.301 | C9H18O5S | 128.0 mg/ml | A non-metabolizable galactose analog that induces expression of the LAC operon. [PubChem] | |
| 578 | Inositol 1,3,4,5-Tetrakisphosphate | https://www.drugbank.ca/drugs/DB01863 | <img src="https://www.drugbank.ca/structures/DB01863/thumb.svg"></img> | -0.45 | 0.33 | 500.0755 | C6H16O18P4 | 11.5 mg/ml | Not Available | |
| 579 | 5'-Guanosine-Diphosphate-Monothiophosphate | https://www.drugbank.ca/drugs/DB01864 | <img src="https://www.drugbank.ca/structures/DB01864/thumb.svg"></img> | -0.24 | 0.91 | 539.246 | C10H16N5O13P3S | 7.89 mg/ml | Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes. [PubChem] | |
| 580 | RU79256 | https://www.drugbank.ca/drugs/DB01866 | <img src="https://www.drugbank.ca/structures/DB01866/thumb.svg"></img> | -0.26 | -1.3 | 216.211 | C8H8O5S | 2.41 mg/ml | Not Available | |
| 581 | Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate | https://www.drugbank.ca/drugs/DB01868 | <img src="https://www.drugbank.ca/structures/DB01868/thumb.svg"></img> | -1.3 | 1.87 | 322.2747 | C11H21N3O6P | 3.71 mg/ml | Not Available | |
| 582 | L-Rhamnose | https://www.drugbank.ca/drugs/DB01869 | <img src="https://www.drugbank.ca/structures/DB02961/thumb.svg"></img> | -2 | 11.84 | 164.1565 | C6H12O5 | 258.0 mg/ml | A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem] | |
| 583 | 1,4-Dithio-Alpha-D-Mannose | https://www.drugbank.ca/drugs/DB01870 | <img src="https://www.drugbank.ca/structures/DB01870/thumb.svg"></img> | -0.41 | 8.59 | 212.287 | C6H12O4S2 | 8.09 mg/ml | Not Available | |
| 584 | [1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester | https://www.drugbank.ca/drugs/DB01871 | <img src="https://www.drugbank.ca/structures/DB01871/thumb.svg"></img> | 2.72 | 12.54 | 460.5216 | C27H28N2O5 | 0.00155 mg/ml | Not Available | |
| 585 | Acetylgalactosamine-4-Sulfate | https://www.drugbank.ca/drugs/DB01872 | <img src="https://www.drugbank.ca/structures/DB01872/thumb.svg"></img> | -2 | -1.9 | 301.271 | C8H15NO9S | 42.9 mg/ml | Not Available | |
| 586 | Epothilone D | https://www.drugbank.ca/drugs/DB01873 | <img src="https://www.drugbank.ca/structures/DB01873/thumb.svg"></img> | 4.54 | 14.09 | 491.683 | C27H41NO5S | 0.00246 mg/ml | Not Available | |
| 587 | Tropinone | https://www.drugbank.ca/drugs/DB01874 | <img src="https://www.drugbank.ca/structures/DB01874/thumb.svg"></img> | 0.44 | 18.02 | 139.1949 | C8H13NO | 541.0 mg/ml | Not Available | |
| 588 | N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide | https://www.drugbank.ca/drugs/DB01877 | <img src="https://www.drugbank.ca/structures/DB01877/thumb.svg"></img> | -0.31 | 8.71 | 345.371 | C13H19N3O6S | 2.32 mg/ml | Not Available | |
| 589 | (S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid | https://www.drugbank.ca/drugs/DB01879 | <img src="https://www.drugbank.ca/structures/DB01879/thumb.svg"></img> | 3.6 | 2.38 | 662.686 | C32H26N2O10S2 | 0.000444 mg/ml | Not Available | |
| 590 | 3,4-Dihydroxycinnamic Acid | https://www.drugbank.ca/drugs/DB01880 | <img src="https://www.drugbank.ca/structures/DB01880/thumb.svg"></img> | 1.15 | 3.64 | 180.1574 | C9H8O4 | 1.61 mg/ml | Not Available | |
| 591 | 2-Methylpentane-1,2,4-Triol | https://www.drugbank.ca/drugs/DB01881 | <img src="https://www.drugbank.ca/structures/DB01881/thumb.svg"></img> | -0.94 | 13.98 | 134.1736 | C6H14O3 | 440.0 mg/ml | Not Available | |
| 592 | (2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol | https://www.drugbank.ca/drugs/DB01882 | <img src="https://www.drugbank.ca/structures/DB01882/thumb.svg"></img> | -0.1 | 10.24 | 228.311 | C10H16N2O2S | 9.28 mg/ml | Not Available | |
| 593 | N-(Sulfanylacetyl)Tyrosylprolylmethioninamide | https://www.drugbank.ca/drugs/DB01883 | <img src="https://www.drugbank.ca/structures/DB01883/thumb.svg"></img> | 1.31 | 9.17 | 482.617 | C21H30N4O5S2 | 0.0197 mg/ml | Not Available | |
| 594 | D-Galctopyranosyl-1-On | https://www.drugbank.ca/drugs/DB01885 | <img src="https://www.drugbank.ca/structures/DB01885/thumb.svg"></img> | -2.2 | 11.62 | 178.14 | C6H10O6 | 586.0 mg/ml | Not Available | |
| 595 | Inhibitor BEA369 | https://www.drugbank.ca/drugs/DB01887 | <img src="https://www.drugbank.ca/structures/DB01887/thumb.svg"></img> | 0.72 | 12.16 | 620.6894 | C34H40N2O9 | 0.148 mg/ml | Not Available | |
| 596 | 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide | https://www.drugbank.ca/drugs/DB01888 | <img src="https://www.drugbank.ca/structures/DB01888/thumb.svg"></img> | 3.03 | 17.55 | 471.619 | C23H33N7O2S | 0.00934 mg/ml | Not Available | |
| 597 | 16,17-Androstene-3-Ol | https://www.drugbank.ca/drugs/DB01889 | <img src="https://www.drugbank.ca/structures/DB01889/thumb.svg"></img> | 5.13 | 18.3 | 274.4409 | C19H30O | 0.000355 mg/ml | Not Available | |
| 598 | N,N-bis(3-(D-gluconamido)propyl)deoxycholamide | https://www.drugbank.ca/drugs/DB01890 | <img src="https://www.drugbank.ca/structures/DB01890/thumb.svg"></img> | 0.25 | 5.13 | 862.056 | C42H75N3O15 | 0.0736 mg/ml | Not Available | |
| 599 | Tl-3-093 | https://www.drugbank.ca/drugs/DB01891 | <img src="https://www.drugbank.ca/structures/DB01891/thumb.svg"></img> | 1.87 | 12.46 | 455.5466 | C25H33N3O5 | 0.00941 mg/ml | Not Available | |
| 600 | Hyperforin | https://www.drugbank.ca/drugs/DB01892 | <img src="https://www.drugbank.ca/structures/DB01892/thumb.svg"></img> | 6.32 | 6.32 | 536.785 | C35H52O4 | 0.000632 mg/ml | Hyperforin is a phytochemical produced by some of the members of the plant genus Hypericum, notably Hypericum perforatum (St John's wort). | |
| 601 | N6-Benzyl Adenosine-5'-Diphosphate | https://www.drugbank.ca/drugs/DB01893 | <img src="https://www.drugbank.ca/structures/DB01893/thumb.svg"></img> | -0.15 | 1.77 | 517.3237 | C17H21N5O10P2 | 2.23 mg/ml | Not Available | |
| 602 | N-acetyl-alpha-neuraminic acid | https://www.drugbank.ca/drugs/DB01894 | <img src="https://www.drugbank.ca/structures/DB03721/thumb.svg"></img> | -2.8 | 3 | 309.2699 | C11H19NO9 | 227.0 mg/ml | An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518) | |
| 603 | Aspartyl-Adenosine-5'-Monophosphate | https://www.drugbank.ca/drugs/DB01895 | <img src="https://www.drugbank.ca/structures/DB01895/thumb.svg"></img> | -2.3 | 0.77 | 462.3086 | C14H19N6O10P | 2.59 mg/ml | Not Available | |
| 604 | M-Aminophenylboronic Acid | https://www.drugbank.ca/drugs/DB01896 | <img src="https://www.drugbank.ca/structures/DB01896/thumb.svg"></img> | 0.21 | 8.79 | 136.944 | C6H8BNO2 | 2.53 mg/ml | Not Available | |
| 605 | 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride | https://www.drugbank.ca/drugs/DB01897 | <img src="https://www.drugbank.ca/structures/DB01897/thumb.svg"></img> | 1.76 | 10.01 | 466.495 | C24H16N7O2S | 0.00281 mg/ml | Not Available | |
| 606 | (2S,3S)-2-azanyl-3-methyl-pentanedioic acid | https://www.drugbank.ca/drugs/DB01898 | <img src="https://www.drugbank.ca/structures/DB01898/thumb.svg"></img> | -3.3 | 2.02 | 161.1558 | C6H11NO4 | 38.1 mg/ml | Not Available | |
| 607 | Nd1-Phosphonohistidine | https://www.drugbank.ca/drugs/DB01899 | <img src="https://www.drugbank.ca/structures/DB01899/thumb.svg"></img> | -1.7 | 0.56 | 236.1424 | C6H11N3O5P | 1.79 mg/ml | Not Available | |
| 608 | Sucrosofate | https://www.drugbank.ca/drugs/DB01901 | <img src="https://www.drugbank.ca/structures/DB01901/thumb.svg"></img> | -1.9 | -3.4 | 982.802 | C12H22O35S8 | 1.45 mg/ml | Not Available | |
| 609 | 5-Bromo-2'-Deoxyuridine-5'-Monophosphate | https://www.drugbank.ca/drugs/DB01903 | <img src="https://www.drugbank.ca/structures/DB01903/thumb.svg"></img> | -0.9 | 1.23 | 387.078 | C9H12BrN2O8P | 7.54 mg/ml | Not Available | |
| 610 | D-Xylitol | https://www.drugbank.ca/drugs/DB01904 | <img src="https://www.drugbank.ca/structures/DB01904/thumb.svg"></img> | -2.5 | 12.76 | 152.1458 | C5H12O5 | 664.0 mg/ml | A five-carbon sugar alcohol derived from xylose by reduction of the carbonyl group. It is as sweet as sucrose and used as a noncariogenic sweetener. [PubChem] | |
| 611 | 2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine | https://www.drugbank.ca/drugs/DB01905 | <img src="https://www.drugbank.ca/structures/DB01905/thumb.svg"></img> | 0.69 | 9.08 | 283.3052 | C15H15N4O2 | 0.0802 mg/ml | Not Available | |
| 612 | 3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-Benzoic Acid | https://www.drugbank.ca/drugs/DB01906 | <img src="https://www.drugbank.ca/structures/DB01906/thumb.svg"></img> | 0.02 | 3.9 | 272.2196 | C11H8N6O3 | 2.83 mg/ml | Not Available | |
| 613 | NADH | https://www.drugbank.ca/drugs/DB01907 | <img src="https://www.drugbank.ca/structures/DB00157/thumb.svg"></img> | -5.1 | -7 | 665.441 | C21H29N7O14P2 | 2.95 mg/ml | NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). It forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed) | |
| 614 | RU85493 | https://www.drugbank.ca/drugs/DB01908 | <img src="https://www.drugbank.ca/structures/DB01908/thumb.svg"></img> | 2.01 | 1.61 | 637.6167 | C32H36N3O9P | 0.00116 mg/ml | Not Available | |
| 615 | Alpha-Cyclodextrin (Cyclohexa-Amylose) | https://www.drugbank.ca/drugs/DB01909 | <img src="https://www.drugbank.ca/structures/DB01909/thumb.svg"></img> | -2.4 | 11.56 | 972.8436 | C36H60O30 | 792.0 mg/ml | Not Available | |
| 616 | Sinefungin | https://www.drugbank.ca/drugs/DB01910 | <img src="https://www.drugbank.ca/structures/DB01910/thumb.svg"></img> | -3 | 1.95 | 381.387 | C15H23N7O5 | 4.63 mg/ml | Sinefungin is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar. The proteins that adenosyl-ornithine target include RdmB, modification methylase TaqI, rRNA (adenine-N6-)-methyltransferase, and modification methylase RsrI. | |
| 617 | N-Methylmesoporphyrin | https://www.drugbank.ca/drugs/DB01911 | <img src="https://www.drugbank.ca/structures/DB01911/thumb.svg"></img> | 4.96 | 3.71 | 580.7165 | C35H40N4O4 | 0.0383 mg/ml | N-methylmesoporphyrin is a solid. This compound belongs to the porphyrins. These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure. This medication is known to target ferrochelatase. | |
| 618 | D-glucose | https://www.drugbank.ca/drugs/DB01914 | <img src="https://www.drugbank.ca/structures/DB01914/thumb.svg"></img> | -2.4 | 11.8 | 180.1559 | C6H12O6 | 261.0 mg/ml | Not Available | |
| 619 | S-Hydroxycysteine | https://www.drugbank.ca/drugs/DB01915 | <img src="https://www.drugbank.ca/structures/DB01915/thumb.svg"></img> | -3.1 | 1.87 | 137.158 | C3H7NO3S | 342.0 mg/ml | S-hydroxycysteine is a solid. This compound belongs to the alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof. It targets the proteins subtilisin BPN', glutathione S-transferase A1, glutathione S-transferase p, myelin P2 protein, and complement c3. | |
| 620 | [Methyltelluro]Acetate | https://www.drugbank.ca/drugs/DB01918 | <img src="https://www.drugbank.ca/structures/DB01918/thumb.svg"></img> | -0.3 | 3.8 | 200.7 | C3H5O2Te | 116.0 mg/ml | [methyltelluro]acetate is a solid. This compound belongs to the organic oxoanionic compounds. These are organic compounds containing an oxoanion. This medication targets the protein monomeric sarcosine oxidase. | |
| 621 | Pentanal | https://www.drugbank.ca/drugs/DB01919 | <img src="https://www.drugbank.ca/structures/DB01919/thumb.svg"></img> | 1.41 | 15.59 | 86.1323 | C5H10O | 14.8 mg/ml | Pentanal is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. This drug targets the protein cAMP-dependent protein kinase catalytic subunit alpha. | |
| 622 | 1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose | https://www.drugbank.ca/drugs/DB01920 | <img src="https://www.drugbank.ca/structures/DB01920/thumb.svg"></img> | -0.58 | 12.2 | 301.2494 | C12H15NO8 | 20.6 mg/ml | Includes ortho-, meta-, and para-nitrophenylgalactosides. [PubChem] | |
| 623 | Xylose-Derived Lactam Oxime | https://www.drugbank.ca/drugs/DB01921 | <img src="https://www.drugbank.ca/structures/DB01921/thumb.svg"></img> | -2.4 | 9.74 | 162.1439 | C5H10N2O4 | 76.7 mg/ml | Not Available | |
| 624 | Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam | https://www.drugbank.ca/drugs/DB01922 | <img src="https://www.drugbank.ca/structures/DB01922/thumb.svg"></img> | -3 | 9.33 | 516.4511 | C18H32N2O15 | 194.0 mg/ml | Not Available | |
| 625 | L-Xylulose 5-Phosphate | https://www.drugbank.ca/drugs/DB01923 | <img src="https://www.drugbank.ca/structures/DB01923/thumb.svg"></img> | -1.8 | 1.49 | 216.1263 | C5H13O7P | 32.6 mg/ml | Not Available | |
| 626 | Benzhydroxamic Acid | https://www.drugbank.ca/drugs/DB01924 | <img src="https://www.drugbank.ca/structures/DB01924/thumb.svg"></img> | 0.26 | 9.65 | 137.136 | C7H7NO2 | 4.57 mg/ml | Not Available | |
| 627 | 2'-Chloro-Biphenyl-2,3-Diol | https://www.drugbank.ca/drugs/DB01925 | <img src="https://www.drugbank.ca/structures/DB01925/thumb.svg"></img> | 3.23 | 9.03 | 220.652 | C12H9ClO2 | 0.105 mg/ml | Not Available | |
| 628 | Carboxymycobactin S | https://www.drugbank.ca/drugs/DB01926 | <img src="https://www.drugbank.ca/structures/DB01926/thumb.svg"></img> | 2.64 | 4.88 | 801.661 | C36H51FeN5O12 | 0.103 mg/ml | Not Available | |
| 629 | Huperzine A | https://www.drugbank.ca/drugs/DB01928 | <img src="https://www.drugbank.ca/structures/DB04864/thumb.svg"></img> | 1.78 | 11.11 | 242.3162 | C15H18N2O | 0.166 mg/ml | Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmossHuperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease. [Wikipedia] | |
| 630 | 5-Chloryl-2,4,6-Quinazolinetriamine | https://www.drugbank.ca/drugs/DB01929 | <img src="https://www.drugbank.ca/structures/DB01929/thumb.svg"></img> | -0.3 | 17.16 | 241.634 | C8H8ClN5O2 | 1.37 mg/ml | Not Available | |
| 631 | 2,4-Dihydroxy-3,3-Dimethyl-Butyrate | https://www.drugbank.ca/drugs/DB01930 | <img src="https://www.drugbank.ca/structures/DB01930/thumb.svg"></img> | -0.34 | 3.96 | 147.1491 | C6H11O4 | 473.0 mg/ml | Not Available | |
| 632 | Dcka, 5,7-Dichlorokynurenic Acid | https://www.drugbank.ca/drugs/DB01931 | <img src="https://www.drugbank.ca/structures/DB01931/thumb.svg"></img> | 3.63 | 3.82 | 258.058 | C10H5Cl2NO3 | 0.156 mg/ml | Not Available | |
| 633 | 7-Hydroxystaurosporine | https://www.drugbank.ca/drugs/DB01933 | <img src="https://www.drugbank.ca/structures/DB01933/thumb.svg"></img> | 2.78 | 7.42 | 482.5304 | C28H26N4O4 | 0.0592 mg/ml | Not Available | |
| 634 | N-Methyl-N-(10-Methylundecanoyl)-D-Seryl-L-Alanyl-N~1~-[(7s,10s,13s)-13-Carboxy-3,18-Dihydroxy-10-Methyl-8,11-Dioxo-9,12-Diazatricyclo[13.3.1.1~2,6~]Icosa-1(19),2(20),3,5,15,17-Hexaen-7-Yl]-N~1~-Methylglycinamide | https://www.drugbank.ca/drugs/DB01934 | <img src="https://www.drugbank.ca/structures/DB01934/thumb.svg"></img> | 2.92 | 3.54 | 824.9594 | C42H60N6O11 | 0.00815 mg/ml | Not Available | |
| 635 | 3-{[(1r)-1-Benzyl-2-Sulfanylethyl]Amino}-3-Oxopropanoic Acid | https://www.drugbank.ca/drugs/DB01935 | <img src="https://www.drugbank.ca/structures/DB01935/thumb.svg"></img> | 1.75 | 4.11 | 253.317 | C12H15NO3S | 0.412 mg/ml | Not Available | |
| 636 | Ribose | https://www.drugbank.ca/drugs/DB01936 | <img src="https://www.drugbank.ca/structures/DB01936/thumb.svg"></img> | -2.32 | 11.31 | 150.1299 | C5H10O5 | 1070.0 mg/ml | Not Available | |
| 637 | Guanosine-2'-Monophosphate | https://www.drugbank.ca/drugs/DB01937 | <img src="https://www.drugbank.ca/structures/DB01937/thumb.svg"></img> | -1.9 | 0.63 | 363.2206 | C10H14N5O8P | 3.56 mg/ml | Not Available | |
| 638 | L-Histidine Beta Naphthylamide | https://www.drugbank.ca/drugs/DB01938 | <img src="https://www.drugbank.ca/structures/DB01938/thumb.svg"></img> | 1.1 | 12.75 | 280.3244 | C16H16N4O | 0.104 mg/ml | Not Available | |
| 639 | 5-Amidino-Benzimidazole | https://www.drugbank.ca/drugs/DB01939 | <img src="https://www.drugbank.ca/structures/DB01939/thumb.svg"></img> | -0.58 | 11.77 | 161.1839 | C8H9N4 | 1.86 mg/ml | Not Available | |
| 640 | Balanol Analog 2 | https://www.drugbank.ca/drugs/DB01940 | <img src="https://www.drugbank.ca/structures/DB01940/thumb.svg"></img> | 3.06 | 7.98 | 474.5051 | C27H26N2O6 | 0.00395 mg/ml | Not Available | |
| 641 | 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-Tetrahydronaphthalen-2-Yl)Cyclopropyl]Pyridine-3-Carboxylic Acid | https://www.drugbank.ca/drugs/DB01941 | <img src="https://www.drugbank.ca/structures/DB01941/thumb.svg"></img> | 6.15 | 3.93 | 363.4926 | C24H29NO2 | 0.000302 mg/ml | Not Available | |
| 642 | Formic Acid | https://www.drugbank.ca/drugs/DB01942 | <img src="https://www.drugbank.ca/structures/DB01942/thumb.svg"></img> | -0.54 | 4.27 | 46.0254 | CH2O2 | 477.0 mg/ml | Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. The principal use of formic acid is as a preservative and antibacterial agent in livestock feed. | |
| 643 | (S)-blebbistatin | https://www.drugbank.ca/drugs/DB01944 | <img src="https://www.drugbank.ca/structures/DB01944/thumb.svg"></img> | 2 | 11.54 | 292.3318 | C18H16N2O2 | 0.198 mg/ml | Not Available | |
| 644 | 4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate | https://www.drugbank.ca/drugs/DB01945 | <img src="https://www.drugbank.ca/structures/DB01945/thumb.svg"></img> | -0.4 | 1.26 | 339.1959 | C9H14N3O9P | 40.7 mg/ml | Not Available | |
| 645 | 3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione | https://www.drugbank.ca/drugs/DB01946 | <img src="https://www.drugbank.ca/structures/DB01946/thumb.svg"></img> | 3.25 | 9.61 | 398.4571 | C24H22N4O2 | 0.0318 mg/ml | Not Available | |
| 646 | RU78262 | https://www.drugbank.ca/drugs/DB01947 | <img src="https://www.drugbank.ca/structures/DB01947/thumb.svg"></img> | 0.04 | 1.75 | 202.1012 | C7H7O5P | 4.44 mg/ml | Not Available | |
| 647 | 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One | https://www.drugbank.ca/drugs/DB01948 | <img src="https://www.drugbank.ca/structures/DB01948/thumb.svg"></img> | 5.52 | 19.58 | 487.368 | C26H22Cl2F2N2O | 0.000122 mg/ml | Not Available | |
| 648 | 2-Amino-N,3,3-Trimethylbutanamide | https://www.drugbank.ca/drugs/DB01949 | <img src="https://www.drugbank.ca/structures/DB01949/thumb.svg"></img> | 0.04 | 16.28 | 144.2147 | C7H16N2O | 73.3 mg/ml | Not Available | |
| 649 | N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea | https://www.drugbank.ca/drugs/DB01950 | <img src="https://www.drugbank.ca/structures/DB01950/thumb.svg"></img> | 2.05 | 10.45 | 308.313 | C12H12N4O4S | 0.0119 mg/ml | Not Available | |
| 650 | Inhibitor of P38 Kinase | https://www.drugbank.ca/drugs/DB01953 | <img src="https://www.drugbank.ca/structures/DB01953/thumb.svg"></img> | 3.9 | 17.28 | 222.2851 | C15H14N2 | 0.00869 mg/ml | Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14. | |
| 651 | Rolipram | https://www.drugbank.ca/drugs/DB01954 | <img src="https://www.drugbank.ca/structures/DB01954/thumb.svg"></img> | 3.16 | 3.83 | 275.348 | C16H21NO3 | 0.0239 mg/ml | A phosphodiesterase inhibitor with antidepressant properties. [PubChem] | |
| 652 | 1,4-Butanediol | https://www.drugbank.ca/drugs/DB01955 | <img src="https://www.drugbank.ca/structures/DB01955/thumb.svg"></img> | -0.83 | 15.67 | 90.121 | C4H10O2 | 675.0 mg/ml | Not Available | |
| 653 | 2-Aminoethanesulfonic Acid | https://www.drugbank.ca/drugs/DB01956 | <img src="https://www.drugbank.ca/structures/DB01956/thumb.svg"></img> | -2.2 | -1.5 | 125.147 | C2H7NO3S | 105.0 mg/ml | A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids. [PubChem] | |
| 654 | 3-Chlorophenol | https://www.drugbank.ca/drugs/DB01957 | <img src="https://www.drugbank.ca/structures/DB01957/thumb.svg"></img> | 2.50 | 8.79 | 128.556 | C6H5ClO | 14.6 mg/ml | Not Available | |
| 655 | 5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine | https://www.drugbank.ca/drugs/DB01958 | <img src="https://www.drugbank.ca/structures/DB01958/thumb.svg"></img> | 4.47 | 16.67 | 324.443 | C18H20N4S | 0.00278 mg/ml | Not Available | |
| 656 | 7n-Methyl-8-Hydroguanosine-5'-Diphosphate | https://www.drugbank.ca/drugs/DB01960 | <img src="https://www.drugbank.ca/structures/DB01960/thumb.svg"></img> | -1.7 | 1.77 | 459.243 | C11H19N5O11P2 | 7.91 mg/ml | Not Available | |
| 657 | Cytidine-3'-Monophosphate | https://www.drugbank.ca/drugs/DB01961 | <img src="https://www.drugbank.ca/structures/DB01961/thumb.svg"></img> | -2 | 0.89 | 323.1965 | C9H14N3O8P | 17.6 mg/ml | Not Available | |
| 658 | Phosphonotyrosine | https://www.drugbank.ca/drugs/DB01962 | <img src="https://www.drugbank.ca/structures/DB01962/thumb.svg"></img> | -0.76 | 1.38 | 261.1684 | C9H12NO6P | 1.93 mg/ml | An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. [PubChem] | |
| 659 | AL5424 | https://www.drugbank.ca/drugs/DB01964 | <img src="https://www.drugbank.ca/structures/DB01964/thumb.svg"></img> | 0.49 | 8.14 | 390.455 | C13H14N2O6S3 | 0.519 mg/ml | Not Available | |
| 660 | 2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate | https://www.drugbank.ca/drugs/DB01965 | <img src="https://www.drugbank.ca/structures/DB01965/thumb.svg"></img> | -0.36 | 0.58 | 467.1569 | C9H16N3O13P3 | 8.34 mg/ml | Not Available | |
| 661 | Di-Stearoyl-3-Sn-Phosphatidylethanolamine | https://www.drugbank.ca/drugs/DB01966 | <img src="https://www.drugbank.ca/structures/DB01966/thumb.svg"></img> | 8.91 | 1.87 | 748.0654 | C41H82NO8P | 5.43e-05 mg/ml | Not Available | |
| 662 | N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide | https://www.drugbank.ca/drugs/DB01967 | <img src="https://www.drugbank.ca/structures/DB01967/thumb.svg"></img> | 2.3 | 11.91 | 403.538 | C21H29N3O3S | 0.288 mg/ml | Not Available | |
| 663 | 2-Thioethenamine | https://www.drugbank.ca/drugs/DB01968 | <img src="https://www.drugbank.ca/structures/DB01968/thumb.svg"></img> | 0.26 | 9.69 | 75.133 | C2H5NS | 17.7 mg/ml | Not Available | |
| 664 | Trifluoroacetonyl Coenzyme A | https://www.drugbank.ca/drugs/DB01969 | <img src="https://www.drugbank.ca/structures/DB01969/thumb.svg"></img> | 0.21 | 0.83 | 877.569 | C24H37F3N7O17P3S | 4.21 mg/ml | Not Available | |
| 665 | Hg9a-9, Nonanoyl-N-Hydroxyethylglucamide | https://www.drugbank.ca/drugs/DB01970 | <img src="https://www.drugbank.ca/structures/DB01970/thumb.svg"></img> | 0.31 | 12.65 | 365.4623 | C17H35NO7 | 9.98 mg/ml | Not Available | |
| 666 | trans-urocanic acid | https://www.drugbank.ca/drugs/DB01971 | <img src="https://www.drugbank.ca/structures/DB01971/thumb.svg"></img> | 0.22 | 3.85 | 138.124 | C6H6N2O2 | 42.5 mg/ml | Not Available | |
| 667 | Guanosine-5'-Monophosphate | https://www.drugbank.ca/drugs/DB01972 | <img src="https://www.drugbank.ca/structures/DB01972/thumb.svg"></img> | -2 | 1.05 | 363.2206 | C10H14N5O8P | 3.56 mg/ml | Guanosine 5'-monophosphate. A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. [PubChem] | |
| 668 | O-Benzylsulfonyl-Serine | https://www.drugbank.ca/drugs/DB01973 | <img src="https://www.drugbank.ca/structures/DB01973/thumb.svg"></img> | -1.4 | 1.53 | 259.279 | C10H13NO5S | 2.3 mg/ml | Not Available | |
| 669 | 2-Amino-3-[5-(Amino-Carboxy-Methyl)-2,3-Dihydro-Isoxazol-3-Ylsulfanyl]-Propionic Acid | https://www.drugbank.ca/drugs/DB01974 | <img src="https://www.drugbank.ca/structures/DB01974/thumb.svg"></img> | -4.1 | 1.02 | 263.271 | C8H13N3O5S | 11.2 mg/ml | Not Available | |
| 670 | AMPCPR | https://www.drugbank.ca/drugs/DB01975 | <img src="https://www.drugbank.ca/structures/DB01975/thumb.svg"></img> | -2 | 0.81 | 557.3429 | C16H25N5O13P2 | 4.24 mg/ml | Not Available | |
| 671 | 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine | https://www.drugbank.ca/drugs/DB01977 | <img src="https://www.drugbank.ca/structures/DB01977/thumb.svg"></img> | 2.46 | 12.14 | 289.3312 | C18H15N3O | 0.0129 mg/ml | Not Available | |
| 672 | 7,9-Dimethylguanine | https://www.drugbank.ca/drugs/DB01978 | <img src="https://www.drugbank.ca/structures/DB01978/thumb.svg"></img> | -2.6 | 9.82 | 180.1872 | C7H10N5O | 2.44 mg/ml | Not Available | |
| 673 | Methyl alpha-D-mannoside | https://www.drugbank.ca/drugs/DB01979 | <img src="https://www.drugbank.ca/structures/DB01979/thumb.svg"></img> | -2.5 | 12.21 | 194.1825 | C7H14O6 | 862.0 mg/ml | Not Available | |
| 674 | Para-Iodo-D-Phenylalanine Hydroxamic Acid | https://www.drugbank.ca/drugs/DB01980 | <img src="https://www.drugbank.ca/structures/DB01980/thumb.svg"></img> | 1.17 | 8.8 | 306.1003 | C9H11IN2O2 | 0.256 mg/ml | Not Available | |
| 675 | 3,6-Anhydro-D-Galactose-2-Sulfate | https://www.drugbank.ca/drugs/DB01981 | <img src="https://www.drugbank.ca/structures/DB01981/thumb.svg"></img> | -2 | -2.1 | 242.204 | C6H10O8S | 105.0 mg/ml | Not Available | |
| 676 | D-Mannuronic Acid | https://www.drugbank.ca/drugs/DB01982 | <img src="https://www.drugbank.ca/structures/DB01982/thumb.svg"></img> | -2.3 | 3.21 | 194.1394 | C6H10O7 | 295.0 mg/ml | Not Available | |
| 677 | 2(S)-Amino-6-Boronohexanoic Acid | https://www.drugbank.ca/drugs/DB01983 | <img src="https://www.drugbank.ca/structures/DB01983/thumb.svg"></img> | -2.9 | 1.9 | 191.998 | C6H15BNO5 | 2.83 mg/ml | Not Available | |
| 678 | 4-[2-(3-Benzyloxycarbonylamino-4-Cyclohexyl-1-Hydroxy-2-Oxo-Butylamino)-5-Guanidino-Pentanoylamino]-4-(1-Carboxy-2-Cyclohexyl-Ethylcarbamoyl)-Butyric Acid | https://www.drugbank.ca/drugs/DB01984 | <img src="https://www.drugbank.ca/structures/DB01984/thumb.svg"></img> | 1.28 | 3.27 | 771.9001 | C38H57N7O10 | 0.00735 mg/ml | Not Available | |
| 679 | N-Alpha-L-Acetyl-Arginine | https://www.drugbank.ca/drugs/DB01985 | <img src="https://www.drugbank.ca/structures/DB01985/thumb.svg"></img> | -1.7 | 3.68 | 216.2376 | C8H16N4O3 | 0.767 mg/ml | Not Available | |
| 680 | Thiamin Diphosphate | https://www.drugbank.ca/drugs/DB01987 | <img src="https://www.drugbank.ca/structures/DB01987/thumb.svg"></img> | -1.2 | 1.78 | 424.306 | C12H18N4O7P2S | 0.372 mg/ml | The coenzyme form of Vitamin B1 present in many animal tissues. It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex. [PubChem] | |
| 681 | Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome | https://www.drugbank.ca/drugs/DB01989 | <img src="https://www.drugbank.ca/structures/DB01989/thumb.svg"></img> | 0.07 | 3.02 | 743.8066 | C36H52N6O9P | 0.00278 mg/ml | Not Available | |
| 682 | Cholesterol-Sulfate | https://www.drugbank.ca/drugs/DB01990 | <img src="https://www.drugbank.ca/structures/DB01990/thumb.svg"></img> | 3.27 | -1.4 | 466.717 | C27H46O4S | 7.48e-05 mg/ml | Not Available | |
| 683 | Tu-514 | https://www.drugbank.ca/drugs/DB01991 | <img src="https://www.drugbank.ca/structures/DB01991/thumb.svg"></img> | 3.77 | 8.9 | 431.5634 | C22H41NO7 | 0.0349 mg/ml | Not Available | |
| 684 | Coenzyme A | https://www.drugbank.ca/drugs/DB01992 | <img src="https://www.drugbank.ca/structures/DB01992/thumb.svg"></img> | -0.61 | 0.83 | 767.534 | C21H36N7O16P3S | 4.64 mg/ml | Coenzyme A (CoA, CoASH, or HSCoA) is a coenzyme, notable for its role in the synthesis and oxidation of fatty acids, and the oxidation of pyruvate in the citric acid cycle. All genomes sequenced to date encode enzymes that use coenzyme A as a substrate, and around 4% of cellular enzymes use it (or a thioester, such as acetyl-CoA) as a substrate. In humans, CoA biosynthesis requires cysteamine, pantothenate, and adenosine triphosphate. [Wikipedia]. It is used as a supplement for the hypothetical treatment of acne. | |
| 685 | N-(5'-Phosphopyridoxyl)-D-Alanine | https://www.drugbank.ca/drugs/DB01993 | <img src="https://www.drugbank.ca/structures/DB01993/thumb.svg"></img> | -1.7 | 1.03 | 320.2356 | C11H17N2O7P | 1.48 mg/ml | Not Available | |
| 686 | 2-(Pyrido[1,2-E]Purin-4-Yl)Amino-Ethanol | https://www.drugbank.ca/drugs/DB01994 | <img src="https://www.drugbank.ca/structures/DB01994/thumb.svg"></img> | 0.85 | 15.33 | 229.2379 | C11H11N5O | 0.199 mg/ml | Not Available | |
| 687 | 5-Methylcytidine-5'-Monophosphate | https://www.drugbank.ca/drugs/DB01995 | <img src="https://www.drugbank.ca/structures/DB01995/thumb.svg"></img> | -1.8 | 1.24 | 337.2231 | C10H16N3O8P | 15.3 mg/ml | Not Available | |
| 688 | 2-[3,4-Dihydroxy-2-Hydroxymethyl-5-(2-Hydroxy-Nonyl)-Tetrahydro-Furan-2-Yloxy]-6-Hydroxymethyl-Tetra Hydro-Pyran-3,4,5-Triol | https://www.drugbank.ca/drugs/DB01998 | <img src="https://www.drugbank.ca/structures/DB01998/thumb.svg"></img> | -0.81 | 11.85 | 454.5091 | C20H38O11 | 15.0 mg/ml | Not Available | |
| 689 | 5,10,15,20-Tetrakis(4-Sulpfonatophenyl)-21h,23h-Porphine | https://www.drugbank.ca/drugs/DB01999 | <img src="https://www.drugbank.ca/structures/DB01999/thumb.svg"></img> | 4.67 | 14.35 | 939.01 | C44H34N4O12S4 | 0.00723 mg/ml | Not Available |
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment